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Abstract
There is a growing body of evidence supporting the association between cannabis use and
the development of mental health disorders, but few studies have addressed this
association following the recent increase in marijuana legalization laws. Therefore, using
the social ecological model and the self-medication theory of addiction as theoretical
frameworks, the purpose of this retrospective database study was to assess the
relationship between marijuana use and major depression and suicidal ideation in both
adults and adolescents in 2008 and 2017. Data from the National Survey on Drug Use
and Health were analyzed using logistic regression at the p < .05 threshold for statistical
significance. Results demonstrated positive, statistically significant relationships between
marijuana use and both major depression and suicidal ideation for both adults and
adolescents in both 2008 and 2017. Further, the strengths of these relationships generally
increased between 2008 and 2017, coincident with the increase in marijuana legalization
laws. These findings provide empirical support to the association between cannabis use
and the development of mental health disorders, and that the strength of these
associations is increasing following the increase in marijuana legalization laws. This
study has important implication for positive social change by identifying significant
relationships between cannabis use and the development of mental health disorders and
revealing that these relationships are strengthening over time, coincident with the
increase in marijuana legalization laws.
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Chapter 1: Introduction to the Study
Substance use, abuse, and misuse is an important public health problem in the
United States. According to the National Institute on Drug Abuse (NIDA) over $700
billion dollars is spent annually on the following substance use related issues: the
associated health care cost (such as cancer, heart disease, and mental illness); loss
productivity and wages; and crime associated with driving while impaired; accidents;
violence; and child abuse (NIDA-The Science of Drug Abuse, 2016; NIDA-Magnitude,
2017). In addition to the aforementioned health care complications, substance abuse is
also associated with other cost due illness, injuries, and death as “approximately 40
million debilitating illnesses or injuries occur” each year as a result of substance use,
misuse, or abuse (NIDA-Magnitude, 2017, para.4). Among the substances of abuse,
marijuana is the most widely used substance in the United States. In 2018, approximately
43 million Americans reportedly used marijuana in the past year (Statista, 2019). Among
these were approximately 11.8 million young adults that reported using marijuana in
2018 (NIH-NIDA, 2019). The World Health Organization (WHO; 2018) further
emphasized the widespread use of marijuana in a report indicating that approximately
147 million people or 2.5% of the world population use marijuana in some form each
year. This is compared to 0.4% combined total of the world’s population that consume
cocaine and opiates annually (World Health Organization [WHO], 2018). Thus,
marijuana is by far the most widely used substance in the world.
More importantly, in the United States differential marijuana legalization policies
have introduced considerable controversy regarding the public health impact of these
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policy changes. While increased use has led to therapeutic effects against certain medical
conditions, other researchers argue that there is an increase in deleterious consequences.
Therefore, understanding the nature of the relationship between marijuana, psychosis,
and mental health conditions is important to developing evidence-based health policies as
this information can serve to inform policy makers, practitioners, and public health
professionals. This is especially important given the changing attitude and increasing
legalization of marijuana which has led to the production of marijuana strains with higher
levels of THC (Briggs, 2015; Cabrera, 2016).
Currently, 33 states and the District of Columbia plus Guam and Puerto Rico have
passed laws legalizing medical marijuana with 11 of these states and the District of
Columbia also implementing recreational marijuana laws (Governing Data, 2019; Hartig
& Geiger, 2018). However, these laws vary by state. For instance, in addition to
legalization of medical marijuana, California’s Prop 64 measure permits adults that 21
and older to possess up to one ounce of marijuana and grow six plants (Governing Data,
2018). In contrast, states like Georgia have legalized the use of marijuana for medical
purposes only (Governing Data, 2018). The Georgia law which passed on April 16, 2015
allows for the use of cannabidiol (CBD) to treat various medical conditions (Governing
Data, 2018). Some these of these uses include: seizure disorders; sickle cell anemia;
cancer; Crohn's disease; ALS (Lou Gehrig's disease); multiple sclerosis; mitochondrial
disease; and Parkinson's disease (ProCon, 2016). CBD is a compound found in marijuana
that is being used for medical benefits (citation). CBD does not produce the psychoactive
effects caused by tetrahydrocannabinol (THC) also found in marijuana (citation). In fact,
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CBD can serve to counteract the psychoactive effects of THC and is used in treat
marijuana induced psychosis (Niesink & van Laar, 2013).
Prior to legalization, THC levels ranged from a low of 4% to a high of 13%
(Ramaekers et al., 2006). However, since legalization these ranges have increased
dramatically. For instance, growers in Colorado have produce strains that range from a
low of 6% THC to a high of 28% THC in the Williams’ Screaming Gorilla strain
(Cabrera, 2016). While numerous studies have been conducted assessing the lower levels
of THC, fewer studies have been conducted to assess higher levels. In this study, I sought
to address this gap in the research by assessing the effects of rising THC levels in
legalized marijuana on mental health. This study may contribute to positive social change
by informing future generations of the risk associated with highly potent marijuana and
the implications of marijuana legalization on the prevalence of mental illnesses like
depression.
Background
Lab tests reveal that the potency of marijuana in Colorado since legalization is
more than twice as potent as illegal marijuana of the past 10 years and some strains of
legal marijuana is three times as potent (Briggs, 2015). Prior to legalization the levels of
THC were typically below 10%. However, research now indicates that the post
legalization levels of Colorado’s marijuana averages around 18.7 % with some marijuana
strains containing THC levels of 30 % or more (Briggs. 2015). These findings
demonstrate that legalization and relaxation of marijuana policies have created an
environment that has led to increased availability of highly potent marijuana. This fact
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justifies the need to address this gap in the research as most previous studies have been
conducted on lower THC levels prior to legalization.
In 2016, Colorado state legislators made efforts to limit THC levels to 16% by
proposing an amendment (Cabrera, 2016). However, these efforts failed as the
amendment did not get enough support. Among the health and safety concerns addressed,
the effects of THC on adolescent brains was one of the primary concerns of the
proponents of this amendment (Cabrera, 2016). Thus, adolescents are included in the
target population of this study which intends to contribute to positive social change by
making information available to inform and understand the effects on future generations
as a return on investment going forward.
The higher levels of THC have had a serious health toll on inexperienced users.
For instance, according to the Colorado Department of Public Health and Environment,
emergency room visits for marijuana associated conditions, such as psychosis has
increased 29% for all Colorado residents since legalization (Cabrera, 2016). However,
when inexperienced users take in too much of the highly potent marijuana, they are more
likely to experience extreme anxiousness and report feelings of “impending doom” when
compared to the regular heavy marijuana users that have built up a tolerance (Cabrera,
2016). This is evidenced by out of state users that are inexperienced when it comes to the
high levels of THC elicited by Colorado’s legal marijuana (Manella, 2016). Wherein
hospitalizations for out of state visitors has risen dramatically from “78 per 10,000 visits,
to 112 per 10,000 in 2013, to 163 per 10,000 in 2014” reflecting an increase of 109%
between the years of 2012 and 2014 (Manella, 2016, para. 4). Thus, marijuana
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legalization has led to a dramatic increase in hospitalizations especially among the
inexperienced user.
Nevertheless, possible marijuana related hospitalizations for Colorado residents in
2000 prior to medical marijuana legalization (MML) was 575 per 100,000 (Colorado
Department of Public Safety [CDPS], 2016). Between the years of 2001 to 2009 post
MML (but prior to commercialization) the rates of hospitalizations rose to 803 per
100,000 (CDPS, 2016). However, between the years of 2010 to 2013 which reflects post
commercialization of medical marijuana the rates of hospitalization rose dramatically to
1,440 per 100,000 (CDPS, 2016). With the most dramatic increase demonstrated after
retail commercialization between the years of 2014 to June 2015 which demonstrated
“2,413 hospitalizations per 100,000 visits” (CDPS, 2016, p.7). The THC in marijuana
elicit its effects by over activating specific regions of the brain that has highest number of
cells with receptors specific for THC (National Institute of Health [NIH] – Marijuana,
2016). Therefore, marijuana with higher levels of THC would be expected to have a more
profound effect.
The notion that marijuana use is associated with the development of psychosis
and mental health disorders is well founded as previous research has demonstrated that in
addition to psychosis, anxiety and depression are also associated with regular marijuana
use (Moore et al., 2007; Volkow, Ruben, Baler, Compton, & Weiss, 2014). Nevertheless,
relatively few studies have addressed this association since the rise in THC demonstrated
after legalization. The mental health effects are reportedly associated with long-term
marijuana use in susceptible users (Cabrera, 2016). The mental effects may include
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temporary symptoms of hallucinations and paranoia, which are exacerbated in
schizophrenia patients. Another mental health issue associated with marijuana is suicidal
thoughts in teens (Cabrera, 2016). This should be a serious public health concern
especially when considering the rising THC levels which may serve to compound this
problem.
As previously indicated, marijuana laws vary by state. Therefore, the availability
of highly potent marijuana also varies by state as research has demonstrated a spillover
effect of highly potent medical marijuana into the recreational using population
(Salomonsen-Saulel, et al., 2012; Wen, Hockenberry, & Cummings, 2015). This trend
has also been demonstrated in states adjacent to states with medical and recreational
marijuana laws as highly potent marijuana is more readily available in states adjacent to
states with relaxed marijuana laws (Hao & Cowan, 201; Ingold, 2014 7). For instance,
representatives of states like Oklahoma and Nebraska have attempted to sue Colorado
citing that legalized marijuana is spilling over state lines and is more readily available in
these states because of legalization in Colorado (Hao & Cowan, 2017; Ingold, 2014).
This understanding is evidenced in a study by Hao and Cowan (2017) wo posited that
counties bordering states with recreational marijuana legalization (RML) demonstrated a
significant increase in arrests for marijuana possession when compared to counties that
did not border states with RML. Thus, legalization and the relaxation of marijuana
policies have increased distribution of highly potent marijuana. However, Hao and
Cowan (2017) did not find evidence indicating that arrest for the selling and growing
marijuana, DUI arrest, and/or arrest for possession of opium/cocaine are affected by
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RML in border states. Nevertheless, the aim of this current study was intended to assess
the effect of marijuana policy on mental health.
Problem Statement
The level of THC in marijuana has been increasing potency since legalization
began in 2012 (Cabrera, 2016). This is a growing concern since THC elicits the desired
psychological effects most marijuana users seek (Bradford, 2015). Addressing this
concern now is particularly important because at present 33 states and the District of
Columbia have passed laws legalizing the use of marijuana for medicinal purposes
(Governing Data, 2019; NCSL, 2018). With 11 of these states and the District of
Columbia also legalizing recreational marijuana use (Governing Data, 2019; National
Conference of State Legislatures [NCSL], 2019). Due to this widespread legalization,
commercial growers of marijuana have been able to significantly improve the potency
(THC content) of their marijuana containing products (Cabrera, 2016). Thus, states like
Colorado now has one of the highest marijuana potency levels in the United States
(Cabrera, 2016). As commercial growers can now produce marijuana strains with
potency levels that can average between 6% to 28% in THC (Cabrera, 2016).
These higher levels of THC are of concern for researchers and public health
officials as adolescents and young adults may be more affected psychologically
(American Psychological Association [APA], 2015; Meier, 2012). Although numerous
studies have been conducted to assess the effects of low THC levels (4% to 13%), few
studies have been conducted to assess the effects of these higher THC levels (6% to 28%)
(Cabrera, 2016; Ramaekers et al., 2006). Since lower levels of THC have been
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demonstrated to have an impact on health then one would expect higher doses to have a
more profound effect. Nevertheless, since legalization only began recently then time has
not permitted adequate study of the effects associated with high potency marijuana. This
lack of research demonstrates a gap in the knowledge that needs further study. An
indication of this gap is further justified in an article presented by the American
Psychological Association, wherein the author posited that "what's clearly lacking and
sorely needed are studies that look at the effect of increased potency, and different modes
and methods of use, on brain-related measures” (Weir, 2015, p.48). Therefore, further
justify the purpose of the study which is intended to address the effects of marijuana on
mental health conditions since potency has increased.
Addressing the modes and methods of use is another area of concern that may
well provide support for this gap in the research. For instance, one method of use results
in the production of highly concentrated resins (Weir, 2015). These resins contain even
higher concentrations of THC than the high potency marijuana strains that are currently
being produced (Weir, 2015). Thus, resins produced from high potency marijuana would
be expected to have an even higher concentration of THC. Production of these
concentrated resins could further compound the issues surrounding the future of
marijuana use and the potential repercussions on health. The aim of this study is to
provide a broader understanding associated with continued marijuana legalization and
rising THC levels. The results of these efforts may also serve to inform the effects
associated with concentrated resins and other methods of use that increase marijuana
potency.
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NIDA (2016) reported that many marijuana users experience feelings associated
with relaxation and euphoria while other users may experience anxiety, fear, distrust, or
panic. Additionally, higher doses of marijuana have been associated with symptoms of
acute psychosis (NIDA, 2016). These symptoms are more profound and include
hallucinations, delusions, and a loss personal identity (NIDA, 2016). NIDA further
posited that “these effects are more common when too much is taken, the marijuana has
an unexpectedly high potency, or a user is inexperienced” (para. 3). These concerns
provide support and justification for this study which is intended to explore the
relationship between marijuana legalization and the higher levels of THC in marijuana
products and the effects on mental health. The primary gap in the knowledge that this
study intends to address is the effect of marijuana legalization and the relationship
between rising THC levels (intensity of marijuana affects) and any association with
mental illness which has not been studied in a nationally representative sample.
In this study, I assessed the association between the continued widespread
legalization of marijuana on mental health. More specifically, I compared an early period
in marijuana legalization when only a few states had implemented MML to a later period
in marijuana legalization, when several states have MMLs with many also implementing
RML. At this point, it is important to emphasize that MML refers to a comprehensive
medical marijuana program that allows the use of both CBD products and smokable THC
products (National Conference of State Legislatures [NCSL], 2018). However, some
states only have limited CBD laws and these states are not included among states with
comprehensive Medical Marijuana Laws (NCSL, 2018).
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Marijuana has become increasingly more available to the general public as
legalization spreads across the country. Since the implementation of MML, a sort of
quasi-legalization has occurred making highly potent marijuana more available to those
who otherwise might not have access (Salomonsen-Saulel, et al., 2012). Quasilegalization refers to the diversion of MML. More specifically, Salmonsen-Saulel et al.
(2012) describes this diversion of MML as “the process in which a supply of marijuana
recommended for one person is given, traded, or sold to someone else who is not a
registered medical marijuana user” (para. 5). This is process is examined in a study by
Salomonsen-Saulel, et al., (2012), in which the researchers used several tools to measure
and analyze adolescent use of medical marijuana among patients treated at two substance
abuse facilities in Denver, Colorado. The results of this study demonstrated that many
adolescents, approximately 74% of the 164 adolescents in treatment, had used medical
marijuana obtained from registered medical marijuana patients (Salomonsen-Saulel, et
al., 2012). Thus, demonstrating a high rate and widespread pattern of medical marijuana
use by the non-patient recreational using population (Salomonsen-Saulel, et al., 2012).
In 2019, 33 states and the District of Columbia plus Guam and Puerto Rico have
passed laws legalizing medical marijuana, with 11 of these states and the District of
Columbia also implementing recreational marijuana laws (Governing Data, 2019; Hartig
& Geiger, 2018; NCSL, 2019). Table 1 provides a timeline for the legalization of both
medical and recreational marijuana by state. I began with 2008 since I analyzed the years
2008 and 2017 to assess the effects of legalization on mental health. In 2008, only 13
states and the District of Columbia had implemented laws legalizing marijuana use for
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medical purposes only (Governing Data, 2018; NCSL, 2019;). Whereas, in 2019, 33
states and the District of Columbia had medical marijuana laws with 11 of these states
and the District of Columbia also implementing recreational marijuana laws (Governing
Data, 2019; Hartig & Geiger, 2018; NCSL, 2019).
Table 1
Medical & Recreational Marijuana Legalization Timeline by State
Year

Medical Marijuana Laws

Recreational Marijuana Laws

2008

California (1996, 2003);
Alaska, Oregon & Washington (1998);
Maine (1999);
Colorado, Hawaii & Nevada (2000);
Montana & Vermont (2004);
New Mexico & Rhode Island (2007);
Michigan (2008);

2009

New Jersey & Washington D.C.

2010

Arizona

2011

Delaware

2012

Connecticut & Massachusetts

2013

Illinois & New Hampshire

2014

Maryland, Minnesota, & New York

Alaska, Oregon, & Washington D.C.

2016

Arkansas, Florida, North Dakota,
Pennsylvania, & Ohio

California, Nevada, &
Massachusetts

2017

West Virginia

2018

Oklahoma, Missouri, & Utah

Colorado & Washington

Vermont, Michigan

2019
Louisiana
Maine
Note. From “State Medical Marijuana Laws,” by National Conference of State
Legislatures, 2019, Retrieved from http://www.ncsl.org/research/health/state-medicalmarijuana-laws.aspx
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Some states with no marijuana laws approved do allow access for special
situations. For instance, Alabama and Mississippi permit access for severe epileptic
conditions (Governing Data, 2018). Another special situation is Virginia, which enacted
laws years before most states that allow individual possession of marijuana if prescribed
by a physician (Governing Data, 2018). However, federal law does not allow physicians
to prescribe marijuana but, doctors can write a recommendation for medical marijuana
(Governing Data, 2018). In addition, several states have CBD only laws that allow the
use of products that are high in CBDs but low in THC (Governing Data, 2018). At
present, only Idaho, South Dakota, Kansas, and Nebraska do not have access to a public
marijuana program of any type (medical or recreational) (NCSL, 2019). Table 2 provides
a breakdown of states which allow limited medical marijuana products for specific
conditions.
Table 2
Limited Medical Marijuana Products [Low THC/High CBD-cannabidiol]
State

Year

Specific Conditions

Florida

2014 Cancer, and medical conditions or seizure disorders treatable
with low THC products

Kentucky

2014 Intractable Seizure Disorders

Mississippi

2014 Debilitating Epileptic condition or related illness

Missouri

2014 Nonresponsive Intractable Epilepsy

North Carolina 2014 Intractable Epilepsy
South Carolina 2014 Lennox-Gastaut Syndrome; Dravet Syndrome (Severe
Myoclonic Epilepsy of Infancy); or any other form of
Refractory Epilepsy;
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State

Year

Specific Conditions

Tennessee

2014 Intractable Seizure conditions

Utah

2014 Nonresponsive Intractable Epilepsy

Wisconsin

2014 Seizure Disorders

Georgia

2015 Cancer (end stage); Amyotrophic Lateral Sclerosis; Multiple
Sclerosis; Seizure Disorders; Crohn's; Mitochondrial Disease;
Parkinson's; Sickle Cell disease

Idaho

2015 Cancer; Amyotrophic Lateral Sclerosis; Seizure
Disorders; Multiple Sclerosis; Crohn's Disease; Mitochondrial
Disease; Fibromyalgia; Parkinson's Disease or Sickle Cell
Disease

Oklahoma

2015 Minors with Lennox-Gastaut Syndrome, Dravet Syndrome, or
other severe Epilepsy

Wyoming

2015 Intractable Epilepsy or Seizure disorders

Texas

2015

Alabama

2016 Debilitating Epileptic conditions; life-threatening Seizures;
Wasting Syndrome; Chronic Pain; Nausea; Muscle Spasms;
any other sever condition resistant to conventional medicine

Pennsylvania

2016 Amyotrophic lateral sclerosis; Anxiety disorders; Autism;
Cancer, including remission therapy; Crohn’s disease;
Damage to the nervous tissue of the central nervous system
(brain-spinal cord) with objective neurological indication of
intractable spasticity, and other associated neuropathies;
Dyskinetic and spastic movement disorders; Epilepsy;
Glaucoma; HIV / AIDS; Huntington’s disease; Inflammatory
bowel disease; Intractable seizures; Multiple sclerosis;
Neurodegenerative diseases; Neuropathies; Opioid use
disorder for which conventional therapeutic interventions are
contraindicated or ineffective, or for which adjunctive therapy
is indicated in combination with primary therapeutic
interventions; Parkinson’s disease; Post-traumatic stress
disorder; Severe chronic or intractable pain of neuropathic
origin or severe chronic or intractable pain; Sickle cell
anemia; Terminal illness; Tourette syndrome.

Intractable Epilepsy
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State

Year

Specific Conditions

Indiana

2017 Resistant Epilepsy

Virginia
2017 Intractable Epilepsy
Note. From “State Medical Marijuana Laws,” by National Conference of State
Legislatures, 2019, Retrieved from http://www.ncsl.org/research/health/state-medicalmarijuana-laws.aspx; “Wisconsin Medical Marijuana Laws and Regulations,” Americans
For Safe Access, 2019, Retrieved from
https://www.safeaccessnow.org/wisconsin_medical_marijuana_laws_and_regulations;
Marijuana Policy Project (MPP) (2019). “Virginia’s Limited CBD and THC-A Oil Law,”
Marijuana Policy Project, 2019, Retrieved from
https://www.mpp.org/states/virginia/virginias-limited-cbd-and-thc-a-oil-law/; Wenner, D.
(2019). “These 23 conditions can qualify you to get medical marijuana in Pa,” by
Wenner, 2019, Penn Live-Patriot News. September 3, 2019

Purpose
The purpose of this study was to provide a greater understanding of the
relationship between marijuana use, legalization and the availability of highly potent
marijuana and the effects on mental health. As previously indicated, since legalization the
THC level of marijuana can now range from 6% to 28 % as oppose to pre-legalization
lower potency levels that typically ranged between 4% to 13 % (Cabrera, 2016;
Ramaekers, et al., 2006). To my knowledge, there have been relatively few studies
conducted post legalization to investigate the potential effects of higher THC levels.
Thus, the originality of this study or gap in the research associated with this study is
based on the premise that most previous studies were conducted based on pre-legalization
low THC levels. However, these studies may prove to be obsolete to informing the public
and health care professionals in the future especially when considering the rising THC
levels, current trend in attitude and continued legalization of high potency marijuana. I
used quantitative secondary data and logistic regression analysis to assess the association
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between marijuana legalization, highly potent marijuana use and mental health conditions
like depression and suicide ideation (see Center for Disease Control [CDC], 2015).
The results of this study are intended to provide relevant information for future
use to advise and/or inform health care professionals and public health personnel who
deal with the health and medical needs of the THC using population. They are also
intended to inform policy makers in states that have legalized marijuana and those
considering marijuana legalization. The general population may also gain knowledge of
the risk associated with high potency legalized marijuana use from this study.
Theoretical Frameworks
There are several theoretical models developed for understanding drug use, abuse,
prevention, and cessation. For instance, there is a growing body of evidence supporting
the association between self-medicating with marijuana and depression (see Shonesy et
al., 2014). In addition, research supports the use of the social ecological model to
understand substance use and abuse from a multifaceted perspective (American College
Health Association [ACHA], 2018). Therefore, for the purpose of this study, the selfmedication theory of addiction and social ecological model served as the conceptual
framework.
The self-medication theory of addiction developed by Khantzian (1977, 1974), is
a theory with over 30 years of use in research (Hall & Queener, 2007). This hypothesis
suggests that individuals who are afflicted with substance abuse may also have a
predisposition for psychological conditions or psychosis (Burnett & Reiman, 2014). An
example appropriate to the aim of this study is described by Hallowell a physician
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experience with attention deficit hyperactivity disorder (ADHD); (Khantzian, 2003). Per
Hallowell, marijuana has been described as having both stimulating and sedating
properties that appeal to individuals with ADHD (Khantzian, 2003). Thus, individuals
with this condition presumably use marijuana for these properties to counter the
restlessness and emotional instability associated with ADHD (Khantzian, 2003).
In a related study, Shonesy (2014) explored the relationship between mental
health conditions like depression and anxiety, and receptors that respond to THC in the
central nervous system. This system is known as the endocannabinoid system and is
medicated by two cannabinoid receptors, CB1 & CB2 (Shonesy et al., 2014). These
receptors respond to both endogenous and exogenous stimulation (Shonesy et al., 2014).
Natural endogenous stimulation of CB1 receptors occurs through one of two THC-like,
anandamide (AEA) and 2-arachidonoylglycerol (2-AG) (Shonesy et al., 2014). According
to Shonesy et al., this system “is heavily implicated in the modulation of anxiety and
depression” (p. #). For instance, the THC in marijuana is capable of binding CB1
receptors of the system and affecting mood (Shonesy et al., 2014). Such that reduced
stimulation of these receptors results in mood destabilization and increased feelings of
anxiety and depression (Shonesy et al., 2014). Thus, marijuana users who suffer from
these conditions may not be able to synthesize enough of THC-like molecules
(particularly 2-AG) so they use marijuana to compensate (Shonesy et al., 2014). Research
suggests that individuals may actually self-medicate without knowing it to compensate
for their inherent low levels of THC-like molecules (Curry, 2014; Shonesy et al., 2014).
These concepts are revisited in Chapter 2.
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In contrast, the social ecological model (SEM) is a theory-based multifaceted
approach to understanding the dynamics associated individual and population level
determinants of health (American College Health Association [ACHA], 2018). The SEM
theorists recognize that health is determined by influences from multiple societal and
environmental factors that affect the individual (ACHA, 2018). According to SEM, the
dynamic interrelationships between five levels or factors of health determinants are
significant and essential to the health behaviors of the individual (ACHA, 2018). These
five levels include (a) individual, (b) interpersonal, (c) organizational/institutional, (d)
community, and (e) policy (CDC-SEM, 2018). The first level is concerned with
sociodemographic (i.e., age, gender, religion, etc.) and intrapersonal factors or
characteristics such as knowledge, beliefs, attitudes, and behaviors of the individual that
affect health decisions and outcomes (ACHA, 2018; CDC-SEM, 2018). The second or
interpersonal level is concerned with close personal relationships or associates that
influence the behavior and contributes to the life experience of the individual (ACHA,
2018; CDC-SEM, 2018). This can include family members, friends, coworkers, health
care providers, and community health workers (ACHA, 2018; CDC-Socioecological
Model [SEM], 2018). The third level is concerned with local organizations and
institutions that affect individual and population health by influencing organizational
systems and policies (ACHA, 2018; CDC-SEM, 2018). This includes health care
systems, state and local health departments, professional organizations, and healthcare
plans (ACHA, 2018; CDC-SEM, 2018). The fourth level explores community and social
relationships that influence individual health determinants. This can include
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employers/worksites; businesses such as bars and restaurants; community-based
organizations; the media; and community; state; and regional organizations (ACHA,
2018; CDC-SEM, 2018). The final or fifth level is associated with interpreting and
implementing local, state, national, and federal laws and policies (ACHA, 2018; CDCSEM, 2018). This level is of particular interest to this study especially given the current
trend in marijuana policies that favor relaxed laws and increased community acceptance
of legalization for recreational and medicinal purposes. Therefore, this model can be used
to inform states’ local marijuana policies and may serve to inform the implementation of
federal laws and regulations as well.
Research Questions
RQ1: Is marijuana use associated with depression and suicidal ideation in adults
in 2008 and 2017, either in isolation using raw (unadjusted) values or using values
adjusted for age, sex, annual family income, and education?
RQ2: Is marijuana use associated with depression and suicidal ideation in
adolescents in 2008 and 2017, either in isolation using raw (unadjusted) values or using
values adjusted for age, sex, annual family income, and education?
RQ3: Are the associations between marijuana use and depression and between
marijuana use and suicide ideation higher in 2017 than in 2008 for both adults and
adolescents, either in isolation using raw (unadjusted) values or using values adjusted for
age, sex, annual family income, and education?
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Study Hypotheses
In accordance with the study research questions, the hypotheses for this study,
each stated in null form, were as follows.
For the 2008 data:
H01: There will be no statistically significant relationship between marijuana use
and depression (major depressive episode in the last year) in the adult 2008
cohort, either in isolation using raw (unadjusted) values or using values adjusted
for age, sex, annual family income, and education.
H02: There will be no statistically significant relationship between marijuana use
and suicidal ideation in the adult 2008 cohort, either in isolation using raw
(unadjusted) values or using values adjusted for age, sex, annual family income,
and education.
H03: There will be no statistically significant relationship between marijuana use
and depression (major depressive episode in the last year) in the adolescent 2008
cohort, either in isolation using raw (unadjusted) values or using values adjusted
for age, sex, annual family income, and education.
H04: There will be no statistically significant relationship between marijuana use
and suicidal ideation in the adolescent 2008 cohort, either in isolation using raw
(unadjusted) values or using values adjusted for age, sex, annual family income,
and education.
For the 2017 data:
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H05: There will be no statistically significant relationship between marijuana use
and depression (major depressive episode in the last year) in the adult 2017
cohort, either in isolation using raw (unadjusted) values or using values adjusted
for age, sex, annual family income, and education.
H06: There will be no statistically significant relationship between marijuana use
and suicidal ideation in the adult 2017 cohort, either in isolation using raw
(unadjusted) values or using values adjusted for age, sex, annual family income,
and education.
H07: There will be no statistically significant relationship between marijuana use
and depression (major depressive episode in the last year) in the adolescent 2017
cohort, either in isolation using raw (unadjusted) values or using values adjusted
for age, sex, annual family income, and education.
H08: There will be no statistically significant relationship between marijuana use
and suicidal ideation in the adolescent 2017 cohort, either in isolation using raw
(unadjusted) values or using values adjusted for age, sex, annual family income,
and education.
For comparing 2008 and 2017 data:
H09: There will be no statistically significant increase in the strength of the
relationships between marijuana use and depression (Major Depressive Episode in
the last year) in the adult 2017 cohort compared to the adult 2008 cohort.
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H010: There will be no statistically significant increase in the strength of the
relationships between marijuana use and suicidal ideation in the adult 2017 cohort
compared to the adult 2008 cohort.
H011: There will be no statistically significant increase in the strength of the
relationships between marijuana use and depression (Major Depressive Episode in
the last year) in the adolescent 2017 cohort compared to the adolescent 2008
cohort.
H012: There will be no statistically significant increase in the strength of the
relationships between marijuana use and suicidal ideation in the adolescent 2017
cohort compared to the adolescent 2008 cohort.
Nature of the Study
For this study, I used a quantitative secondary data analysis using archived data.
Logistic regression was used to assess the association between the predictor variable,
marijuana and the response or outcome variable, mental health (see CDC, 2015). The
analysis also used multiple logistic regression to analyze any associations between “no
marijuana use” and “marijuana use” on mental health conditions like depression and
suicide ideation based on national marijuana legality status. The study considered
increasing marijuana potency that has risen drastically since legalization as a potential
reason for increased mental health conditions from marijuana use (see CDC, 2015). The
study data for 2008 and 2017 were collected by the National Survey on Drug Use and
Health (NSDUH) datasets, which consisted of responses from 67,928 and 68,032
participants respectively, in the target population sample sizes (National Survey on Drug
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Use and Health [NSDUH]-codebook, 2008; NSDUH-codebook, 2017). These were
noninstitutionalized civilians 12 years and older living in the United States at the time of
the survey (NSDUH-codebook, 2008; NSDUH-codebook, 2017).
Operational Definitions
Throughout this dissertation, terminology specific to this topic may not be
familiar to the reader. Therefore, the following terms have been defined for clarification:
2-arachidonoylglycerol (2-AG): A natural ligand, 2-arachidonoylglycerol
specifically activates CB1 receptors of the endocannabinoid system (Shonesy et al.,
2014) Low levels of this ligand are associated with increase anxiety and depression as
demonstrated in animal and human studies (Shonesy et al., 2014).
Anandamide (AEA): Anandamide is a THC-like ligand found naturally
(endogenous) in the human body interacts with cannabinoid receptors of the
endocannabinoid system (Shonesy et al., 2014).
Cannabidiol (CBD): Cannabidiol is a cannabinoid found in cannabis (marijuana)
and is preferred for its medicinal value and is used to treat various conditions(Atakan,
2012). CBD also interacts with the endocannabinoid system of the body (Atakan, 2012).
However, CBD does not bind CB1 receptors and therefore does not have psychoactive
properties. CBD is used to reverse effects of marijuana-induced psychosis (Atakan,
2012).
Cannabis: Cannabis refers to a subspecies of plant, Cannabis Indica and
Cannabis Sativa of which C. Sativa is preferred by users for its high THC content
(Atakan, 2012).
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Δ9-tetrahydrocannabinol (THC): one of many cannabinoids found in cannabis
(marijuana) and is primarily responsible for the psychoactive effects that recreational
users seek (Atakan, 2012). Binds to CB1 receptors in the brain and central nervous
system acting as a partial agonist to elicit its effects (Atakan, 2012).
Dabbing: Dabbing is a slang term used to describe a method of using marijuana
concentrates (i.e. wax) that involves conduction as the form of heating (Krauss et al.,
2015). In this process the user heats the dab (marijuana or BHO concentrate) to a high
temperature using a torch on a conduction surface or “hot plate” which is typically a nail;
the user then inhales the vapor produced (Krauss, et al., 2015).
Depression: Depression is operationally defined as a state of an individual “who
reported that during the past 12 months they had a period of depression lasting 2 weeks or
longer, while also having some of the other symptoms mentioned, were classified as
having past year depression” (NSDUH-codebook, 2015, p. 848).
Endocannabinoid system: Endocannabinoid system “refers to endocannabinoids
and the proteins that regulate their production and degradation, as well as to the receptors
through which they signal” (Silvestri & Di Marzo, 2013, para. 2).
Endogenous: Endogenous refers to the bodies naturally occurring ligands,
molecules, and substances (Onaivi, Sugiura, & Di Marzo, 2005; Shonesy et al., 2014).
Such as the naturally occurring cannabinoids that interact with the endocannabinoid
system (Onaivi, Sugiura, & Di Marzo, 2005; Shonesy et al., 2014).
Exogenous: Exogenous refers to ligands, and other molecules and substances that
are produced outside the body but are capable of interacting within the body (Onaivi,
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Sugiura, & Di Marzo, 2005; Shonesy et al., 2014). Such as the THC in marijuana that
interacts with receptors of the endocannabinoid system (Onaivi, Sugiura, & Di Marzo,
2005; Shonesy et al., 2014;).
Marijuana (aka cannabis): Marijuana “refers to the dried leaves and flowers from
the cannabis plant which contain the mind-altering chemical delta-9tetrahydrocannabinol (Δ9-THC) and other related compounds” (Addiction Policy Forum,
2019, para. 1).
Marijuana use: For the purpose of this study, marijuana use refers to frequency of
use and states legality status (only medical marijuana legal; both recreational and medical
marijuana legal; no legal marijuana status), as detailed in Chapter 3.
Rhabdomyolysis: Rhabdomyolysis is muscle injury/damage leading to breakdown
and release of these contents which can in turn serious health complications such as renal
failure (WebMD, 2019).
Schedule I Narcotic: A Schedule I Narcotic is a substance or chemical that does
not have a currently accepted medical use and has a high potential for abuse (Drug
Enforcement Agency, 2018). Examples of these drugs/narcotics include: marijuana,
heroin, lysergic acid diethylamide (LSD), ecstasy (3,4methylenedioxymethamphetamine), methaqualone, and peyote (DEA, 2018).
Vaping: Vaping is a slang term used to describe a method of using marijuana,
marijuana products such as butane hash oil (BHO), CBD oils, synthetic marijuana and
nicotine use in e-cigarettes (Budney, Sargent & Lee, 2015; Yang et al., 2018). During the
vaping process, the substance to be used (liquid, oil, or plant material) is vaporized using
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convection heat which releases the aerosolized active ingredients of the desired substance
(i.e. THC) in the form of a water vapor mixture that is inhaled by the user (Budney,
Sargent & Lee, 2015; Lepkoff, 2018; Yang et al., 2018).
Assumptions
There are several assumptions associated with this study that must be considered
when reviewing the results. The first two assumptions are concerned with the sampling
method as this study used secondary data. Therefore, one assumption is that the NSDUH
survey provides an adequate national sample that is representative of the U.S. population.
Second, since the NSDUH survey uses self-reporting then recall bias and honesty in
survey responses are a serious concern. I therefore assumed that research participants
answered questions truthfully and to the best of their ability, as recall bias and dishonest
answers can limit the reliability and of study results (see Davis et al., 2013). Another
assumption is concerned with the legal status of states under consideration and their
geographical location to other states with differing laws. This is an important concern, as
states with relaxed marijuana laws and policies that border states without marijuana laws
may significantly affect the data obtained in the states without marijuana laws. I assumed
that bordering states had no effect and the marijuana laws in the state of interest is the
primary source of influence on the data obtained in the NSDUH survey.
Scope and Delimitations
The scope of this study was concerned with the association between legalization
and the relaxation of marijuana policies that have made high potency marijuana more
readily available. This study was intended to assess the effect of marijuana policy on
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mental health. The study was limited to respondents of the 2008 and 2017 NSDUH,
which included 67,928 and 68,032 respondents respectively, in the target population
sample sizes (NSDUH-codebook, 2008; NSDUH-CODEBOOK, 2017). These were
noninstitutionalized civilians 12 years and older living in the United States at the time of
the survey (NSDUH-codebook, 20008; NSDUH-CODEBOOK, 2017).
Limitations
There are a several limitations associated with this study. First, since this study
used secondary data, one possible limitation is residual confounding which can occur
when variables that are critical to the current study have been omitted from the data set
being used (see LaMorte & Sullivan, 2016). For instance, variables deleted to protect the
confidentiality of the respondents. Therefore, data such as race, names of respondents,
and zip codes that are important to the intended study may have been deleted. Residual
confounding can also occur when data collected on variables of interest is not precise
enough for the current study, or when no attempt is made to adjust for confounding
factors as would be the case when critical variables are not included in the dataset
(LaMorte & Sullivan, 2016). Another limitation is associated with the NSDUH survey
which uses self-reporting to gather data on the participants. This is a concern because the
reliability of self-reporting on sensitive issues like substance use and mental health issues
is questionable as respondents may not be truthful due to the potential stigma associated
with substance use (Davis et al., 2013). In addition, self-reporting may also be subject to
recall bias and memory bias that would further limit the reliability of study results.
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(Hasan, 2005). And finally, the cross-sectional nature of this study may limit inferences
on causality as observations are made at one point in time (Davis et al. (2013).
Additionally, there is another potentially limiting factor associated with the
NSDUH. The survey does not differentiate between the marijuana patient and nonpatient
populations participating in the study (Wen, Hockenberry, & Cummings, 2015). Thus,
the spillover effect may not solely reflect an increased marijuana use among registered
marijuana patients as the non-patient or recreational using population may potentially
contribute to a greater percentage of the individuals participating in the study (Wen et al.,
2015). This limitation is evidenced in a study by Wen et al. (2015) which indicates that,
among the states studied with MMLs, medical marijuana patients comprised only 0.8% of
the total population.
Significance of the Study
There is a growing body of evidence supporting the association between cannabis
use and the development of psychosis and mental health disorders (Moore et al., 2007).
However, few studies have addressed this association since the rise in THC demonstrated
post legalization. From a public health stance, addressing this concern is essential as
individual with marijuana use disorder are likely to continue use despite findings of
clinically significant conditions such as mental health disorders (NIDA, 2016). For many
years, substance abuse and substance dependence were considered two separate
categories. However, in 2013 the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) was updated such that abuse, and dependence are classified under the category
of substance use disorder (NIDA, 2016). In this case marijuana or cannabis use disorder.
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Note, throughout this paper the terms marijuana and cannabis are used interchangeable
and considered to have the same meaning. This will become evident as some scholarly
sources used in the literature and other areas of this study use cannabis whereas other
sources use marijuana.
Volkow et al., (2014) posited that previous research has demonstrated that
anxiety, depression, and psychosis are associated with regular marijuana use. However,
causality is not well founded as addressing this association is hindered by confounders
that also contribute to the development of these conditions (Volkow et al., 2014). For
instance, individuals with a family history of schizophrenia and psychosis have a greater
risk of developing these conditions (Volkow et al., 2014). In addition, heavy use of
marijuana, highly potent marijuana, and using marijuana at an early age also exacerbate
the occurrence of mental health conditions like psychosis (Volkow et al., 2014). These
findings provide additional support for the current study which intends to explorer the
effects of marijuana legalization on rising THC levels (increased drug potency) and
mental health conditions, such as depression and suicide ideation psychosis and mental
illness.
Furthermore, several studies have demonstrated that heavy marijuana use has the
potential to cause psychosis or exacerbate a pre-existing psychotic illness (Bushak, 2013;
Sevigny, Pacula, & Healon, 2014). Bushak (2013) listed the following symptoms of
marijuana induced psychosis: hallucinations, paranoia, confusion, and anxiety. One
would expect marijuana with higher THC levels to have a more profound effect. This
assumption was demonstrated in a study which found that in areas where marijuana was
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legalized there was a statistical correlation between increased THC levels and hospital
admissions for marijuana induced psychosis (Bushak, 2013). This conjectured
relationship between marijuana use and psychiatric illness is an established area of
interest. Previous epidemiological studies have demonstrated that there is an increased
risk of developing psychiatric disorders such as schizophrenia, associated with increased
frequency of marijuana use (see Kahn & Akella, 2009). Studies have also demonstrated
that marijuana is the most commonly abused substance among individuals diagnosed
with bipolar disorder (Kahn & Akella, 2009). In addition, Kahn and Akella (2009)
indicated that short-term, intense use of marijuana can produce exacerbations of
psychotic symptoms in those with preexisting conditions. In a related study, researchers
surveyed marijuana users to assess the association between marijuana and the occurrence
of psychotic like symptoms (Kahn & Akella, 2009). The results of this study revealed
that psychosis-like symptoms were demonstrated in 15% of survey respondents (Kahn &
Akella, 2009). The most common symptoms reported included hearing voices and
unwarranted feelings of persecution (Kahn & Akella, 2009). Additional related symptoms
of acute marijuana intoxication include depersonalization, fear of dying, irrational panic,
and paranoid ideas (Kahn & Akella, 2009). Thus, knowing how marijuana effects
psychosis is also important to informing the community as well as health care and public
health professionals.
As indicated, previous studies have demonstrated that brief episodes of psychosis
can lead to more serious psychotic disorders, such as schizophrenia, which causes the
most severe health loss of all human disorders affecting how these individuals think, feel,
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and behave, and many of these patients seem to lose touch with reality (NIH, 2016). This
disorder not only impacts the health of the individual but also impacts the community and
effects public health (NIH, 2016), (Schoeler, Petros, & Forti, 2016). Thus, knowing how
marijuana effects mental health is particularly important to the formulation of evidencebased health policies concerned with marijuana use (Schoeler et al., 2016). This is
especially important considering changing public attitudes and continued legalization of
marijuana (Schoeler et al., 2016). In addition, psychotic disorders such as schizophrenia
are associated with a significant financial burden and are also associated with a high rate
of comorbid abuse of marijuana (Schoeler et al., 2016). Therefore, knowing how
marijuana effects mental conditions is important to inform policy makers and
practitioners to reduce the burden of these conditions and the impact on the health of
individual users, as well as public health, and the community at large (Schoeler et al.,
2016). Furthermore, understanding the potential effects of increasing THC levels is
essential as most studies addressing these concerns were conducted based on prelegalization lower THC levels.
As previously stated, this research project addressed a gap in the literature by
providing a better understanding of the relationship between marijuana legalization,
highly potent marijuana, and the indicated variables associated with mental conditions
like depression and suicide ideation. The results of this study can support professional
practice by expanding the body of knowledge available to health care and public health
professionals, thereby informing the practical applications addressing this concern. In
addition, as indicated practical applications of the research may be demonstrated in the
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form of policy making and the development of informational campaigns. These efforts
may also serve in the development of training programs for personnel involved with
informing the public about the responsible use of marijuana.
Finally, it is also important to understand that the effects of marijuana have a
more profound neurological effect in those who started persistent use at an early age
versus those who started smoking in adulthood (APA, 2015). Studies have also
demonstrated that approximately 9% of adults who use marijuana become addicted
versus 17% for those who began smoking as teenagers (Weir, 2015). Thus, marijuana
producers have added incentive to market their product to younger users. (Weir, 2015).
Therefore, I focused on younger generations for this study with the premise of effecting
positive social change as a return on investment in future generations. In addition, this
study is intended to contribute to positive social change by providing information
relevant to informing the development of policy on states marijuana legality status and
the development of evidence-based health policies as well as training programs for
personnel involved with informing the public about the responsible use of marijuana.
Summary and Transition
Marijuana use is associated with both mental health issues and psychosis or
psychotic events (Moore et al. 2007). Nationwide marijuana laws vary by state as 33
states and the District of Columbia plus Guam and Puerto Rico have passed laws
legalizing medical marijuana with 11 of these states and the District of Columbia also
implementing recreational marijuana laws (Governing Data, 2019; Hartig & Geiger,
2018). Wherein, widespread marijuana legalization and the relaxation of marijuana
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policies has made high potency marijuana more readily available (Sevigny et al., 2014).
This study is intended to assess the effect of marijuana policy on mental health conditions
like depression and suicide ideation. Chapter 2 will provide a more detailed synthesis of
available literature related to the epidemiology of marijuana use and the effects on mental
health and psychosis. In Chapter 2, the following topics are discussed: history of
marijuana, marijuana in the United States, health effects of marijuana use, marijuana
legalization and potency, marijuana and mental health disorders, marijuana and
psychosis, therapeutic effects of marijuana on mental health, the endocannabinoid
system, and lessons learned from states with legalized marijuana.
Chapter provides an in-depth description of the research design and statistical
analysis of the NSDUH data set. In addition, Chapter 4 presents an analysis of the data
explored. And finally, Chapter 5 presents the final summary of these findings, provide a
discussion, comparison to current literature, and addresses recommendations for future
research.
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Chapter 2: Literature Review
Introduction
In the United States, substance abuse and addiction cost the American taxpayer
over $700 billion dollars a year (NIDA, 2016). This spending is related to the increased
cost of health care, loss of productivity and earnings in the workplace, and crime
associated with theft, drugged driving, accidents, violence, and child abuse (NIDA, 2016;
NIDA-Magnitude, 2017). The consequences of substance abuse are evidenced by
approximately 90,000 Americans that die every year as a result of illicit and prescription
drug and alcohol use (NIDA, 2016). Thus, substance abuse is an important public health
concern that has a prodigious impact on our society.
Among the substances of abuse, marijuana is by far the most commonly used as n
2018, approximately 43 million Americans reportedly used marijuana in the past year
(Statista, 2019). Among these were approximately 11.8 million young adults that reported
using marijuana in the past year in 2018(NIH-NIDA, 2019). Additionally, marijuana is
second only to alcohol for the highest rates of dependence and abuse, and in 2013
statistics indicated that with exception to marijuana and methamphetamine, the rate of
use for all other drugs had stabilized or declined (NIDA-Nationwide Trends, 2015). This
includes prescription drugs (i.e. pain relievers, tranquilizers, stimulants, and sedatives);
hallucinogens (i.e. ecstasy and LSD); and cocaine (NIDA-Nationwide Trends, 2015).
And as indicated, methamphetamine use increased between 2010 to 2013 (NIDANationwide Trends, 2015).
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In 2016, the NIDA reported the following rates of marijuana use among high
school students: “5.4 percent among 8th graders, 9.8 percent among 10th graders, and
14.3 percent among 12th graders” (NIDA-Monitoring the Future Survey, 2016, p. or
para. #). In contrast, the overall trend for “past-year prevalence of marijuana use was
4.1% (SE, 0.15) in 2001-2002 and 9.5% (SE, 0.27) in 2012-2013, a significant increase
(P < .05)” (Hasin et al., 2015, p. #). An interesting finding that may prove relevant to this
current study is that the highest rates of marijuana use was observed in states where
marijuana has been legalized for medicinal purposes (NIDA-Monitoring the Future
Survey, 2016).
This quantitative study focused on the use of high potency marijuana and the
association with mental health disorders as it pertains to state marijuana legality status
after controlling for age, sex, and socioeconomic status. Since the legalization of
marijuana, the level of THC has been rising in medical and recreational marijuana
(Cabrera, 2016). Thus, the purpose of this study is to provide a better understanding of
the relationship between highly potent marijuana use and the indicated variables—
depression and suicide ideation. The level of THC in marijuana has been increasing in
potency since legalization began in 2012 (Cabrera, 2016). Since THC elicits the desired
psychological effects most marijuana users seek, addressing this concern now is
particularly important. Additionally, as of 2019, 33 states and the District of Columbia
plus Guam and Puerto Rico have passed laws legalizing medical marijuana with 11 of
these states and the District of Columbia also implementing recreational marijuana laws
(Governing Data, 2019; Hartig & Geiger, 2018).
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Literature Review Strategy
Part of my strategy for this literature review included using the following search
terms and/or phrases: marijuana; THC levels; mental health disorders; psychosis;
substance use, abuse and misuse; marijuana and THC levels; THC levels and
legalization; marijuana and mental health disorders; history of marijuana; health effects
of marijuana; marijuana and psychosis; adolescents, young adults and marijuana; at risk
behavior; personality traits; quasi-legalization; de facto legalization of marijuana;
marijuana distribution and trafficking; methods of marijuana use; vaping; dabbing; and
consumption of marijuana/cannabis-infused edibles. The search was limited to articles or
text written in English from the following search engines or sources: Google and Google
Scholar, Walden University library, ProQuest, SAGE Premier, Academic Premier
database, MEDLINE, CINHAL Plus, and Science Direct Database.
This literature review also includes a history of marijuana in the United States,
which will cover drug scheduling or classification, consumption, and medicinal use. In
addition, the literature review was organized to discuss the following topics: physical,
psychological and pharmacological effects of marijuana; an understanding of mental
health and psychosis; rising THC levels and improved growing techniques since
legalization; increasing/Rising emergency room and hospitalizations post legalization and
association with rising THC levels (pre- vs. post legalization comparisons); marijuana
and employment in zero tolerance environments (post legalization); marijuana and public
health; substance use versus abuse; trends in marijuana consumption; at risk groups (high
usage groups & age ranges); implications of marijuana legalization; previous studies on
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association between marijuana, mental health disorders and psychosis; and marijuana
distribution and preference.
History of Marijuana
Understanding the history of marijuana is an important aspect of this study. Thus,
human consumption and utilization of marijuana (cannabis) began around 10,000 BC
during the Neolithic period or the “dawn of agriculture” (Lee, 2012, p. 3). These early
people realized the versatility of this resource and cultivated marijuana making use of the
entire plant for various purposes. For instance, Lee (2012) posited that the plant’s stem
and stalk are rich in fiber and were utilized to make cords/rope and clothing; the seeds in
addition to providing a source for continued cultivation were also eaten as this portion of
the plant provided a source of protein and essential fatty acids; finally, the roots, leaves,
and flowers were utilized for both medicinal and ritualistic purposes. While the plant is
native to central Asia, knowledge of its multiple uses as a tough fiber and therapeutic
agent gradually spread around the world. Thus, use of this plant or herb spread from its
early origins in the Kush region of the Himalayan foothills across Eurasia into northern
Europe and beyond (Lee, 2012). Documentation of marijuana for medicinal purposes
occurred in 2008, when a gravesite in northwest China was discovered containing well
preserved marijuana flower tops. These flower tops contained THC, the psychoactive and
pharmacological agent of marijuana (Lee, 2012). The researchers concluded that this was
a demonstration that the plant was being cultivated for its psychoactive properties nearly
27 centuries ago (Lee, 2012). This determination is supported by Chinese history dating
back to 2700 BC during the reign of Emperor Shen Nung, commonly called the father of
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traditional Chinese medicine (Lee, 2012). During this period, marijuana was introduced
as a drinking tea that was utilized for a host of ailments (Lee, 2012). According to Lee
(2012), a few of these uses included “female weakness; gout; rheumatism; malaria;
constipation; beri-beri, and absent-mindedness” (Lee, 2012, p.5). Thus, marijuana has a
long-standing history with many uses among several cultures throughout the world.
Marijuana in the United States
In the United States, marijuana has experienced a controversial and highly
debated path. For many years during the 1800s and early 1900s, marijuana had multiple
medicinal uses in Western world medicine (Thomas, 2010). During this time, over 100
articles were published in American and European medical journals enthusiastically
praising the herb’s (marijuana) medicinal purposes (Thomas, 2010). In fact, in the United
States marijuana was specifically recommended for several medical conditions and was
prescribed on a regular basis until the late 1930s when the Marijuana Tax Act of 1937
was enacted (Thomas, 2010). This action resulted in a tax on marijuana for both medical
purposes ($1 per ounce) and recreational or other purposes ($100 per ounce) Thomas,
2010). This tax act was viewed as deception by artful subterfuge in the form of a health
care policy that required the completion of arduous and burdensome amounts of
paperwork required to prescribe marijuana (Thomas, 2010). The process became so
troublesome that physicians eventually stopped prescribing marijuana not long after the
enactment of the Tax Act of 1937 (Thomas, 2010).
Then in 1970, during the Nixon administration, the Controlled Substance Act
(CSA) was signed into law (Thomas, 2010). This action placed regulated substances into
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one of five categories or schedules based on the substances medicinal value, potential for
abuse, and psychological and physical effects (Thomas, 2010). Marijuana was initially
placed in the Schedule I category, which is the highest category and the only one that
prohibits all use of the substance whether medicinal or recreational. Other drugs placed in
a schedule I category include: “heroin; ecstasy; Lysergic acid diethylamide (LSD); (γHydroxybutyric acid) GHB; and peyote” (Thomas, 2010, para. 8). In contrast, the
following substances were placed in a less restrictive Schedule II category, that allows
medicinal use by prescription: “cocaine; codeine; OxyContin; and methamphetamine”
(Thomas, 2010, para. 8). However, marijuana’s categorization as a Schedule I narcotic
was intended to be temporary pending additional reconsideration based on an upcoming
report from the National Commission on Marijuana and Drug Abuse (Thomas, 2010).
This study group was comprised of members appointed and commissioned by President,
Nixon. The group was in favor of decriminalizing marijuana for personal possession and
private use as well non-profit private distribution of the substance in small amounts
(Thomas, 2010). However, President Nixon was adamantly opposed to this decision.
Ultimately the president’s opinion prevailed and to this day marijuana remains a
Schedule I narcotic. Being classified as a Schedule I Narcotic means that the substance is
not recognized as having any medical use in the United States (U.S. Department of
Justice, 2017). It also means that the substance has a high abuse potential and cannot be
used safely even under medical supervision (U.S. Department of Justice, 2017). Schedule
I narcotics are considered the most dangerous and as a substance scheduling numeral
increases, the less dangerous they are considered (U.S. Department of Justice, 2017). For
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instance, substances classified as Schedule II Narcotics are considered less dangerous
than those classified as a Schedule I Narcotic with drugs classified as Schedule V
Narcotics being the least dangerous.
Health Effects of Marijuana Use
A current trend in attitude favoring marijuana use for medical and recreational
purposes is growing. This is evidenced by reports indicating a decline in individuals who
consider the occasional use (1-2 times per week) of marijuana as a perceived risk
(Schuermeyer et al., 2014). For instance, in Colorado the percent of a those who believe
marijuana use is a perceived risk declined from 45% to 31% between groups studied from
2007 to 2008 and those studied from 2010 to 2011, respectively (Schuermeyer et al,
2014). This trend was consistent for all age groups studied during these time frames.
While medical marijuana was approved in Colorado in November 2000, it was not until
2012 that residents of Colorado voted for Amendment 64 legalizing marijuana for
recreational use as 55% of voters approved (Monte, Zane & Kennon, 2015).
In light of this current trend in marijuana liberalization, it is important for policy
makers, public health, and health care personnel to emphasize or reiterate the potential
adverse effects of the substance. This is especially important given the rising THC levels
seen in recreational marijuana and products produced from marijuana. It is also
reasonable to assume that as legalization gains greater acceptance the use of marijuana
will also increase and therefore so will the occurrence of adverse effects.
The adverse effects of marijuana include a host of considerations. For instance,
despite the notion that marijuana is not addictive, evidence to the contrary is widely
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available and risk of dependence is based on several factors (Volkow, Baler, Compton,
Weiss, 2014). This understanding is based on the dependence criteria outlined in the
Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV). The DSM-IV
dependence criteria indicate that approximately nine percent or 1 out of 11 individuals
who experiment with marijuana will become addicted (Volkow et al., 2014). In contrast,
for those who begin using marijuana in adolescents, approximately 16% or one out of six
will become addicted and the same is true for approximately 25 to 50% of those who
smoke marijuana daily (Volkow et al., 2014). Thus, among other factors the risk of
dependence is based on age of initial use and regularity of use. However, these criteria
were presumably set prior to or does not take into consideration the rising THC content
of marijuana. Hence, demonstrating support for this current study which intends to
address this gap in the literature (rising THC levels). This presumption is further
supported by NIDA which posited that
Researchers do not yet know the full extent of the consequences when the body
and brain (especially the developing brain) are exposed to high concentrations of
THC or whether the recent increases in emergency department visits by people
testing positive for marijuana are related to rising potency. (NIDA – Marijuana,
2017, p. 16)
Addiction to marijuana is associated with the body’s endocannabinoid system of
neurotransmitters within the brain. This system is concentration dependent such that large
amounts of marijuana can result in reduced sensitivity of this system which causes an
increased dependence on marijuana. (NIDA-Marijuana, 2017).
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When someone smokes or ingest marijuana, there are effects on both cognitive
and motor functions. These effects can range from impairments associated with memory
and perception of time to impairments in coordination (Volkow et al., 2014). Regular use
can have long term consequences that affect education and professional accomplishments
as well as affect one’s social interaction (Volkow et al., 2014). These effects can be
hazardous to the public as marijuana intoxication can affect one’s ability to drive and
therefore operate machinery. This is evidenced by driving simulation studies which
demonstrate a dose dependent relationship between blood THC concentration and an
increased risk of getting involved in an accident while driving (Volkow et al., 2014). The
statistical analysis presented in Volkow et al. (2014) indicated that
Persons testing positive for THC (typical minimum level of detection, 1 ng per
milliliter), and particularly those with higher blood levels, were 3 to 7 times as
likely to be responsible for a motor-vehicle accident as persons who had not used
drugs or alcohol before driving. (para. 12).
Add summary and synthesis to fully integrate the quote into the paragraph and create a
solid conclusion.
Consequently, marijuana has promising clinical applications for treatment of
various conditions. According to Volkow et al. (2014) the following conditions are
receptive to treatment with marijuana or other form of cannabinoid: “Glaucoma, Nausea,
AIDS – associated anorexia and wasting syndrome, Chronic pain, Inflammation, and
Multiple sclerosis” (Volkow et al., 2014, para. 1-7). These are only a few of the
medicinal uses of marijuana as the substance has shown to be beneficial for many more.
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Marijuana Legalization and Potency
Lab test reveal that the potency of marijuana in Colorado since legalization is
more than twice as potent as illegal marijuana of the past ten years and some strains of
legal marijuana is three times as potent (Briggs, 2015). Prior to legalization the levels of
THC were typically below ten percent. However, research now indicates that the post
legalization levels of Colorado’s marijuana averages around 18.7 % with some marijuana
strains containing THC levels of 30% or more (Briggs. 2015). These results were
provided by Charas Scientific, a Denver based lab licensed and hired by the state to test
and measure the THC levels of marketable marijuana (Briggs, 2015).
Samples were also tested for the amount of cannabidiol (CBD), which is the
component in marijuana with medicinal value. These samples averaged around 0.1
percent CBD and many families have relocated to Colorado to obtain a strain of
marijuana referred to as ‘Charlotte’s Web’, which reportedly can control seizures due to
its CBD concentration (Briggs. 2015). Thus, while CBD has the potential to control
depression, anxiety, and pain; a product with little CBD that has high THC levels could
potentially exacerbate these conditions and may even increase seizures (Briggs, 2015).
In a related study, Sevigny, Pacula & Heaton (2014) addressed the potency of
medical marijuana that has reportedly increased since legalization. This increase in
potency is presumably due to less restrained regulations that created an environment of
improved cultivation and production techniques (Sevigny, Pacula & Heaton, 2014). The
researchers identify two marijuana markets, medical and recreational, indicating that
these markets are interrelated such that cross over in technological advances for
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production and cultivation occurs (Sevigny, Pacula & Heaton, 2014). The authors further
posited that surplus medical marijuana is being diverted to the recreational market
(Sevigny, Pacula & Heaton, 2014). In fact, this reported diversion of marijuana has been
documented by the Denver area drug trafficking program. This agency implicates
marijuana dispensaries, registered marijuana receiving patients and licensed caregivers as
potential sources of medical marijuana diverted to the recreational market (Sevigny,
Pacula & Heaton, 2014). In a related study Salomonsen-Sautel, et al. (2012) presented
evidence that adolescents in two Denver substance abuse treatment programs used
medical marijuana obtained from registered medical marijuana patients. Thus, the effects
of producing high-potency medical marijuana potentially impacts the quality and
availability of these highly potent marijuana strains to the recreational using market.
To address the effects of medical marijuana on potency, Sevigny, Pacula &
Heaton, (2014) utilized data obtained from approximately 39,000 marijuana samples
seized from all 50 states and the District of Columbia. The data was retrieved from the
Mississippi’s Potency Monitoring Program (PMP) which measured and reported the THC
content for all samples observed. The results of this study initially demonstrated a
significant increase in marijuana THC content in jurisdictions that legalized marijuana for
medical purposes (Sevigny, Pacula & Heaton, 2014). The study also completed four other
models which gradually increased in sophistication with each model by the addition of
control and other potentially competing variables (Sevigny, Pacula & Heaton, 2014). This
sequential increase in model complexity or competitiveness resulted in a decrease in the
effects on marijuana potency (Sevigny, Pacula & Heaton, 2014). For instance, while the
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addition of observable control variables, such as states decriminalization status of
marijuana, and state law enforcement policies, resulted in a slight reduction in model two.
The relationship was still positive and statistically significant, approximately 1.5
percentage points higher THC content. As oppose to the remaining three models which
demonstrated results that were not statistically significant, approximately 0.5 percentage
points higher THC content.
This study is important to this study because it provides information relevant to
the premise that marijuana acceptance, use, potency, and adverse effects have been on the
rise. This is evident as the article presented by Sevigny, Pacula & Heaton (2014)
referenced several studies that support the association between the rising THC levels in
marijuana and a host of negative mental health consequences, such as psychosis and
anxiety.
In another study, Salomonsen-Saulel, et al. (2012) addressed the extent of medical
marijuana use by the non-registered (non-patient) marijuana using population. This was
achieved by assessing adolescents in substance abuse treatment programs to determine
the extent of medical marijuana use among this group (Salomonsen-Saulel, et al. (2012).
This sort of de facto legalization is believed to occur because of loopholes in the
regulations that allows surplus medical marijuana to find its way into the hands of the
non-patient recreational marijuana using population (Anderson & Rees, 2014). For
instance, in Colorado medical marijuana caregivers can have up to two ounces of
marijuana on-hand for distribution and three mature growing plants for each patient the
caregiver supplies (Wirfs-Brock, Seaton, & Sutherland, 2010). The mature plants can
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produce more than one pound of marijuana per plant and since there are roughly 100,000
registered marijuana users in Colorado, that transpires into approximately 300,000 plants
or 300,00 pounds (150 tons) of potential surplus marijuana. (Wirfs-Brock, Seaton, &
Sutherland, 2010). In fact, the Colorado Department of Public Health and Environment
estimates a 20 to 64-ton surplus and that’s if the plants only produce three to eight ounces
per plant as oppose to the 16 ounces per pound max yield per plant (Wirfs-Brock, Seaton,
& Sutherland, 2010). Most of which is surplus based on current Colorado regulations and
therefore subject to diversion to the non-patient recreational using population.
The study by Salomonsen-Saulel, et al. (2012) is based on the premise that
legalizing marijuana for medical use promotes the perception that marijuana is safe for
recreational use (Salomonsen-Saulel, et al., 2012). Thus, increasing acceptance and
encouraging recreational use as the risk or the perception of harmful health consequences
decreases (Salomonsen-Saulel, et al., 2012). This premise is in converse to those who
would argue that medical marijuana laws have no effect on marijuana use. Nevertheless,
studies have been conducted that support both positions (Salomonsen-Saulel, et al.,
2012).
Participants for the study conducted by Salomonsen-Saulel, and colleagues
consisted of 164 adolescents being treated at two substance abuse facilities in Denver
Colorado (Salomonsen-Saulel, et al., 2012). Patients were referred to these facilities for
treatment of ‘conduct and substance use disorder’ by one of the following: “social
services, the juvenile justice system, primary care physicians, schools as well as selfadmitted participants” (Salomonsen-Saulel, et al., 2012, para. 14). The results of this
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study demonstrated that, approximately 74% of the 164 adolescents in treatment had used
medical marijuana obtained from registered medical marijuana patients (SalomonsenSaulel, et al., 2012). Thus, demonstrating a high rate and widespread pattern of medical
marijuana use by the non-patient recreational using population. The results also revealed
that the likelihood of medical marijuana use increased with decreasing age of onset of
regular marijuana use (Salomonsen-Saulel, et al., 2012). Such that the younger
participants began using marijuana the more likely they were to use medical marijuana.
Additionally, while both the medical marijuana using and non-medical marijuana using
groups were comprised of individuals with conduct disorder and substance use disorder.
Salomonsen-Saulel (2012) reports a 16% increase in the likelihood of using medical
marijuana corresponding to each additional symptom of conduct disorder; such that those
who used medical marijuana had at least one more symptom of conduct disorder than
those who did not use medical marijuana. Similar observations were made for
participants with symptoms of substance abuse or dependence. In this instance,
Salomonsen-Saulel (2012) reports a 31% increase in the likelihood of using medical
marijuana corresponding to increasing symptoms of substance abuse or dependence.
Wen, Hockenberry, and Cummings (2015) conducted a related study entitled: The
effect of medical marijuana laws on adolescent and adult use of marijuana, alcohol, and
other substances use of marijuana, alcohol, and other substances in ten states with
medical marijuana laws. This article is relevant to the current study because it presents
information pertaining to the implementation of medical marijuana laws (MMLs) and the
availability of high potency marijuana. Wen, Hockenberry, and Cummings (2015)
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posited that MMLs are intended to provide medicinal use of marijuana to a select group
of patients. However, the potential for spillover also allows the availability of these
typically highly potent marijuana strains to the non-patient or recreational using
population (Wen, Hockenberry, & Cummings, 2015). The process of obtaining legal
access in states with MMLs, usually involves obtaining a recommendation from a
qualified physician for a condition considered eligible under state specific MMLs (Wen,
Hockenberry, & Cummings, 2015). After which the patient can obtain a state issued
identification card for medical marijuana use. The patient is then allowed to have a
certain amount of marijuana and may also cultivate marijuana at home. (Wen,
Hockenberry, & Cummings, 2015). Additionally, the patient can also purchase marijuana
from nonprofit retail dispensaries, also called compassionate centers in some states
(Wen, Hockenberry, & Cummings, 2015). This spillover effect which makes these highly
potent strains available to the non-patient population occurs via one of the following four
methods: 1) Patients present to physicians requesting medical marijuana for a complaint
of chronic pain which is difficult to confirm or refute, thus, individuals can deceive
doctors and obtain prescription MM; 2) Poorly defined eligibility criteria in some states
fail to adequately distinguish between patient and non-patient populations as some states
do not use a ‘registry/renewal’ process to re-assess and establish eligibility on a
continuous basis; 3) As with prescription opioids, medical marijuana makes its way to the
non-patient population through patients with marijuana prescriptions; and 4) spillover
occurs because MMLs tend to support or encourage marijuana acceptance which in turn
results in a reduced risk of association for recreational marijuana use in these states; thus,
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in areas with MMLs individuals may be more willing to use or experiment with
marijuana. (Wen, Hockenberry, & Cummings, 2015). Therefore, MMLs can result in a
sort of de facto legalization through which medical marijuana with a high THC content is
made available to the non-patient or recreational using population (Anderson & Rees,
2014).
Wen, Hockenberry, and Cummings (2015) pooled cross-sectional data obtained
between 2004 and 2012 from the National Survey on Drug Use and Health (NSDUH) to
address the effect of MMLs on the use of marijuana, alcohol, and other hard drugs as well
as pain medication misuse. This national and state represented survey is conducted
among those 12 years of age and older and is considered an important source of
information on substance use behavior within the non-institutionalized portion of this
population (Wen, Hockenberry, & Cummings, 2015). The study used a self-administered
audio computer-assisted self-interviewing (ACASI) method for interviewing because this
approach is private and confidential and tends to promote honesty which is essential as
substance use behavior is a sensitive subject (Wen, Hockenberry, & Cummings, 2015).
This study demonstrated that implementation of MMLs resulted in a parallel
increase in past-month marijuana use among participants age 21 and older. These
increases occurred immediately after MMLs were implemented and continued for three
years after implementation. Conversely, this increase was not observed among
participants aged 12 to 21. The relative increase was approximately 14% from baseline or
1.32 percentage points for those age 21 and older (Wen, Hockenberry, & Cummings,
2015). Bear in mind that the NSDUH data used by this study does not differentiate
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between medical marijuana and non-medical marijuana populations. Nevertheless, among
states with available data the registered medical marijuana using population comprised an
average of 0.8 percent of the state population (Wen, Hockenberry, & Cummings, 2015).
Thus, the results obtained is not entirely from registered marijuana users and tends to
support the spillover effect of MMLs on the availability of highly potent marijuana to the
recreational or self-medicating non-patient using population (Wen, Hockenberry, &
Cummings, 2015). The results further demonstrate an increase in daily marijuana use
among those age 21 and older while those aged 12-20 continued to demonstrate no
increase in frequency of use in the past month (Wen, Hockenberry, & Cummings, 2015).
However, for adolescents and young adults age 12 to 21 there was a 0.32 increase in
percentage points for initiation or first-time marijuana use. This translates into a five
percent increase in the probability of using marijuana for the first time among these
participants (Wen, Hockenberry, & Cummings, 2015). These results were not consistent
among those 21 and older as this group did not demonstrate an increase in first-time use
with the implementation of MMLs (Wen, Hockenberry, & Cummings, 2015).
With respect to alcohol use, the results of this study indicated that MML
implementation did not affect the total number of drinks consumed by those aged 21 and
older (Wen, Hockenberry, & Cummings, 2015). However, the results further
demonstrated a positive association between binge drinking and MML implementation
which was observed as a 10% increase (effect size of 0.16) in the number of binge
drinking days (Wen, Hockenberry, & Cummings, 2015). This observation was also
demonstrated in concurrent use of marijuana and binge drinking in the past month for
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adults aged 21 and older as the simultaneous use of these substances increased by 22
percent or 1.44 percentage points with the implementation of MMLs (Wen, Hockenberry,
& Cummings, 2015). In addition, there was an increase of 18% (0.82 percentage points)
for the probability of using marijuana while drinking among those age 21 and older.
However, these findings were not observed among the adolescent and young adult
population age 12 to 20 years as no significant change in alcohol use was observed in this
group with the implementation of MMLs (Wen, Hockenberry, & Cummings, 2015).
In addition, Wen, Hockenberry, & Cummings (2015) report a 10% increase in
marijuana abuse/dependence among participants age 21 and older. Thus, indicating cause
for public health concern as MMLs may have the potential to increase risk of progressing
to marijuana abuse/dependence (Wen, Hockenberry, & Cummings, 2015). However, this
finding was not consistent in either age group for alcohol abuse/dependence, non-medical
use of prescription pain meds, and heroin or cocaine use as no increases was observed for
these variables among adolescents and young adults or the adult population (Wen,
Hockenberry, & Cummings, 2015).
Effects of Marijuana Legalization and Lessons Learned from States with Legalized
Marijuana
The long-term effects of marijuana legalization and trends in acceptance have yet
to be demonstrated. Nevertheless, several studies have been conducted in an attempt to
assess these effects. One of which conducted by the nonprofit organization known as
Smart Approaches to Marijuana or SAM was recently released. This study entitled:
Lessons Learned from Marijuana Legalization in Four U.S. States and D.C. presented
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some interesting and disturbing findings. The authors of this study posited that “Today’s
highly potent marijuana represents a growing and significant threat to public health and
safety, a threat that is amplified by a new marijuana industry intent on profiting from
heavy use” (Smart Approaches to Marijuana [SAM] 2018, p.3). The authors further
posited that while the consequences of marijuana legalization will not be realized for
decades, the results of this study present some disturbing early indicators of the potential
effects. Thus, marijuana legalization is leading to increased availability of highly potent
marijuana that public health professionals must address as the long-term effects of highly
potent marijuana remains to be seen.
SAM (2018) reports on trends demonstrated in the following five jurisdictions
since legalization: Colorado; Washington; Oregon; Alaska; and the District of Colombia.
Among the findings presented by SAM, includes a detailed report on the impact that
marijuana legalization has had on the youth or adolescent population in these areas. SAM
(2018) indicated that in the jurisdictions observed adolescents age 12-17 report an
increase in past-month use of marijuana that continues to rise above the national average.
In addition, states with marijuana legalization report an increase in marijuana use among
young adults aged 18 to 25 (SAM, 2018). While Alaska and Oregon also report an
increase in past-year marijuana use among adolescents (aged 12-17) and Colorado has
seen a 65% increase in first-time marijuana use among adolescents (SAM, 2018).
Colorado has also reported an increase in adolescent suicide victims testing positive for
marijuana and approximately half of adolescents in outpatient treatment report using
diverted medical marijuana (SAM, 2018).
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Unfortunately, this is not the end of these disturbing trends as marijuana
legalization has a multitude of effects on the community and health. For instance, in
Washington and Oregon law enforcement has documented numerous incidents where
licensed marijuana retailers were selling marijuana to minors. There has also been a rise
in arrest for public consumption and distribution as in Washington, D.C. where arrest for
these offenses nearly tripled. With a disproportionate number of arrests occurring among
people of color in both D.C. and Colorado (SAM, 2018). In Colorado this racial
discriminatory trend carries over into school related suspension for marijuana as schools
with fewer children of color (25% or less) had fewer suspensions (313) when compared
to schools that had more than 76% children of color which had 658 marijuana related
suspensions (SAM, 2018). Marijuana legalization is also affecting the use and
consumption of other drugs as alcohol consumption is not decreasing as some predicted.
In fact, alcohol consumption is either not affected or increasing as Oregon State
University reports that underaged (less than 21 years old) binge drinkers are among the
primary groups of marijuana user’s post-legalization (SAM, 2018). In addition, according
to the Institute for Behavior and Health, the percentage of marijuana users who are using
opioids frequently has risen dramatically as peer-reviewed research has also
demonstrated that the likelihood of opioid use more than doubles for those who began
using marijuana in early in life (SAM, 2018; Secades-Villa, Garcia-Rodríguez, Jin, Wang
& Blanco, 2015). SAM (2018) further posited that marijuana legalization in Colorado and
Washington resulted in the development of a multibillion-dollar addiction-for-profit
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industry. With the goal of this industry being to convert adolescents and young adults
from casual marijuana users into more frequent heavy users (SAM, 2018).
There is also growing concern to address the adverse health outcomes that can
result because of increased legalization and acceptance of marijuana as a natural
substance that is perceived as less harmful and healthier than alcohol and tobacco (SAM,
2018). This trend continues as the perceived risk of harm associated with marijuana is
decreasing with increased acceptance and legalization (SAM, 2018). In converse, these
assumptions and attitudes couldn’t be further from the truth as research has demonstrated
a direct association between the use of highly potent (higher THC) marijuana and
increased frequency of marijuana use with the development of mental health conditions
(SAM, 2018). Which may include conditions like psychosis, depression, anxiety,
addiction and suicidal tendencies (SAM, 2018). There has also been links made between
the use of highly potent legalized marijuana with the reshaping of brain matter, lung
damage and cardiovascular complications like hypertension, heart attack, and stroke
(SAM 2018). In addition, SAM (2018) also provides information supporting the gateway
effect whereby marijuana use leads to a risk of progressing from marijuana to the use of
other illicit.
The effects of marijuana policies are impactful and widespread as SAM (2018)
further posited that in addition to having some of the highest rates of marijuana
consumption in the country. According to SAM (2018) states with legalized marijuana
also demonstrate the following trends: higher rates of marijuana-related driving fatalities;
more marijuana-related emergency room visits, hospitalizations, and accidental
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exposures; expansion of a lucrative criminal market; increases in marijuana-related
crimes and juvenile offenses; and increases in workplace problems, including labor
shortages and accidents as well as disproportionate legal impacts among communities of
color and low-income populations.
Regarding marijuana-related driving incidents and fatalities in Colorado between
2013 and 2015 there was an 88% increase in the number of drivers charged with driving
while intoxicated with marijuana and fatal car accidents associated with marijuana
intoxication (SAM, 2018). In addition, the National Highway Traffic and Safety
Administration reports a 66% increase in the number of marijuana traffic deaths since
legalization (SAM, 2018). This trend is common across states with marijuana legalization
as Washington State reports that traffic deaths related to drugged driving has doubled
since legalization (SAM, 2018). Driving under the influence of drugs (DUIDs) is on the
rise across states with marijuana laws (SAM, 2018). For instance, Colorado has seen a
76% increase in the number of DUIDs where marijuana was involved, and Oregon
reports that in 2015, 50% of drivers tested positive for THC after being assessed by drug
recognition experts (SAM, 2018).
SAM, (2018) also indicated that marijuana-related emergency room visits,
hospitalizations, and accidental exposures are also on the rise as a result of legalization
(SAM, 2018). This is evidenced by reports from the poison controls centers in Colorado
and Washington State that report increases of 210% and 70% respectfully, in the number
of marijuana related calls received after legalization (SAM, 2018). Colorado also reports
a 35% increase in the number of individuals seen in hospital emergency rooms (ER) for
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marijuana-related events. And Central Oregon reports that marijuana-related ER visits
increased by 200% as in January 2016 there were 434 marijuana-related ER visits,
whereas prior to legalization ER visits for marijuana averaged around 32 visits per month
(SAM, 2018).
In addition, there has also been an increase in problems in the workplace as
employer’s report problems with labor shortages and on the job accidents (SAM, 2018).
For example, labor shortages may be associated with the increase in number of
individuals testing positive for marijuana which is double the national average in both
Washington and Colorado (2018). Employers are finding it difficult to find employees
because so many people cannot pass the preemployment drug screen. In one instance, a
Colorado construction company had to seek employees from out of state because too
many local construction workers were failing the preemployment drug screening (SAM,
2018). The drug screening problem has gotten to the point where during the three periods
from 2013 to 2016 after legalization of recreational marijuana in Colorado and
Washington, positive oral-fluid screening test for marijuana increased by about 75% and
urine test for marijuana are now twice that of the national average (SAM, 2018). This is a
serious concern as on the job accidents and therefore insurance claims are also a growing
concern among employers and insurance companies in states where marijuana has been
legalized (SAM, 2018). One study found that among marijuana users, work-related
injuries and illnesses were 8.9% higher than non-users (SAM, 2018). Thus, companies in
states with legalized marijuana are at risk of liability claims if marijuana use is tolerated
or if they choose to eliminate or ignore drug screening (SAM, 2018).
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SAM (2018) also showed that crime is on the rise in jurisdictions with legalized
marijuana. In Colorado, since legalization took place, crime has increased at a rate that is
11 times faster than states without marijuana legalization (SAM, 2018). The Colorado
Bureau of Investigation (CBI) indicated that property crimes and violent crimes have
increased by 8.3% and 18.6%, respectively (SAM, 2018). The increase in crime is
reportedly associated with the distribution of marijuana dispensaries as the National
Institute of Health demonstrated a correlation between the density of marijuana
dispensaries and an increase in property crime in regions. Police in Boulder, Colorado
also report an increase of 54% in citations for public consumption of marijuana postlegalization (SAM, 2018). This disturbing trend holds true across legalized states as
Alaska also reports an increase in misdemeanors and vehicle thefts since legalization.
Prior to legalization, Alaska was ranked nationally as 16th for larceny and motor vehicle
theft. However, post-legalization statistics has Alaska ranked second and fifth nationally
for larceny and motor vehicle theft, respectively (SAM, 2018). In contrast, prior to
legalization Oregon was ranked nationally as 12th for larceny, 13th for motor vehicle theft
and 17th for property crime However, after legalization statistics has Oregon ranked 7th
for larceny, 8th for motor vehicle theft and 11th for property crime (SAM, 2018).
In addition, the Black Market is also thriving and prospering in the wake of
marijuana legalization as legalization is not only affecting the population within the state
wherein marijuana is legalized but also effects adjacent states and other states throughout
the country (SAM, 2018). For instance, SAM (2018) reports that Colorado has seen a
50% increase in the number of illegal marijuana growers across the rural areas within the
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state and in 2016 law enforcement officers seized around 7,116 pounds of marijuana and
made 252 felony arrest. There were also 346 highway trafficking interdictions wherein
marijuana seized was destined for one of 36 other states in the U.S. (SAM, 2018). Black
market activity is also affecting the mail system in the United States as there has been an
844% increase in the number of marijuana seizures since legalization. The situation has
gotten so extreme that the U.S. Attorney in Oregon stated that “Oregon has a massive
marijuana overproduction problem” (SAM, 2018, p.22). This comment was made in
response to seizures in 2017 which amounted to “2,644 pounds of marijuana in outbound
parcels and over 1.2 million dollars in cash” (SAM, 2018, p.22).
The claims by SAM (2018) about the effects of marijuana legalization on adjacent
and other states throughout the nation are supported by other articles and researchers. For
instance, in an article entitled: The Cross-Border Spillover Effects of Recreational
Marijuana Legalization by Hao & Cowan (2017) explored this effect on counites in states
bordering states with Recreation Marijuana Legalization (RML), compared to non-border
counties in these states. This study focused on Colorado and Washington as these were
the first two states to pass laws allowing for the use of recreational marijuana (Hao &
Cowan, 2017). The effects of RML in Colorado was observed in bordering counties of
the following six states: Wyoming; Utah; New Mexico; Oklahoma; Kansas; and
Nebraska (Hao & Cowan, 2017). And in Washington, the researchers observed effects of
RML on bordering counties in Idaho and Oregon (Hao & Cowan, 2017).
Hao & Cowan (2017) posited that RML may lead to positive fiscal impacts as
demonstrated in Washington state which collected approximately $186 million in tax
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revenue generated from the sale of legal recreational marijuana in 2016. RML is also
expected to generate savings due to reduced cost in law enforcement and the criminal
justice system which will not be investigating and prosecuting certain crimes related to
the possession and use of marijuana (Hao & Cowan, 2017). However, RML has the
potential for negative and detrimental effects on bordering states as marijuana purchased
and possessed legally in states with RML could increase arrest and convictions for
marijuana possession and marijuana-related crimes in these neighboring regions (Hao &
Cowan, 2017). Thus, contributing to an increased burden on law enforcement and the
criminal justice system. In fact, while the Supreme Court denied the lawsuit. Nebraska
and Oklahoma, which border Colorado did initiate a lawsuit against Colorado,
maintaining that legalization of marijuana in Colorado contributed to an increased
financial burden on law enforcement for marijuana-related crimes and other social cost
within their state (Hao & Cowan, 2017). This was a sharp increase in arrest for marijuana
possession as states that shared a physical border saw an increase of 30% for this offense
(Hao & Cowan, 2017).
The study by Hao & Cowan (2017), revealed a statistically significant increase in
arrests for marijuana possession in counties that border regions of Colorado and
Washington relative to counties that did not border these states. This observation was
only seen among the adult populations within these regions as RML did appear to impact
arrests of juveniles for possession of marijuana (Hao & Cowan, 2017). The researchers
also found that these findings were consistent with previous studies on MMLs
demonstrating that MMLs do not lead to increased consumption of marijuana by
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teenagers (Hao & Cowan, 2017). The study further revealed that RML did not have a
statistically significant effect on arrest for the following: the sale and/or manufacture of
marijuana; DUIs; or possession of opium/cocaine (Hao & Cowan, 2017). Hao & Cowan
(2017) recommend that states considering RML, also consider the potential regional and
national impact as the costs and benefits of these decisions should include the
consequences of the spillover effect on states without RML.
In another study, Cerda, et al., (2012) addressed the association between statelevel medical marijuana legalization and marijuana use, abuse, and dependence. Cerda, et
al., (2012) acknowledges that individual behaviors are not only influenced by the
perceived cost and benefits of an individuals’ actions but also by the approval or
disapproval of society. This study is based on the premise that earlier studies on norms
that predict marijuana use do not provide information of group-level norms that also
likely influence individual behavior (Cerda, et al., 2012). These group norms are
essentially group level acceptance or approval of a particular behavior. Such that
individuals in regions where marijuana is received with societal or group level approving
norms have a greater likelihood of using marijuana (Cerda, et al., 2012). The study also
considers societal norms that may influence behavior independent of individual beliefs as
well as policies and program interventions aimed at societal norms that have a much
broader effect than individual interventions (Cerda, et al., 2012). Therefore, with respect
to marijuana, the implementation of state-level MMLs can be considered an indication of
group-level approval of marijuana use (Cerda, et a., 2012). Thus, implementation of
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MMLs can viewed as an indicator of societal-level norms for marijuana acceptance
because public opinion influences decisions on marijuana policies (Cerda, et al., 2012).
Cerda, et al., (2012) addressed the following three research questions: (1) did
states that legalized medical marijuana by 2004 exhibit higher rates of past-year
marijuana use and abuse/dependence in 2004-2005 than states that did not legalize it?; (2)
were individuals living in states that legalized medical marijuana at higher risk for
marijuana use, abuse and dependence in the past year than individuals who live in states
that did not legalize medical marijuana?; and (3) among marijuana users, was residence
in a state that legalized medical marijuana associated with increased risk for meeting
criteria for marijuana abuse and dependence?
The study utilized data for states that had implemented MMLs by 2004. These
states were coded as exposed and included the following 10 states: Alaska; California;
Colorado; Hawaii; Maine; Montana; Nevada; Oregon; Vermont; and Washington (Cerda,
et al., 2012). And the remaining 40 states without MMLs by 2004 were coded
(designated) as unexposed (Cerda, et al., 2012). Participant data was obtained using
secondary data from the following two surveys: 1) the National Epidemiologic Survey on
Alcohol and Related Conditions (NESARC); and 2) National Survey on Drug Use and
Health (NSDUH) (Cerda, et al., 2012). The NESARC served as the source for primary
outcome data and is a national survey that used face-to-face surveying techniques to
gather data on 43,093 participants (Cerda, et al., 2012). The participants were aged 18
years and older living in the United States in homes or group quarters (Cerda, et al.,
2012). In contrast, the NSDUH served as the secondary data source and is also a national
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survey that used self-reporting surveying techniques to gather data on approximately
68,000 respondents (participants) (Cerda, et al., 2012). This study gathers data on U.S.
residents 12 years and older living in households, non-institutional group quarters and
civilians living on military bases (Cerda, et al., 2012). Participants were categorized into
the following three age groups: 1) 12-17 years old; 2) 18-25 years old; and 3) 26 years
old and older (Cerda, et al., 2012). However, for this study, the researchers used only
those participants aged 18 years and older, yielding approximately 45,000 respondents
for this studies sample from the NSDUH (Cerda, et al., 2012).
The results of this study for state-level marijuana use, abuse and dependence,
demonstrated statistically significant differences between states with MMLs versus states
without MMLs. For instance, based on NESARC data, in states with MMLs the average
state-level prevalence of past-year marijuana use was higher (7.13%) than in states
without MMLs (3.57%). In addition, according to NESARC data, the average state-level
prevalence of marijuana abuse/dependence was also significantly higher in states with
MMLs (2.61%) than in states without MMLs (1,27%). In contrast, NSDUH data also
revealed that in states with MMLs the average state-level prevalence of past-year
marijuana use was significantly higher (12.17%) than in states without MMLs (9.77%)
(Cerda et al., 2012).
In addition, individual level results for odds of past-year marijuana use, abuse and
dependence also yielded statistically significant results for states with MMLs versus
states without MMLs (Cerda, et al., 2012). For instance, for individuals living in states
with MMLs the odds of marijuana use in the past year were 1.92 times higher than
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individuals living in states without MMLs (Cerda, et al., 2012). In addition, the odds of
marijuana abuse/dependence were 1.81 times higher for individuals residing in states
with MMLs versus individuals living in states without MMLs (Cerda, et al., 2012).
Cerda et al. (2012) conclude that the results of this study demonstrated that a
causal relationship exist between MMLs and marijuana use and marijuana
abuse/dependence. To understand and explain this relationship. Cerda et al. (2012)
considers the following four mechanisms: 1) state-level community norms more
supportive of marijuana use may contribute to the legalization of medical marijuana and
to higher rates of marijuana use; 2) the enactment of medical marijuana laws could lead
to a change in community attitudes on both medical and non-medical marijuana use,
including reduced disapproval and perceived riskiness of use, which could subsequently
influence marijuana use and abuse/dependence; 3) medical endorsement of marijuana for
medical purposes encourages acceptance and use; and 4) which is related to the
availability of marijuana, such that legalization of medical marijuana may lead to greater
commercial promotion and availability of the substance for recreational purposes, which
may contribute to greater illicit use of marijuana.
In another study, three years after Colorado legalized marijuana for recreational
use the Colorado Department of Public Health Environment and The Colorado
Department of Public Safety published an article to address the lessons learned from
recreational legalization (Ghosh, Vigil, Maffey, Tolliver, Van Dyke, Kattari, Krug, Reed
& Wolk, 2017). After legalized sales of recreational marijuana began in 2014, the
Colorado department of public health developed a framework to monitor, address and
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prevent or reduce harmful effects on the population (Ghosh et al., 2017). The article
presented here is a testament to the lessons learned thus far. These lessons were divided
into the following three broad categories: 1) lessons on health behaviors; 2) lessons on
health outcomes; and 3) lessons on health policy (Ghosh, et al., 2017). Considering the
importance of monitoring trends in marijuana use and identifying high risk
subpopulations. Ghosh et al., (2017) stressed how essential it is for states with legal
marijuana and those considering legalization to establish surveys or add marijuana
questions to population-based surveys to monitor regional trends in marijuana use.
Optimally, these surveys or questions should be implemented prior to changes in policies
that effect marijuana legalization (Ghosh et al., 2017).
In retrospect, lessons learned on health behaviors, Ghosh et al (2017) present
some interesting trends. The first lesson learned was that marijuana use did not appear to
increase as a result of recreational legalization (Ghosh et al., 2017). This trend was
demonstrated among the adult and youth populations as past 30-day use among adults did
not change significantly between 2014 when use was observed at 13.6% and 2015 when
adult 30-days use was recorded at 13.4% (Ghosh et al., 2017). In contrast, high school
student marijuana use in the past 30-days and lifetime demonstrated no statistically
significant change between 2013 (30-day use: 19.7%; lifetime: 36.9%) and 2015 (30-days
use 21.2%; lifetime 38.0%) (Ghosh et al., 2017). However, there was a small but
statistically significant decrease in youth perception of perceived risk of marijuana use as
this value decreased from 54% in 2013 to 48% in 2015 (Ghosh et al., 2017). This
observation may explain why the highest rates of use were seen among young adults
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between the age of 18 to 25 years old with a rate of 26.1% and high school juniors and
seniors with a rate of 26.3% and 27,8%, respectively. Thus, marijuana legalization while
not apparently affecting marijuana use at this time, may well influence future use as
youth decreased perception of perceived risk may have a significant impact on future
population use. It was also learned that individuals who identified as gay, lesbian, or
bisexual were far more likely than heterosexuals to use marijuana (Ghosh et al., 2017).
This trend was true for all ages as adult marijuana use among those who identify as gay,
lesbian or bisexual was 36.9% versus adult heterosexuals with a rate of 12.4% and youth
rates for those identifying as gay, lesbian, or bisexual demonstrating a rate of use of
34.9% versus 19.5%, for heterosexual youths (Ghosh et al., 2017).
In addition, while there was lower marijuana use among Asians, there was not a
significant difference in use by race/ethnicity. Ghosh et al., (2017) also report what was
learned about methods of marijuana use, frequency as well as marijuana storage habits.
For instance, among adults it was reported that the most common methods of use
included: smoking (83.2%); eating (34.4%) and vaping (32.4%) (Ghosh et al., 2017).
However, while the majority of both adult and youth users report smoking as the most
common method, approximately half report using marijuana by multiple methods, such
as vaping, eating and/or dabbing (Ghosh et al., 2017). Vaping is a method of use that
involves using a vaporizing device to heat marijuana and the user inhales vaporized
marijuana instead of smoke (Ghosh et al., 2017). Dabbing on the other hand is method
that involves using solvents such as butane to create a highly concentrated form of
marijuana which the user then heats and inhales the smoke (Ghosh et al., 2017). Lessons
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on behavior also revealed that 7.4% of parents who use marijuana report storing
marijuana and 73.4% of these parent’s report storing marijuana in locked containers
(Ghosh et al., 2017). This is an important public health concern as the unintentional
exposure of children 8 years old and younger increased by 63% during the first year of
legalization (Ghosh et al., 2017).
To evaluate health outcomes, Ghosh et al., (2017) observed data related to
hospital discharges codes for marijuana related conditions and Emergency Department
(ED) visits. These observations revealed a 70% increase for hospitalizations related to
marijuana between 2013 and 2015 (Ghosh et al., 2017). These observations also
demonstrated an increase of 19% for ED visits related to marijuana use (Ghosh et al.,
2017). However, it is important to mention that the observations for marijuana related ED
and hospitalizations were significantly lower than alcohol as ED visits was approximately
five times higher than marijuana and hospitalizations for alcohol was almost three times
higher (Ghosh et al., 2017). Post-legalization observations also revealed an increase in
calls to the Poison center for adult marijuana exposure (Ghosh et al., 2017). However,
unlike children eight years old and younger where exposure was usually accidental, adult
exposure was usually intentional and was approximately evenly distributed for smoked
and edible marijuana consumption (Ghosh et al., 2017). In addition, marijuana-related
DUI’s increased by 16% post-legalization and driving fatalities associated with a positive
marijuana test increased by 80% (Ghosh et al., 2017).
Regarding marijuana policy post-legalization, Colorado implemented the
following policy changes: added marijuana to its Clean Indoor Act; established
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childproof packaging requirements for edible marijuana products; strengthened safety
regulations for edible products by establishing limitations for the maximum amount of
THC in a single serving; set requirements for sticker packaging or labels to identify
marijuana products with universal symbols; and established restrictions to
eliminate/reduce packaging of products that entice children (Ghosh et al., 2017). In
addition, Colorado policy decisions were informed by social marketing research that
revealed varying attitudes for marijuana use exist between the English and Spanish
speaking populations, between users and non-users, and between older and younger
populations (Ghosh et al., 2017). This information was used to maximize and target the
impact of public health messaging for a variety of audiences (Ghosh et al., 2017).
Informative messaging not only focused on health concerns, but also on general
marijuana law awareness (Ghosh et al., 2017). A final major policy lesson learned was
associated with aligning medical and recreational regulations. For instance, varying
regulations between medical and recreational marijuana have contributed to discrepancies
in marijuana taxation, testing requirements and labeling/packaging (Ghosh et al., 2017).
Ghosh et al (2017) concludes that many lessons were learned from the Colorado
experience and recommends that states with and those considering marijuana legalization
should establish strong surveillance systems. This system should be established to
monitor both health behaviors and outcomes (Ghosh et al., 2017). Another key
component should include a health policy approach that is adaptable to a rapidly
changing and emerging environment (Ghosh et al., 2017).
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In yet another article entitled: “Marijuana Legalization: Impact on Physicians and
Public Health” presents a review of marijuana legalization and the potential impact it
may have on public health (Wilkinson et al., 2016). This article also presented a review
of health conditions for which marijuana has been identified as a recognized treatment
option (Wilkinson et al., 2016). Wilkinson et al (2016) posited that while the relationship
between marijuana legalization and prevalence is not clear. There are still serious public
health concerns that states should consider relevant, especially considering the continued
widespread legalization of marijuana (Wilkinson et al., 2016). Some of these concerns
include: the effects of acute marijuana intoxication on driving abilities; unintentional
ingestion of marijuana products by children; the relationship between marijuana and
opioid use; and whether there will be an increase in health problems related to marijuana
use, such as dependence/addiction, psychosis, and pulmonary disorders (Wilkinson et al.,
2016). According to Wilkinson et al. (2016) in 2013 approximately 3.1 million
Americans reported using marijuana in the last year and 8.1 million Americans reported
using marijuana almost daily in the last month. Thus, addressing these concerns are
essential given that marijuana is not only the most used illicit substance, but also gaining
acceptance and the legalization trend continues as more states are considering legalizing
marijuana for medical and/or recreational use (Wilkinson et al., 2016). Nevertheless,
marijuana legalization remains a controversial topic as proponents persist that the
positive aspects of marijuana legalization include the following: more stringent regulation
and safer use of marijuana; more efficient use of law enforcement resources; a possible
decline in the prevalence of marijuana use among adolescents; and a decline in the use of
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“harder drugs” like cocaine and heroin (Wilkinson et al., 2016). In converse, opponents
of marijuana legalization persist that adverse effects of legalization may include the
following: an increase in marijuana use; and increases in health problems associated with
marijuana use (Wilkinson et al., 2016). Thus, one of the primary arguments between
advocates and opponents of marijuana legalization is the relationship between
legalization and prevalence of use (Wilkinson et al. 2016). In general, according to
Wilkinson et al. (2016), states with legalized marijuana tend to have higher rates of
marijuana use than states without any form of marijuana legalization (Wilkinson et al.
2016). However, Wilkinson et al. (2016) also points out that this was often the case prior
to legalization. Thus, regional variances in acceptance and permissive attitudes that
contribute to a decreased in perceived risk associated with marijuana use may be
contributing factors of increased use in these states (Wilkinson et al. 2016). Another
important public health concern is the prevalence of use among adolescents as this group
may be more susceptible to the negative health consequences of marijuana as well as
poor social outcomes (Wilkinson et al., 2016). These health consequences may include:
increased susceptibility to addiction/dependence; psychosis and cognitive impairment
(Wilkinson et al., 2016). While poor social outcomes may include: unemployment, lower
income; and lower levels of life and relationship satisfaction (Wilkinson et al., 2016).
These may well be warranted as previous research data has demonstrated a clear inverse
relationship between marijuana use and the perceived risk of harm associated with
marijuana use (Wilkinson et al., 2016). Such that as perceived risk decreases marijuana
use increases (Wilkinson et al., 2016).
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Another public health concern is the diversion of legal medical and recreational
marijuana from the adult population with legal access to adolescents or other individuals
without legal access (Wilkinson, 2016). Support for this concern is demonstrated by a
Colorado study of adolescents in outpatient treatment for substance-abuse (Wilkinson,
2016). In which, approximately half of these adolescents reported using marijuana
diverted from legal access (Wilkinson, 2016). In another study, the researchers
discovered even higher rates of diversion as approximately 74% of adolescents
participating in substance-abuse treatment reported using marijuana diverted from or
intended for medical use (Wilkinson, 2016). This sort of de facto distribution of
marijuana has contributed to the occurrence of unintentional ingestion of marijuana by
children age nine or younger (Wilkinson, 2016). This evidenced by reports indicating that
there were no such marijuana-related emergency room cases between 2005 to October
2009 (Wilkinson, 2016). However, after October 2009 through 2011 there were 14 cases
of unintentional marijuana ingestion by children nine years old or younger (Wilkinson,
2016). This trend holds true across states where medical marijuana is legal as an analysis
of national data of states with medical marijuana laws revealed that between 2005 to
2011 there was a 30% annual rate of increase for unintentional ingestion of marijuana by
children (≤ 9 yrs. old) (Wilkinson, 2016). In contrast, states without legalization
demonstrated no change in the rates of unintentional ingestion by children (Wilkinson,
2016). Another important concern is the association between marijuana and opioid use.
Wilkinson et al. (2016) posited that while some evidence may indicate that marijuana
and/or cannabinoids can be used to treat pain or discomfort. Thus, allowing opioid users
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to taper off or reduce the amount of prescribed opioid they use to manage their condition.
However, at the time of this study no clinical trials demonstrating that marijuana or
cannabinoids could be used for this purpose (Wilkinson et al., 2016). In fact, marijuana
use has traditionally been considered to contribute to an increase in opioid use
(Wilkinson et al., 2016). In converse, a recent study demonstrated that MMLs may
ultimately contribute to a decrease in opioid mortality when compared to estimates where
these MMLs not been implemented (Wilkinson et al., 2016). However, Wilkinson et al
(2016) indicates that “states with medical marijuana laws have higher rates of ageadjusted opioid overdose mortality than do states without such laws”. Therefore,
additional research is needed to further asses this relationship and determine if marijuana
or its products will actually allow opioid patients to taper off or reduce the amount of
prescribed opioid they use to manage their condition (Wilkinson et al., 2016, p. 459).
Additionally, while marijuana is still illegal at the federal level, there are several
marijuana containing medications that have been approved by the Food and Drug
Administration (FDA) for treatment of certain conditions (Wilkinson et al., 2016). These
include: Dronabinol (Marinol®) approved for treatment of HIV/AIDS cachexia and
chemotherapy induced nausea/vomiting; Nabilone (Cesamet®) for treatment of
chemotherapy induced nausea/vomiting; and Nabiximols (Sativex®) approved in Canada
and many European countries for spasticity in multiple sclerosis (Wilkinson et al., 2016).
Wilkinson et al (2016) ultimately concludes that given the ever-evolving legal
landscape, growing social acceptance, and increasing potency of marijuana, more
research is needed to ascertain the long-term effects of legalization on public health.
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Literature Review on Marijuana and Mental Health Disorders
There is a growing body of evidence supporting the association between cannabis
use and the development of psychotic or mental health disorders (Moore, et al., 2007).
However, few studies have addressed this association since the rise in THC demonstrated
post legalization. From a public health stance, addressing this concern is essential as
individuals with marijuana use disorder are likely to continue use despite findings of
clinically significant conditions such as mental health disorders (NIDA, 2016). For many
years, substance abuse and substance dependence were considered two separate
categories. However, in 2013 The Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) was updated such that abuse, and dependence are classified under the category
of substance use disorder (NIDA, 2016). In this case marijuana or cannabis use disorder
Volkow et al., (2014) posited that previous research has demonstrated that
anxiety, depression, and psychosis are associated with regular marijuana use. However,
causality is not well founded as addressing this association is hindered by confounders
that also contribute to the development of these conditions (Volkow et al., 2014). For
instance, individuals with a family history of schizophrenia and psychosis have a greater
risk of developing these conditions (Volkow et al., 2014). In addition, heavy use of
marijuana, highly potent marijuana and using marijuana at an early age also exacerbate
the occurrence of psychosis (Volkow et al., 2014). These findings provided additional
support for the current study which intends to address the effects of marijuana
legalization and the rising THC levels (increased drug potency) on mental health.
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Volkow et al., (2014) indicated that in a predisposed individual the first psychotic
episode can occur years sooner in the presence of marijuana use. The importance of
addressing mental health concerns early in life is essential as the Substance Abuse and
Mental Health Services Administration (2017) indicated that approximately half of adults
with mental illness had signs and symptoms associated with their condition that began
before age 14 and three-fourths of adult mental illness began before age 24 (SAMHSA,
2017). Thus, addressing mental illness and factors such as marijuana use that may
negatively impact, exacerbate or cause these conditions is a serious public health concern.
This issue is especially concerning when considering current trends in attitude to toward
marijuana and the rising THC levels exhibited post-legalization.
In a previous related study, Lev-Ran, et al. (2014), conducted a systematic review
and meta-analysis of existing longitudinal studies to determine patterns of cannabis use
that are associated with the development of depression. The authors of this study cited the
following three reasons as cause for concern and justification for the study: 1) high
cannabis use among adolescents and young adults; 2) the increasing potency of cannabis;
and 3) the association between cannabis and mental illness (Lev-Ran, et al, 2014).
The researchers of the Lev-Ran study screened nearly 5000 peer-reviewed articles
on marijuana use and the risk of developing depression. The criteria for depression was
based on studies addressing major depressive disorder, dysthymia, or depressive
symptoms. Ultimately, 57 studies were selected for the meta-analysis with 14 of these
designated for quantitative analysis.
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Statistical analysis for this study used an odds ratio as measure of risk. Studies
were pooled to determine the association or increased odds of developing depression with
cannabis use versus controls (Lev-Ran et al., 2014). This procedure was followed for
regular to moderate cannabis use and heavy cannabis use. The results demonstrated that
regular or moderate marijuana users have an increased risk of developing depression
when compared to those who do not use marijuana (Lev-Ran et al., 2014). In contrast, the
greatest risk of developing depression was demonstrated by heavy marijuana users (LevRan et al., 2014). This is evidenced by an odds ratio of 1.17 for developing depression
among regular or moderate marijuana users versus an odds ratio of 1.62 among heavy
marijuana users (Lev-Ran et al., 2014).
Lev-Ran, et al. (2013) concluded that the risk of developing depressive disorders
is increased by cannabis use, and this risk is more significant among heavy cannabis
users and those with cannabis use disorder (CUD). Lev-Ran, et al. (2013) posited that the
results of this study emphasize the importance of recognizing and addressing the potential
risk of heavy cannabis use, especially among adolescents as this group has the highest
rates of cannabis use.
These findings are supported by van Gastel et al. (2013) which also indicated that
marijuana use has been associated with psychiatric symptoms and the risk is increased by
regular or heavy marijuana use. In addition, according to van Gastel et al. (2013) the risk
of developing depression is more pronounced in those who began using marijuana before
age 16. Observations among young adolescent marijuana users typically included:
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delinquent behavior; conduct disorder; attention problems; anxiety as well psychotic and
depressive symptoms (van Gastel, 2013).
Additionally, van Gastel, et al. (2013) further posited that among those who began
using before the age of 16 the risk is more pronounced as increased rates of use among
this group has resulted in an increase in the following: psychotic symptoms; adjustment
problems; depression; crime and suicidal behavior; anxiety; externalizing behavior;
attentional dysfunction; poor educational achievement and poor executive functioning.
In the study by van Gastel, et al. (2013), the researchers conducted a populationbased analysis to determine whether cannabis use is associated with poor psychosocial
functioning and therefore a risk factor for mental health problems in adolescents (van
Gastel, et al., 2013). The sample population was select from Dutch secondary school
children and included 5,179 girls and 5,145 boys ranging in age from 11 to 16 years
(average age 13.9). A total of 10,324 participants who had completed a Public Health
Service School Survey collecting information on demographics, substance use, school
factors and stressful life events. Participants had also completed the Strengths and
Difficulties Questionnaire (SQD) (van Gastel, et al., 2013). Researchers used an in-class
computer-based assessment to gather data on psychosocial functioning, lifestyle and
social environment, and perceived school safety (van Gastel, et al., 2013).
Data analysis used the following measurements: psychosocial functioning; use of
cannabis and other substances; sociodemographic factors; school variables; and stressful
life events (van Gastel, et al., 2013). This information was obtained via the Strengths and
Difficulties Questionnaire (SQD), which according to van Gastel, et al., (2013) is a self-
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reporting survey specifically designed for adolescents aged 11 to 16 years and intended to
measure psychosocial adjustment and assess psychopathology. The SDQ reportedly has
an accuracy as high as 91% for correctly predicting psychiatric diagnoses among
adolescents (van Gastel, et al., 2013). Sociodemographic factors included the following
four measures include: 1) age; 2) gender; 3) ethnicity; 4) level of education; and 4)
household composition (refers to whether adolescent lived with both parents, just one
parent or did not live with either parent) (van Gastel, et al., 2013). Additionally, having a
parent that is mentally ill was considered as a genetic predisposition for mental health
problems.
While van Gastel, et al. (2013) indicated that there was no significant difference
between groups with respect to age, gender, and ethnicity; the study ultimately concludes
that cannabis use can be considered a “risk indicator for mental health problems in
adolescents.” (van Gastel, et al., 2013). However, other confounding variables in the
presence of cannabis use contribute to poor psychosocial functioning (van Gastel, et al.,
2013). Thus, cannabis use may serve as a “marker for adolescents at risk for mental
health problems” (van Gastel, et al., 2013, para. 19).
In yet another study, Medina et al. (2007) addressed the association between
depression and marijuana use, decreasing white matter and hippocampal volumes in
adolescents. Previous studies have demonstrated reductions in hippocampal volumes
among adults with depression. Similarly, studies have demonstrated white matter
reductions in adults with symptoms of depression and suicide ideation. These white
matter reductions are revealed on brain magnetic resonance imaging (MRI) as
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hyperintensities, which are lesions within brain white matter that results from the
demyelination and degeneration of axons (Wardlaw, Hernandez, & Munoz-Maniega,
2015). While these reductions were exhibited in depressed adults, this was not the case in
depressed children and adolescents as these individuals typically displayed hippocampal
and white matter volumes consistent with non-depressed (healthy) controls (Medina,
Nagel, Park, McQueeny, & Tapert, 2007). This is of concern as addressing adolescent
marijuana use is an important topic especially considering evidence indicating that
marijuana is the most commonly used substance among high school students as
approximately 42% of high school seniors admit to trying marijuana in their lifetime
(Medina, Nagel, Park, McQueeny, & Tapert, 2007).
The study conducted by Medina, Nagel, Park, McQueeny, and Tapert, (2007)
focused on the following two goals: 1) the relationship between white matter and
hippocampal volumes and depressive symptoms; and 2) whether marijuana use
moderates the relationship between brain structure and depressive symptoms in a sample
of 32 adolescents.
In this study, participants were fluent English-speaking adolescents aged 16 to 18
years with at least one parent or guardian available to give consent for those under age 18
and provide a history for the participant (Medina, Nagel, Park, McQueeny, & Tapert,
2007). The sample included 16 marijuana users and 16 non-drug users that were recruited
from high schools, universities and through various ads (Medina, Nagel, Park,
McQueeny, & Tapert, 2007). Marijuana users were excluded if they were considered
heavy alcohol drinkers and if they used any substance other than marijuana, alcohol (in
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moderation) or nicotine. The study also noted adolescent history, drug use and symptoms
of depression with a parental interview conducted to corroborate information provided by
their children
The results of this study demonstrated an additive and interactive relationship
between marijuana use and white matter volume for predicting depressive symptoms.
However, it is not clear which came first as Medina et al., (2007) posited that “it remains
difficult to determine whether abnormal neurodevelopment caused depression, or if
depression interrupts developmental myelination” (para. 30). In contrast, this study did
not demonstrate a significant association between hippocampal volume and depression.
Nevertheless, this study demonstrated support for the hypothesized relationship between
reductions in white matter volume, depression, and marijuana use (Medina, Nagel, Park,
McQueeny, & Tapert, 2007). This is evident as the reductions in white matter was most
prominent among marijuana users that also exhibited symptoms of depression (Medina,
Nagel, Park, McQueeny, & Tapert, 2007).
Marijuana and Psychosis
The notion that marijuana use may cause psychosis is not a new concept as
several studies have demonstrated this association (Murray, Quigley, Quattrone, Englund
& Di Forti, 2016). However, many of these previous studies were conducted prior to the
legalization of marijuana and the concurrent increase in marijuana potency as the level of
THC has been rising (Murray, Quigley, Quattrone, Englund & Di Forti, 2016). Therefore,
the current study intended to address this gap in the research as the potential implications
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of highly potent marijuana with elevated THC levels should be a major public health
concern.
In a related study, the researchers addressed the association between marijuana
use, psychosis, and schizotypal personality disorder (Davis, Compton, Wang, Levin, &
Blanco, 2013). While marijuana is the most commonly used as an illicit drug in the
United States it is also the most commonly used substance among those with
schizophrenia and there is a growing body evidence which suggest the substance may
also increase the risk of developing schizophrenia (Davis, et al., 2013). However, Davis,
et al. (2013) posited that marijuana use alone is insufficient to cause schizophrenia as a
host of complex factors contribute to the development of this condition and marijuana
may serve to exacerbate or promote the development of psychotic symptoms (Davis, et
al., 2013). In order to examine the relationship between marijuana use and these
psychotic symptoms, Davis (2013) and fellow researchers examined the association
between marijuana use and schizotypal personality disorder (SPD). The primary
difference between SPD and Schizophrenia is concerned with duration of signs and
symptoms. In SPD these symptoms are transient and not as intense as those seen in
schizophrenia (Mayo Clinic, 2017).
Participants for this study included 34,365 adults (aged 18 years and older) that
were selected from those completing the National Epidemiologic Survey on Alcohol and
Related Conditions (NESARC) (Davis, et al, 2013). This is a national survey that covered
all 50 states and the District of Columbia. Diagnostic assessment for the study utilized the
Alcohol Use Disorder and Associated Disabilities Interview Schedule, which is a
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structured interview designed to assess mood, anxiety, psychotic, and personality
disorders (Davis, et al., 2013). The DSM-IV was used to assess substance use disorder for
marijuana and nine other drug classes. In addition to substance use disorder, respondents
were also evaluated for drug-specific abuse and dependence for the selected substances
(Davis, et al., 2013). Lifetime cannabis users were defined as those who used cannabis at
least once in their lifetime. The study compared sex, age, and race of lifetime cannabis
users and non-users and assessed the “percentage of participants with lifetime cannabis
use, a diagnosis of lifetime schizophrenia or a psychotic illness or episode (SPIE), and
Schizotypal Personality Disorder (SPD)” (Davis, et al., 2013, para. 15).
The study used logistic regression to assess the association between the outcome
variables psychosis and SPD and the following three predictor variables: 1) lifetime
cannabis use; 2) lifetime cannabis abuse; and 3) lifetime cannabis dependence on
psychosis (Davis, et al, 2013). This analysis provided the following results: for lifetime
cannabis use “the association between cannabis use and psychosis was 1.27 (95% CI 1.03
-1.57)” and for lifetime cannabis abuse the association was 1.79 (95% CI 1.35 – 2.38)
and for lifetime cannabis dependence this association was 3.69 (95% CI 2.49 – 5.47)
(Davis, et al., 2013). Thus, demonstrating a dose-dependent relationship between
increasing cannabis use and psychosis. Similarly, the relationship between SPD and
extent of cannabis use also demonstrated a dose-dependent relationship. As observations
revealed an odds ratio (OR) of 2.02 for lifetime cannabis users; OR = 2.83 for lifetime
cannabis abusers; and OR = 7.32 for lifetime cannabis dependence (Davis, et al, 2013).
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The results of this population-based study demonstrated cannabis use as a possible risk
factor for psychosis and SPD, and the risk increases with the extent of cannabis use in a
dose-dependent fashion. Furthermore, Davis et al. (2013) posited that
“the association between cannabis use and SPIE and SPD found in this study
could be explained by three mechanisms: (1) Direct pharmacological effects of
cannabis lead to psychosis or schizotypal traits; (2) Psychosis or schizotypal traits
lead to cannabis use as a means for individuals to cope with these symptoms; or
(3) Another associative factor influences both tendency toward psychosis or
schizotypal traits and cannabis use” (Davis, et al., 2013, para. 19).
The study conducted by Davis, et al. (2013) is relevant to this current research
effort as the results demonstrated a dose-dependent relationship between marijuana use
and psychosis and schizotypal personality disorder. Thus, confirming the importance of
addressing the effects of higher THC concentrations that would be expected to simulate a
higher dose in this dose-dependent relationship. Therefore, these findings further support
the gap in the research as one would expect an increased prevalence of psychosis and
schizotypal personality disorder to coincide with rising THC levels. My study is intended
to explore this hypothesis with respect to states legality status. In addition, data obtained
for the study conducted by Davis et al. (2013) was collected between 2001 and 2002 for
wave 1 and between 2004 and 2005 for wave 2 by which in either case was prior to the
elevated THC levels in marijuana demonstrated post-legalization.
In another study, Moore et al. (2007) conducted a literature review to address the
association between psychotic or affective mental health outcomes and cannabis use. The
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authors of this study stressed the importance of addressing these concerns in adolescence
as these individuals are particularly susceptible to environmental exposures, such
cannabis use. Moore et al. (2007) further posited that while it is established that cannabis
use can produce short-lived signs and symptoms associated with psychotic and affective
mental health outcomes. The long-term or chronic effects are not clearly founded and
present cause for greater public health concern.
In this review of the literature, only population-based longitudinal studies or casecontrol studies with a longitudinal design were selected. For this study, the following
conditions described psychosis: “schizophrenia, schizophreniform, schizoaffective, or
psychotic disorders, non-affective or affective psychoses, psychosis not otherwise
specified, psychotic symptoms, delusions, hallucinations, or thought disorder” (Moore, et
al., 2007, para.10). In contrast, the following described affective health outcomes:
“Affective, mood, or bipolar disorder, affective disorder not otherwise specified,
depression, suicidal ideation or suicide attempts, anxiety, neurosis, and mania” (Moore, et
al., 2007, para.10).
Overall, the results of this study demonstrated an increased incidence of psychosis
among cannabis users wherein the rate of psychosis among regular to moderate cannabis
users was approximately 40% (Moore et al., 2007). In contrast, these rates increased
approximately 50-200% for heavy cannabis users as the relationship between psychosis
and cannabis use exhibited a dose-response relationship (Moore, et al.,
2007). Furthermore, the concept that early age of cannabis use and development of
psychosis is not necessarily associated with the sensitivity of younger individuals. But
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more so with a cumulative exposure effect of cannabis (Moore, et al., 2007). The
literature review conducted by Moore et al. (2007) also revealed that cannabis users were
at greater risk for developing affective mental health outcomes. Such as, a psychotic
illness.
In a related study, Di Forti, et al. (2014) also addressed the association between
the regular use of highly potent marijuana and the occurrence of psychosis. According to
the researchers, marijuana users are subject to psychosis at an earlier age than non-users
(Di Forti, et al., 2014). However, causality for this association is not fully understood (Di
Forti, et al., 2014). Di Forte and colleagues posited that psychosis among marijuana users
occurs approximately three years earlier than in non-users (Di Forti, et al., 2014).
However, the researchers further posited that these results may not be generalizable as
studies have demonstrated that males are subject to schizophrenia at an earlier age and
are more susceptible to recreational drug use than females (Di Forti, et al., 2014). Thus,
implicating gender as a potential confounding variable in previous studies (Di Forti, et
al., 2014). Additionally, the association between psychosis and schizophrenia is relevant
as the National Collaborating Centre for Mental Health (2014) indicates that “the term
psychosis covers a set of related conditions, of which the commonest is schizophrenia,
and includes schizoaffective disorder, schizophreniform disorder, delusional disorder and
the so-called non-affective psychoses” (National Collaborating Centre for Mental Health
[NCCMH], 2014, para.1). Nevertheless, causality for this association has been described
by various theories. One of which suggest that the under-developed brain of an
adolescent is more susceptible to marijuana’s adverse effects (Di Forti, et al., 2014).
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While another theory describes the amount of time one uses marijuana as the cause of
psychosis at an earlier age than non-users or less frequent users (Di Forti, et al., 2014).
Based on this understanding, Di Forte (Di Forti, et al., 2014). and colleagues
aimed to assess whether psychosis at an early age is more associated with being male
versus a specific pattern of marijuana use (Di Forti, et al., 2014). To accomplish this aim,
in addition to gender, Di Forte et al. (2014) also addressed the following patterns of
marijuana use: 1) how often individuals used marijuana; 2) the potency (‘low potency
hash-type versus high potency skunk-type’) of marijuana used 3) whether an individual
used marijuana or not and 4) for marijuana users the age that these individuals first began
using marijuana. This study is particularly relevant to the current study because it
addresses the effects of highly potent marijuana such as the Skunk type described here
with an approximate THC level of 16% versus low potency marijuana (hash-type) with
an approximate THC content of four percent (Di Forti et al., 2014).
Participants for this study ranged in age from 18 to 65 years and were selected
from patients admitted to one of two mental health facilities in the United Kingdom with
a diagnosis of either non-affective or affective psychosis (Di Forte, et al., 2014). This
study had varying results. For instance, with respect to gender, the study demonstrated
that both male and female marijuana users had a greater likelihood of psychosis at earlier
age than non-marijuana users. However, while male users demonstrated an earlier age of
psychosis than females with similar marijuana using patterns. This observation was not
considered statistically significant (P=.28) for the association between gender and
marijuana use according to the results of the regression analysis conducted (Di Forte, et
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al., 2014). In contrast, individuals who used highly potent marijuana and those who used
marijuana daily had an earlier onset of psychosis than those who used lower potency
marijuana and those who used marijuana less than daily, respectfully (Di Forte, et al.,
2014). The study also revealed that individuals who began using marijuana at an earlier
age (less than 15 years old) experienced their first psychotic episode at an earlier age (Di
Forte, et al., 2014). Ultimately, daily marijuana users that preferred highly potent
marijuana had the greatest risk of early psychosis (Di Forte, et al., 2014). This group on
average experienced a psychotic episode approximately 6 years earlier than those who
did not use marijuana (Di Forte, et al., 2014).
The Endocannabinoid System
The identification of THC as the psychoactive component in marijuana ultimately
led to the discovery of an endogenous endocannabinoid system that is involved in a range
of biological functions. The endocannabinoid system is comprised of cannabinoid
receptors; endogenous cannabinoids; and enzymes involved in their regulation as well as
an endocannabinoid receptor (Shonesy, 2014). The system is located in the central and
peripheral nervous system (CNS & PNS) and mediated by two cannabinoid receptors
referred to as CB1 & CB2 (Shonesy et al., 2014). CB1 receptors are primarily located in
the CNS while CB2 receptors are located peripherally (Vinod and Hungund, 2006).
However, recent evidence suggests that CB2 receptors are also located in the CNS
(Vinod and Hungund, 2006). These receptors respond to both endogenous and exogenous
stimulation (Shonesy et al., 2014). Natural endogenous stimulation of CB1 receptors
occurs through one of two THC-like molecules, anandamide (AEA) and 2-
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arachidonoylglycerol (2-AG) (Shonesy et al., 2014). According to Shonesy (2014) this
system “is heavily implicated in the modulation of anxiety and depression”. The THC in
marijuana is capable of binding CB1 receptors of the system and affects mood (Shonesy
et al., 2014). Such that reduced stimulation of these receptors results in mood
destabilization and increased feelings of anxiety and depression (para. 1). Thus,
marijuana users who suffer from these conditions may not be able to synthesize enough
of THC-like molecules (particularly 2-AG) so they self-medicate with marijuana to
compensate. Suggesting the potential for treatment regimens that focus on the
endocannabinoid system and ligands that bind to its receptors (Shonesy et al., 2014).
Finally, Shonesy, et al., (2014) posit that the data presented may well lend support
for an endocannabinoid deficiency type state that can contribute to the development of
anxiety and depression and therefore encourage the use of cannabis in an attempt to
counter these effects. Shonesy et al., (2014) further posited that evidence demonstrating
that restoration of the 2-AG signaling system can reverse the symptoms of anxiety and
depression brought on by the endocannabinoid deficiency lends support for therapeutic
approaches that target the ECS.
In a related article, Vinod and Hungund (2006) provided support for a possible
role of the endocannabinoid system (ECS) in depression, suicide, mood disorders and
substance use disorders. This article presented a review of the literature on the role of the
ECS. The authors explain that CB2 receptors are associated with the immune system and
located peripherally (Vinod and Hungund, 2006). While CB1 receptors are located
primarily in the CNS. More specifically, within the CNS CB1 receptors are most
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abundant in the cortex, hippocampus, cerebellum, and basal ganglia (Vinod and
Hungund, 2006). The authors further explained that depression and suicide are associated
with alterations in the prefrontal region of the cortex (Vinod and Hungund, 2006). Such
that alterations in glucose metabolism in this region has been implicated in the
development of depression (Vinod and Hungund, 2006). In addition, depression is also
associated with reduced activity and volume of the prefrontal cortex as well as injuries to
this region are commonly observed in depressed patients (Vinod and Hungund, 2006).
There are also possible implications of the prefrontal cortex in behavioral inhibition,
decision making, and the expression of emotions (Vinod and Hungund, 2006).
As previously indicated, the endogenous endocannabinoids (ECs), anandamide
(AEA) and 2-arachidonoylglycerol (2-AG) are lipid mediators that act on cannabinoid
(CB) receptors of the endocannabinoid system (Vinod and Hungund, 2006). These ECs
are found in greatest abundance in the cerebral cortex, basal ganglia, and limbic
structures (Vinod and Hungund, 2006). Post-mortem studies have demonstrated that
depressed suicide patients have higher than normal levels of CB1 receptors in the prefontal cortex and also demonstrate increased activation of these G-protein linked
receptors (Vinod and Hungund, 2006). Studies have also implicated an association
between cannabis use, mood alteration and the endocannabinoid system in the
development of schizophrenia (Vinod and Hungund, 2006). This premise is supported by
postmortem studies demonstrating high than normal CB1 receptors in schizophrenics
(Vinod and Hungund, 2006). In addition, animal studies on the mechanism of action of
antidepressant medications indicate a possible role of CB1 receptors. For instance,
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administration of Fluoxetine, an antidepressant that acts by increasing 5hydroxytryptamine (5-HT) also known as Serotonin, a neurotransmitter that is associated
with depression and suicide (Vinod and Hungund, 2006; Serra & Fratta, 2007). Animal
studies have demonstrated that the rise in 5-HT caused by fluoxetine, in turn causes a
decrease in CB1 receptors. Thus, suggesting a possible function of the endocannabinoid
system CB1 receptors in the regulation of mood disorders (i.e. depression), cognition,
motivation and emotional behavior (Vinod and Hungund, 2006).
In yet another study, Serra & Fratta (2007) presented a synthesis of the literature
on available studies that address the association between the endocannabinoid system and
the development of depression. Serra & Fratta (2007) present current hypotheses that
attempted to explain the neurobiology behind the development of depression. One of
which is the monoamine hypothesis of depression. Which posited that the development of
depression is caused by reduced monoaminergic transmission (Serra & Fratta, 2007).
More specifically, reduced action of neurotransmitters like noradrenaline (NA) and
serotonin (5HT) are associated with the depression (Serra & Fratta, 2007). This premise
has led to the development of antidepressant drugs such as selective serotonin reuptake
inhibitors (SSRIs) and selective noradrenaline reuptake inhibitors (SNRIs) that increase
the availability of 5HT and NE by inhibiting the reuptake of these substances (Serra &
Fratta, 2007). Thereby increasing the levels of 5HT and NE at the synaptic cleft which is
located between neurons where monoaminergic transmission (Serra & Fratta, 2007).
Another hypothesis of depression implicates reduced hippocampal volume with the
development of depression (Serra & Fratta, 2007). This hypothesis is supported by
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clinical neuroimaging studies that demonstrate reduced hippocampal volume in untreated
depressed patients versus no reduction in hippocampal volume in patients treated with
antidepressants (Serra & Fratta, 2007). These results suggested that long-term treatment
with antidepressants, such as SSRIs & SNRIs in conjunction with electroconvulsive
therapy (ECT) can lead to cell proliferation and neurogenesis resulting in an
antidepressant effect (Serra & Fratta, 2007).
Regulation or control of the endogenous endocannabinoids, anandamide (AEA)
and 2-arachidonoylglycerol (2-AG) occurs via degradation that utilizes one of two
enzymes (Serra & Fratta, 2007). Whereby the enzymes fatty acid amide hydrolase
(FAAH) and monoacylglyceride lipase (MAGL) degrade and remove the activity of
anandamide (AEA) and 2-arachidonoylglycerol (2-AG), respectively. Thus, studies
addressing the effects of endocannabinoid system (ECS) on depression can proceed by
inhibiting the activity of these enzymes (Serra & Fratta, 2007). In addition, studies of this
system can also be conducted using substances that act as either agonist or antagonist of
CB1 receptors (Serra & Fratta, 2007). For instance, an agonist of CB1 receptors would
bind to and increase activity of this receptor. Whereas an antagonist would block or
reduce the activity of CB1 receptors (Serra & Fratta, 2007). Therefore, an agonist of the
ECS would be expected to increase antidepressant effects, thereby reducing symptoms of
depression. Whereas, an antagonist would be expected to reduce or block the action
elicited by CB1 receptors resulting in an increased risk of depression (Serra & Fratta,
2007).
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Serra and Fratta (2007) present results from animal studies demonstrating that
upon administration of either a re-uptake inhibitor, CB1 receptor agonist, or a
competitive inhibitor of FAAH (all of which increase activity of CB1 receptors) results in
an antidepressant like effect. These results support the notion that the ECS plays an
important role in the development of depression. In contrast, the action of these
substances is antagonized (blocked) by administration of a CB1 receptor blocker (Serra &
Fratta, 2007). Thus, further supporting the role of the ECS in depression as stimulation of
CB1 receptor results in antidepressant-like effect and blocking CB1 receptors reduces the
antidepressant effects elicited by stimulation of these receptors (Serra & Fratta, 2007).
In contrast, Serra and Fratta (2007) report on animal studies that utilize CB1
knock out mice, which have been bred and manipulated to reduce or eliminate the
presence of CB1 receptors. In this study researchers observed that CB1 knock out mice
were more susceptible to developing depressive-like behavior (Serra & Fratta, 2007).
These results provided additional support for the role of the ECS in the regulation of
depression.
In addition to depression, the ECS has also been implicated in the development of
psychosis (Bioque et al., 2009). There are several hypotheses which exist to explain the
development of psychosis. Among them include several demonstrating alterations in the
immune system as a possible etiology (Bioque et al., 2009). It has been proposed that
immune system involvement may include both the peripheral and central nervous system
in this etiological explanation of psychosis (Bioque et al., 2009). As previously indicated,
CB2 receptors of the ECS are primarily located in and associated with the peripheral
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nervous system (PNS) (Vinod and Hungund, 2006). Bioque et al., (2009) conducted a
study to assess the expression and involvement of components of endocannabinoid
system in the development of first-episode psychosis (FEP) versus health controls. The
employed multiple logistic regression to determine which components of the ECS have a
potential role as either risk or protective factors in the development of FEP (Bioque et al.,
2009). This study also assessed possible alterations in the ECS due to prolonged heavy
cannabis use (Bioque et al., 2009).”
The ECS components identified and studied from peripheral blood mononuclear
cells (PBMC) include: Protein expression of the cannabinoid receptor 2 (CB2), which is
located the PNS and associated with immune system function (Bioque et al., 2009);
Protein levels of N-acyl phosphatidylethanolamine (NAPE) and diacylglycerol lipase
(DAGL), the main enzymes involved in the synthesis of regulatory endocannabinoids
[i.e. anandamide (AEA) and 2-arachidonoylglycerol (2-AG)]; and Fatty acid amide
hydrolase (FAAH) and monoacylglycerol lipase (MAGL) the main enzymes involved in
the degradation, removal and therefore inactivation of regulatory enzymes of the ECS
(Bisque et al., 2009).
The researchers recruited 95 participants with FEP and 90 controls from among
patients at Spanish university hospitals (Bisque et al., 2009). The results of this study
revealed that individuals with FEP also had decreased expression of CB2 receptors
suggesting reduced ECS activation as a possible contributor to FEP (Bisque, 2009). In
addition, FEP patients also demonstrated decreased levels of NAPE and DAGL, the
enzymes responsible for synthesizing the regulatory endocannabinoids, AEA and 2-AG
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(Bisque, 2009). This suggest that reduced levels of these components may contribute to
the development of FEP via reduced activity of the ECS (Bisque, 2009). In contrast, FEP
individuals demonstrated an increased expression of FAAH and MAGL, the enzymes
responsible for degrading and removing the activating/regulatory components of the ECS
(Bisque, 2009). This implies that reduced activity of AEA and 2-AG led to reduced ECS
function and increased risk of FEP (Bisque, 2009). Thus, CB2 receptor expression and
the regulatory endocannabinoids may well serve as protective factors of the ECS,
reducing the potential for the development of FEP (Bisque, 2009). While the degradation
and removal enzymes, NAPE and DAG may serve as risk factors for FEP (Bisque, 2009).
Finally, Bisque et al., (2009) suggest a potential role of heavy prolonged cannabis use in
the etiology of FEP as these individuals demonstrated a large dysregulation of the ECS
when compared to the healthy control group (Bisque et al., 2009).
Therapeutic Effects of Marijuana on Mental Health
While this literature review has focused on the causative nature of marijuana as
the substance has been demonstrated to exacerbate or potentially cause psychosis,
anxiety, and mental illnesses like depression and schizophrenia. However, ironically
marijuana or more specifically its constituents has the potential to counteract these
conditions.
Marijuana also known as Cannabis contains numerous Cannabinoids. Two of the
most significant include Delta-9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD).
According to Zuardi et al., (2006) these substances have a divergent pathway exhibiting
properties that are opposite in nature. For instance, THC is reportedly responsible for the
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psychoactive effects most recreational marijuana users seek. While CBD demonstrates
the opposite effects as this cannabinoid has anti-psychotic activity (Zuardi et al., 2006).
Zuardi et al. (2006) further posited that the cannabinoid, Delta-9-THC can cause
anxiety and psychotic-like symptoms as demonstrated in healthy volunteers exposed to
intravenous THC. Conversely, CBD does not produce these psychological effects (Zuardi
et al., 2006). Studies assessing the interaction between CBD and THC demonstrated that
CBD has anxiety reducing (anxiolytic) and anti-psychotic effects when co-administered
with THC (Zuardi et al., 2006). Additional properties of CBD are associated with the
following effects: hypnotic, anticonvulsive, neuroprotective, and hormonal (increased
corticosterone and cortisol levels) (Zuardi et al., 2006). Thus, marijuana’s properties,
effects, and potency can vary based on the ratio of THC and CBD, and this ratio can vary
based on the particular strain of marijuana, the growing conditions, and other factors
(Radhakrishnan, Wilkinson & D’Souza, 2014; Zuardi et al., 2006). Nevertheless, it is this
researcher’s understanding that typically, as the amount of THC increases, the amount of
CBD decreases and vice versa. This understanding is supported in a study by ElSohly et
al. (2016) which concluded that
“overall, the potency of illicit cannabis plant material has consistently risen over
time since 1995 from approximately 4% in 1995 to approximately 12% in 2014.
On the other hand, the CBD content has fallen on average from approximately
0.28% in 2001 to <0.15% in 2014, resulting in a change in the ratio of THC to
CBD from 14 times in 1995 to approximately 80 times in 2014” (ElSohly et al.,
2016, pg.613).
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This observation provides further support to address the gap in the research
created by highly potent marijuana as additional research is warranted to address the
rising levels of THC demonstrated post-legalization.
Individuals may unknowingly reduce the risk of psychosis by smoking marijuana
that is high in CBD as evidenced in the study by Morgan & Curran (2008), wherein the
researchers support the premise of opposing actions for THC (psychotomimetic) and
CBD (antipsychotic; anxiolytic). Morgan & Curran (2008) examined hair samples of
known drug users and non-drug users for the presence or absence of THC and CBD. The
results of the hair samples identified the following four groups of individuals: 1) THC
only; 2) THC and CBD; 3) CBD only; and 4) those with no cannabinoids. Among those
identified as THC only, these individuals were included only if the hair sample contained
the presence of Delta-9-THC-carboxylic acid in addition to the normal Delta-9-THC
(Morgan & Curran, 2008). This is because the presence of Deltal-9-THC-carboxylic acid
is indicative of actual marijuana use rather than secondary or passive exposure to the
substance (Morgan & Curran, 2008). In addition, the CBD only group was excluded
because this sample consisted of 8 individuals and too small for statistical analysis
(Morgan & Curran, 2008). The final sample therefore included the following three
groups: 1) THC only; 2) THC-CBD and 3) no cannabinoids (Morgan & Curran, 2008).
The results of this study reveal that the THC only group was more prone to psychosis and
unusual experiences (i.e. hallucinations and delusions) than both the no cannabinoid
group and the THC-CBD group (Morgan & Curran, 2008). In addition, scores for
delusional thinking was higher in the THC only group than in the no cannabinoid group
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and the THC-CBD group (Morgan & Curran, 2008). However, this score was also higher
in the THC-CBD group than in the no cannabinoid group (Morgan & Curran, 2008).
Another interesting trend is lower scores for anhedonia in the THC-CBD group than in
the THC only and no cannabinoid groups (Morgan & Curran, 2008). This observation
may reflect some potential protective effects of CBD, as anhedonia is described as an
inability to experience pleasure and this is one of the main symptoms associated with
major depressive disorder, which is an important mental health issue (Brynie, 2009;
Morgan & Curran, 2008).
It is important to mention that the target population included ketamine users and
this substance may have properties that could be confused with the mental health and
psychotic-like conditions exhibited by THC in marijuana (Morgan & Curran, 2008;
Davis, 2017). For example, ketamine is used recreationally for its hallucinogenic and
dissociative properties (Davis, 2017). Thus, demonstrating a potential limitation of this
study.
In yet another study, Morgan et al. (2012) further addressed the effects of
THC/CBD ratios. In the previous study Morgan et al (2008) provided evidence indicating
that individuals who smoked marijuana containing high or detectable levels of CBD were
less prone to psychotic-like symptoms than individuals who smoked marijuana high in
THC or no CBD. In this more recent study, Morgan et al. (2012) sought to determine if
the potential protective effects of CBD extended beyond psychosis (psychotic-like
symptoms). Thus, Morgan et al. (2012) addressed the effects of CBD on memory,
depression, anxiety, and psychological well-being among marijuana users. In this study,
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marijuana users were again placed into groups based on hair sample analysis. The results
of this study demonstrated fewer psychosis-like symptoms in those with detectable levels
of CBD than those without, and increased depression and anxiety among those with high
levels of THC (Morgan et al., 2012). In addition, those with high THC levels had more
problems with memory and recall than those with CBD detected (Morgan et al., 2012).
Thus, while highly potent marijuana which has elevated THC levels may contribute to the
development of mental health issues and psychosis (Morgan et al., 2012). This
occurrence may be attenuated by marijuana with higher CBD/THC ratios as detectable
levels of CBD may be protective in nature (Morgan et al., 2012).
In a related study, McGuire et al. (2017) addressed the potential antipsychotic
properties of Cannabidiol (CBD) in the treatment of Schizophrenia (McGuire et al.,
2017). In this study, McGuire et al. (2007) added CBD to the existing treatment regimen
of schizophrenia patients. The double-blind study randomly placed schizophrenia patients
into two groups (McGuire et al., 2017). Group 1 or the treatment group received CBD as
an adjunct to their existing treatment antipsychotic regimen. The control group received a
placebo in addition to their regular antipsychotic medication (McGuire et al., 2017).
The study results demonstrated a reduction in positive psychotic symptoms
among schizophrenic patients treated with CBD and their existing antipsychotic
medication (McGuire et al., 2017). In addition, the evaluating clinicians report that the
CBD group demonstrated reductions in disease severity, and general improvements in
overall health and cognitive function (McGuire et al., 2017). A small percentage of
patients in both the CBD and placebo groups report mild adverse effects with treatment.
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However, most symptoms were mild and resoled without treatment (McGuire et al.,
2017). This is an important benefit as antipsychotic medications have been associated
with adverse effects that can cause poor patient compliance resulting in less favorable
health outcomes (McGuire et al., 2017). Another important aspect of this study is
concerned with the mechanism of action associated with typical schizophrenia drugs.
These drugs typically function through a dopamine receptor process (McGuire et al.,
2017). Therefore, CBD which does not use this mechanism of action may offer and
alternative approach that can be used in conjunction with traditional drugs (McGuire et
al., 2017).
Marijuana Distribution and Preference
Since legalization began trends in marijuana potency, usage, distribution,
preference and methods of use have also changed somewhat dramatically. For instance,
during the period between the 1960s through the mid-1990s the THC content of
marijuana ranged from 2 to 4%. Which is far less potent than marijuana used today as the
THC content increased significantly by 212% between 1995 and 2015 (Stuyt, 2019).
Such that by 2017 this sharp rise in THC concentration led to the availability of
marijuana with THC levels ranging between 14 to 28 percent as found in Colorado
dispensaries at that time (Stuyt, 2019). This dramatic rise in THC content is largely due
to the unchecked growth and manipulation by the marijuana industry to produce far more
potent strains of marijuana (Stuyt, 2019). The production of highly potent marijuana
strains is advantageous to the marijuana industry as THC concentration is associated
increased psychoactive effects, increased use and greater risk of addiction (Stuyt, 2019).
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Ironically, this approach reflects a strategy employed by big tobacco companies. Which
gradually developed and marketed tobacco products that were far more addictive,
appealing and accepted (Richter & Sharon, 2014). These innovations led to changes in
tobacco consumption from 1% among the American consumer in the 1880s to roughly
half of the population using tobacco by the 1950s (Richter & Sharon, 2014).
As such, legalization has demonstrated a rise in marijuana use as according to
Carroll (2018) “one in seven adults report using marijuana in 2017” with an overall use
rate of 14.6 percent among adults in U.S. The portion of use also varies based on states
legality status (para. 1). For instances, in states with no laws allowing marijuana use only
12 percent of adult’s report using marijuana in the past year (Carroll, 2018). In contrast,
in states with laws legalizing medical marijuana the rate of use for adults was 14 percent
(Carroll, 2018). Whereas in states with recreational marijuana laws adult use in the past
year rose to 20 percent (Carroll, 2018). Thus, the adult use of marijuana has doubled in
the general population over the last decade according to reports in 2014. Indicating that
13.3 percent of adults reported past-year marijuana use (Keyhani, et al., 2018). These
statistics are the result of a national study reported in the Annals of Internal Medicine,
entitled: Risks and Benefits of Marijuana Use: A National Survey of U.S. Adults
(Keyhani, et al., 2018). In this study, Keyhani et al., (2018) used federal surveys, peerreviewed literature, and media reports to develop a comprehensive survey to gain a
greater understanding of how adults in U.S. view marijuana. This national survey was not
only designed to provide an understanding of opinions associated with marijuana
acceptance and legalization. But also, to address topics such as: frequency of marijuana
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use; reasons for using marijuana; as well as knowledge and behaviors associated with
marijuana use (Keyhani, et al., 2018). In addition, specific areas of content included:
“perceptions of specific risks and benefits of marijuana use, possible preventive
health benefits of different methods of marijuana consumption (smoking, vaping,
ingestion), addiction potential, safety of use during pregnancy, and societal effects
(including secondhand smoke and driving under the influence)” (Keyhani, et al.,
2018, para 14).
Finally, the survey addressed how adults view the use and effects of marijuana
when compared to other legal drugs with abuse potential, such as tobacco and alcohol
(Keyhani, et al., 2018).
The results of this survey had surprising and widely varied results. Regarding
perceived risks and benefits, the respondent’s results revealed that most adult in the U.S.
(81%) believed that marijuana has at least one benefit with only 17% of respondents
indicating that marijuana has no benefit (Keyhani, et al., 2018). The following is a list of
perceived benefits identified and the percentage of respondents that believe marijuana is
associated with those benefits. These include: 1) Pain management (65.7); 2) Treatment
of disease (such as epilepsy or multiple sclerosis) (47.9%); 3) Relief of stress, anxiety, or
depression (46.8%); 4) Improved appetite (35.1%); 5) Improved sleep (28.9%); 6) Help
decreasing or stopping other medicines (23.3%); 7) Improved creativity (16.2%); 8)
Improved focus or concentration (10.6%); 9) Increased energy (8.1%); and 10) Other
benefit (5.1%) (Keyhani, et al., 2018). Regarding risk, the following is a list of the most
common perceived risk identified by respondents: 1) Legal problems (51.8%); 2)
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Addiction (50%); 3) Impaired memory (42%); Increased use of other drugs (37.4%);
Personal or relationship problems (34.8%); Decrease in Intelligence (IQ) (28.6%);
Decrease in energy (27.4%); New or worsening health problems (18%); Increase in
stress, anxiety, or depression (15%); Disrupted sleep (11.3%).; and 8.8% of respondents
believe marijuana use is without risk. However, most respondents (21.3%) indicated that
addiction is the most important risk associated with marijuana use. The second most
important risk identified was legal problems (20.7%) followed by an increased risk of
using other drugs (18%) (Keyhani, et al., 2018). Nevertheless, based on the results
identified it is evident that most adult respondents (81.1%) believe marijuana have some
benefits whereas only 17% of respondents indicate that marijuana has no benefits. This
finding is consistent with the growing trend in marijuana perception and acceptance as
according to an article published by the Pew Research Center, approximately 62% of
Americans believe marijuana should be legalized (Hartig & Geiger, 2018). Thus,
reflecting a decrease in perceived risks associated with marijuana use. This belief and
acceptance have increased steadily and relatively rapidly as in the year 2000 only 31% of
Americans favored legalization (Hartig & Geiger, 2018). This finding is further
evidenced by a national survey that indicates Americans perception of “great risk from
weekly marijuana use dropped from 50.4% in 2002 to 33.3% in 2014” (Keyhani, et al.,
2018, para. 5).
The results of Keyhani et al., (2018) also reveal that many Americans believe
marijuana can reduce the risk of negative health outcomes. As 36.9% of U.S. adults
surveyed believed to some degree that edible marijuana has some preventative health
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benefits. Whereas, 61.9% of U.S. adults disagree with this notion (Keyhani, 2018). In
contrast, 29.2% of respondents believe that smoking marijuana has some preventative
health benefits with 69.8% of respondents disagreeing (Keyhani, 2018). Additionally,
29.2% of respondents indicate that vaping marijuana has preventative health benefits
while 69.6% disagreed to some degree (Keyhani, 2018).
All the same, while the most common method of use is still smoking as 12.9%
report smoking as their preferred method of use (Carroll, 2018). There is growing
preference for other methods of use that increase potency and duration of action as 6% of
respondents prefer consumption of marijuana infused products (Carroll, 2018). Followed
by vaping at 4.7% then use of marijuana concentrates 1.9%, and use of topical marijuana
products 0.8% (Carroll, 2018). Thus, there is a growing preference among marijuana
users for highly potent marijuana and marijuana products with higher THC levels, and
methods of use that produce longer and more profound effects.
In addition, when compared to other substances of use, misuse and abuse such as,
tobacco and alcohol. Respondents generally believe marijuana is safer. For instance,
more than one-third (37.3%) of adults surveyed believe that secondhand marijuana smoke
is safer than secondhand tobacco smoke. Many respondents also believe secondhand
marijuana smoke is completely safe for adults (18%) and children (7.6%). In addition,
Keyhani et al., (2018) posited that 38.2% of respondents believe “that smoking 1
marijuana joint a day is much safer or somewhat safer than smoking 1 cigarette a day”,
and “about 13.5% agree that smoking 1 marijuana joint per day is safer than drinking 1
glass of wine per day” (para. 18).
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Regardless of public perception, evidenced based research to substantiate the risk
and benefits of marijuana is limited. Moreover, unlike tobacco and alcohol, the marketing
of marijuana is relatively free of constraints (Keyhani, 2018). As public health leaders
have yet to implement widespread accompanying messages to warn the public of the
potential harms associated with marijuana use (Keyhani, 2018). With such unchecked
promotion, growing acceptance and continued widespread legalization it is important
now more than ever to emphasize these risks, and develop strategies and regulations to
protect, warn and inform the public and future generations of the potential implications of
continued widespread legalization and acceptance.
Another growing concern in the wake of continued widespread legalization is
trafficking and therefore distribution of legal marijuana. Which has been a concern since
legalization began for recreational purpose in Colorado (Schwarz, 2017). This is
evidenced by a lawsuit in which Nebraska and Oklahoma attempted to sue Colorado
alleging that the state’s decision to legalize recreational marijuana is a violation of the
U.S. constitution and places significant burden on bordering states’ law enforcement and
legal systems (Schwarz, 2017). While the supreme court denied these challenges, the
concern still exists as according to an article published by the Hazelden Betty Ford
Foundation (HBFF) (2017),
“Marijuana legalization efforts alter black market economics but are not effective
in stopping black market sales. Perhaps due to poor regulation or supply chain
issues, many young people I see from across the country talk about getting their
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‘high quality’ marijuana and concentrates from ‘legitimate’ growers who liquidate
their surplus at a heavily discounted price.” (para. 20)
This premise is further evidenced by reports from California which indicated that
the majority of marijuana produced within the state, approximately 85 to 90% is
trafficked out to regions without laws legalizing marijuana (Fuller, 2019). In fact, the
California Department of Food and Agriculture estimates that the state produces
approximately 15.5 million pounds of marijuana annually and only consumes about 2.5
million pounds within the state. This surplus marijuana is estimated at 13 times the total
amount produced annually in Colorado (Fuller, 2019). Most of which is smuggled east
across the Rocky Mountains and Mississippi into areas like Illinois, Connecticut and
Washington, D.C. where this surplus marijuana can sale for as much as three times the
original wholesale price (Fuller, 2019). Thus, highly potent marijuana produced and sold
in states with medical and recreational laws is making its way into other areas without
such laws (Fuller, 2019). While this trend in rising THC levels demonstrated nationally
since legalization should be a growing concern. Another challenge for public health
leaders is the methods of marijuana use as users and distributors are constantly finding
new and innovative ways to use the substance (Keyhani, 2018). These methods have the
potential to further enhance the effect of marijuana by increasing THC levels or duration
of action. Dabbing, vaping, synthetic marijuana, shatter, and consumption of edible
marijuana products are methods of use that have emerged to improve the psychoactive
effects of marijuana (Keyhani, 2018; Murray, Quigley, Quattrone, Englund & Di Forti,
2016). In states where marijuana has been legalized for medicinal and/or recreational
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purposes these methods of use are growing in popularity and are increasingly widely
available (Keyhani, 2018; Murray et al., 2016). Consumption of edible products and
production of concentrated oils either increase duration of action and/or THC
concentration (Murray et al, 2016). For instance, methods of extracting THC from the
marijuana plant have been found to produce resin oils with a THC concentration as high
as 80%. Additionally, other methods of use such as vaping and wax dabbing also deliver
a high THC concentration to the user (Murray, et al., 2016).
Dabbing is a method of marijuana use wherein the user smokes a highly potent
marijuana extract commonly referred to as wax (Marijuana Factcheck-potency, 2019;
Murray, et al., 2016). While dabbing or the use of butane hash oil is commonly
considered a new method of marijuana use when in fact this method has been around
since the 60s and may date back even further (Al-Zouabi, Stogner, Miller, Lane, 2018).
During the Vietnam conflict (war) soldiers would use acetone or petrol to extract the
THC in marijuana to create a liquid concentrate that could then be smeared on cigarettes,
rolling papers or used to saturate tobacco prior to rolling or smoking by other means (AlZouabi, et al., 2018). Nowadays marijuana users create THC concentrates using butane
instead and therefore the resulting product is termed “butane hash oil” or BHO (AlZouabi, et al., S2018). The concentrate produced is referred to by several names and the
terminology typically describes the products consistency. For instance, other names of
BHO, dabs and oils include: shatter; honeycomb; crumble wax; budder; and earwax (AlZouabi, et al., 2018, para. 2). Among these shatter is considered the most difficult form to
produce and appears as a clear amber solid (Stogner & Miller, 2015). Nevertheless, since
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legalization of medical and recreational marijuana these extracts are becoming
increasingly popular as evidenced by studies in the United States. For instance, Zhang,
Zheng, Zeng, and Leischow (2016) conducted a case study in which the researchers
tracked query searches on dabs or Dabbing of BHO concentrates in the United States
from January 2004 to December 2015. The study revealed that dabbing searches
increased with time to reach an estimated high of 1,526,280 searches on dabbing in 2015
(Zhang, et al., 2016). In yet another study, Daniulaityte and colleagues (2015) conducted
an analysis of “Twitter data on marijuana concentrates across the U.S.”. The results
revealed that “dabs-related tweets were highest in states that allowed recreational and/or
medicinal cannabis use and lowest in states that have not passed medical cannabis use
laws” (Daniulaityte, et al., 2015, p. 307). Thus, resources and information are readily
available as instructional videos on various websites, and social media platforms
provided easy access for the recreational home users and producers (Stogner & Miller,
2015). Reportedly these BHO concentrates can have THC levels that range as high as 80
percent (Stogner & Miller, 2015). In one study conducted in Switzerland, researchers
found that while the marijuana flowers being used had a THC level of 17% the BHO
concentrate produced was as much as four times that with a THC concentration as high as
71% (Cannabis Technology News, 2019).
The BHO concentrate is commonly used by one of two methods, dabbing and/or
vaping. Dabbing is a method that involves using conduction as the form of heating
(Krauss, et al, 2015). In this process the user heats the dab (marijuana or BHO
concentrate) to a high temperature using a torch on a conduction surface or hot plate
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which is typically a nail. The user then inhales the vapor produced (Krauss, et al., 2015).
Many marijuana users believe that dabbing is a cleaner method of using marijuana that is
less harmful than smoking (Sandoiu, 2017). However, this may not be the case as
discovered by Dr. Strongin and fellow researchers at the University of Portland. While
simulating the conditions of dabbing in the lab and monitoring the composition of vapor
produced (Sandoiu, 2017). They found that the butane hash oil produced relatively high
levels of benzene, a known cancer-causing chemical as well as methacrolein. While
methacrolein is generally considered a noxious irritant, another chemical acrolein which
is similar in structure to methacrolein is also a known human carcinogen (Sandoiu, 2017).
Dr. Strongin and colleagues posit that “Given the widespread legalization of cannabis in
the [United States], it is imperative to study the full toxicology of its consumption to
guide future policy” (Sandoiu, 2017, para. 17).
In contrast, vaping and the use of e-cigarettes is growing in popular particularly
among adolescents as according to one report “one in 11 middle and high school students
report using an e-cigarette for marijuana, hash oil or wax” (Marijuana Factcheck [MFC]vaping 2019, para. 1). Unlike dabbing which uses conduction heating of a metal surface
where heat is directly applied to and transferred to a heating element, vaping involves
convection heat (Krauss, et al., 2015). In this process the material to be inhaled
(marijuana leaves, BHO concentrated oil or dab) is heated indirectly usually using a
battery powered heat source that heats the coil that heats the air. The hot air moves
through the marijuana product, which is vaporized, and the resulting vapor is inhaled by
the user (Lepkoff, 2018; Yang et al., 2018). Users prefer vaping and e-cigarettes (e-cigs)
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because they are easily concealed as these methods do not produce visible smoke and are
nearly odorless (MFC-vaping, 2019; Yang et al., 2018). Users also prefer vaping and ecigs because they are a cost-effective as a smaller amount of concentrated marijuana
product (high potency THC) is required to achieve the desired effect (MFC-vaping, 2019;
Yang et al., 2018).
In addition, much like with dabbing many marijuana users believe that vaping and
the use of e-cigarettes are safer than traditional methods of smoking marijuana (Yang et
al., 2018). While not much is known about the long-term effects of vaping and ecigarettes as few to no studies have been conducted to address these concerns. There may
be some merit to the perceived potential health benefits or reduced health risk (Budney,
Sargent & Lee, 2015). This is because the use of e-cigarettes and/or vaping of marijuana
and marijuana products such as waxes oils and concentrates does reduce the amount of
toxins and carcinogens typically inhaled by traditional smoking methods. Thus, reducing
the amount of carbon monoxide, tar, ammonia and hydrogen cyanide inhaled by the user
(Budney, Sargent & Lee, 2015). In fact, Blundell, Dargan & Wood (2017) posited that
“Cannabis smoke is also comparable to tobacco smoke containing phenols, ammonia,
hydrogen cyanide, nitrosamines and carcinogens such as benzopyrene and
benzanthracene” (para, 9). However, according to an article published in the Public
Health England review. Vapor produced and inhaled from e-cigarettes is approximately
“95% safer than cigarette smoke from this perspective as the harmful constituents of ecigarette vapour are below 5% of smoking doses and far below safety limits for
occupational exposure” (para. 9).
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Another potential benefit is a reduction in exposure to secondhand smoke to other
non-users since these methods typically do not produce smoke and are virtually odorless
(Budney, Sargent & Lee, 2015). Additionally, those who vape or use e-cigarettes to
consume marijuana (cannabis) also report fewer symptoms of respiratory problems.
However, once again no long-term studies are available to compare vaping versus
traditional smoking methods (Budney, Sargent & Lee, 2015).
Despite these seemingly potential benefits, vaping and use of e-cigarettes are not
without risk and great concern for the community and public health leaders. Yang et al.,
(2018) points out a particularly troublesome aspect of these methods of use is marijuana
marketing to our youths and young adults. Which is overwhelmingly provided, promoted
and obtained through social media platforms that are difficult to monitor, control and/or
regulate (Yang et al., 2018). These various sources often contribute to a reduction in
perceived risk associated with vaping and the use of e-cigarettes. In one study by Budney,
Sargent and Lee (2015), the researchers posited that several studies have been conducted
and indicate that these reductions in perceived risk may in turn lead to the following: an
earlier age of initial use; increased frequency of use; and a decreased motivation to quit
or reduce use. In addition, marijuana users typically smoke or use less marijuana than the
average tobacco user. This comparatively results in the perception (and rightly so) that
marijuana users should have fewer concerns about complications associated with regular
tobacco use (i.e. lung cancer and chronic lung disease). However, while this may be the
case. The primary concerns with a reduction in perceived marijuana risk are associated
with misuse and addiction. This is of particular importance for our youths and young
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adults as according to Budney, Sargent & Lee (2015), chronic marijuana use can lead to
the following psychological and neurocognitive consequences: increased risk behaviors;
poor school or job performance; family and interpersonal problems; accidents; memory
and motivational problems; and the development of addiction.
Another concern associated with vaping and e-cigarettes is the use of these
methods to inhale or ingest synthetic cannabinoids or other substances. The synthetic
cannabinoids are structurally similar and function much like THC (Castellanos &
Gralnik, 2016). These substances also known as cannabimimetics have been around since
the 1960s. However, their popularity increased between 2004 and 2008 when they
evolved into recreational drugs across Europe and then growing in acceptance worldwide
(Castellanos & Gralnik, 2016). Since then producers have been developing newer and
more potent forms that when coupled with methods of use like vaping and e-cigarettes
pose a much more dangerous threat (Castellanos & Gralnik, 2016). Synthetic
cannabinoids are a serious concern for public health leaders as youths and young adults
are using and abusing these substances in increasing numbers. Which are reportedly
much more potent than natural forms of marijuana (Castellanos & Gralnik; Pelt, 2012;
Wood, 2013).
Originally synthetic cannabinoids and synthetic stimulants referred to as incense
and bath salts respectively were sold legally in the United States (Perrone, Helgesen &
Fischer, 2013). The incense or synthetic cannabinoids are intended to mimic the effects
of marijuana whereas the synthetic stimulants or bath salts are intended to mimic the
effects of methamphetamine. As mentioned in the mid-2000s the US Drug Enforcement
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Agency (DEA) had not yet banned mephedrone (the stimulant found in bath salts) nor
had they banned the synthetic cannabinoids. Thus, many users perceived these substances
as legal substitutes to the illegal substances they mimic (Perrone, Helgesen & Fischer,
2013). In a study conducted by Perrone et al., (2013) some users sought to avoid positive
test on drug screenings and still others sought to avoid criminal prosecution for position
of illegal substances. While other users were classified as into one of the following
groups: attending abstinence-only drug treatment programs; under community correction
programs; or pursuing a career in the US military, all of which require mandatory random
drug testing (Perrone et al., 2013). The availability of these substances is only
exacerbated by the internet which has not only made it easier to purchase these
substances, but also serves to promote their use as some websites not only promote these
substances but also provide directions for new users (Pelt, 2012).
The trend in abuse of Bath salts and Synthetic Cannabinoids demonstrated an
increase from 2009 to 2011 (Wood, 2013). However, in 2012 the abuse of bath salts
began to decline while the abuse of synthetic marijuana increased with most bath salts
users being young men who primarily inhaled the substance (Wood, 2013). In addition,
Wood (2013) provides the following demographics for total exposure to synthetic bath
salts and cannabinoids (THC) by age range for 2009 – 2012. For synthetic bath salts: Age
range 13-19 (16.2%); 20-29 (43.1%); 30-39 (23.7%); 40-49 (12.1%); 50-59 (3.1%). For
Synthetic THC: Age range 13-19 (48.8%); 20-29 (34.4%); 30-39 (9.1%); 40-49 (3.9%);
50-59 (1.7%) (Wood, 2013). Values for age ranges below 12 years of age and above 60
years of age were negligible. Nevertheless, this trend demonstrates that most bath salts
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users were between the age of 20-29. Whereas most Synthetic marijuana users were
between the ages of 13-19 (Wood, 2013).
The misconception that these substances are safe substitutes has been dismissed
as the National Institute of health reports that “Thousands of teens and young adults,
mostly young males, are ending up in emergency rooms with severe symptoms that may
include vomiting, racing heartbeat, elevated blood pressure, seizures, or hallucinations”
because of synthetic marijuana use (NIH-NIDA, 2013, para. 1). In addition, per a news
release from the U.S. Substance Abuse and Mental Health Services Administration and
reported in Health Day (2013) the “Street drugs called ‘bath salts’ were linked to nearly
23,000 emergency department visits in the United States in 2011” (para. 1).
In a more recent study, Castellanos & Gralnik (2016) provided an update on
synthetic cannabinoids informing pediatricians of clinical presentations to look for when
treating adolescents and encourage physicians to become familiar with these drugs.
According to the researchers, the synthetic cannabinoids have evolved rapidly since their
introduction with the potential for dangerous health effects that exceed that of traditional
marijuana use (Castellanos & Gralnik, 2016). The potential detrimental health effects of
these compounds include: Gastrointestinal problems (nausea and vomiting); Neurologic
signs and symptoms (such as tremors, ataxia, fasciculations, and hyperreflexia);
Metabolic disturbances (hypokalemia, hyperglycemia, acidosis and diaphoresis);
Rhabdomyolysis (muscle damage and breakdown); Renal Damage; Seizures; and
Myocardial Infarction; (Castellanos & Gralnik, 2016; WebMD, 2019). In addition,
Castellanos & Gralnik (2016) also report the following psychoactive effects: Cognitive
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complications (attention, concentration and memory deficits, confusion); Affective
disorders (anxiety and panic); as well as Behavioral disfunctions (restlessness, agitation,
violence, and aggression) and Psychosis (hallucinations, delusions and disorganized
thoughts). Further compounding the challenge of addressing this concern are the new
methods of use. Vaping and e-cigarettes allow manufactures to present these products as
natural cannabis resins, CBD oils, and liquid cartridges (Castellanos & Gralnik, 2016;
Popp, 2018).
While the prevalence of marijuana use, vaping, dabbing and the use of
concentrated products may be higher in areas with medical and/or recreational marijuana
laws (Keyhani, 2018). Areas without medical marijuana laws or limited medical
marijuana laws are not immune. For instance, in the Atlanta Georgia area with only
limited medical marijuana laws there have been numerous incidents where individuals
(most notably youths and young adults) have utilized these products with detrimental
effects. In many cases they are being sold legally as bath salt or labeled as not for human
consumption (Castellanos & Gralnik, 2016; Popp, 2018). In Forsyth County, which is
located just North of Atlanta two high school students had to be transferred to the
hospital in 2017 after vaping CBD oils (Popp, 2018). In another situation, authorities in
Forsyth county have been warning parents and students about new types of synthetic
THC and CBD oils (Popp, 2018). Proper use of these liquids involves adding them to ecigarette nicotine liquid allowing the user to achieve an added high. However, problems
arise when individuals, mostly students, vape the liquid straight as oppose to adding them
to nicotine liquid (Popp, 2018). Authorities warn that the outcome can be disastrous
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resulting in a medical emergency with symptoms of suppressed respiratory function and
increased heart rate. Consequently, mimicking that of an opioid overdose (Popp, 2018).
The names of these products (synthetic marijuana or CBD oils) include: Kronic Juice,
Galaxy, Diamond and Lyft and they are being sold in vape shops, head shops and CBD
shops in and around the Atlanta area (Popp, 2018). Among these, Kronic Juice has been
associated with seizures and unconsciousness when not used as instructed (Popp, 2018).
One reason vaping, and e-cigarettes are growing in popularity is because the use
of substances by these means are easily concealed, smokeless and virtually odorless
(Yang et al., 2018; MFC-vaping, 2019). School administrators, principals and teachers in
Forsyth county Georgia emphasize the problems with addressing this concern as they
have observed vaping devices designed in the form of everyday objects like phones, pens,
and flash drives (Popp, 2018). Thus, making them difficult to detect (Popp, 2018).
While the use of concentrated marijuana products such as BHO and methods of
use like dabbing, vaping and e-cigarettes are a growing concern. Another issue facing
public health and health care professionals is the consumption of edible products infused
with marijuana. These products are growing in popularity and come in many forms such
as, candy; cookies; brownies; and even popular breakfast cereal (i.e. Fruity Pebbles)
(Cao, Srisuma, Bronstein & Hoyte, 2016; Haney, 2019)
Even though smoking marijuana remains the most common method of use
(Keyhani et al., 2018). Since the implementation of medical marijuana laws alternative
methods of marijuana use have been on the rise and warrants public health attention
(Keyhani et al., 2016). This rise in alternative methods of use is evidenced in a study by
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Borodovsky, Crosier, Lee, Sargent, & Budney (2016), in which the researchers sought to
assess whether marijuana (cannabis) legalization impacted methods of marijuana use
(Borodovsky, et al., 2016). Based on States medical marijuana status, duration of medical
marijuana status, and the density of marijuana dispensaries in the state. The researchers
analyzed whether individuals ever used marijuana, preference for marijuana use, and age
at which individuals started smoking, vaping and eating marijuana (Borodovsky, et al.,
2016). The results revealed that in states with MMLs the odds of an individual using
alternative methods were significantly higher for vaping and edibles (OR: 1.78, 99% CI:
when compared to states without MMLs (Borodovsky, et al., 2016). The rise in use via
vaping and edibles would be expectedly higher in states with both medical marijuana
laws (MMLs) and recreational marijuana laws (RMLs) as in states with RMLs the
availability of BHO concentrates and edible products is greater and more highly marketed
to the public (Borodovsky et al.; 2016Carroll, 2018; Keyhani et al., 2018;).
Thus, consumption of marijuana-infused products have been gaining popularity
along with the spread of medical and recreational marijuana legalization (Barrus et al.,
2016; Montgomery, 2017). This is evidenced by booming sales of marijuana infused
edibles and drinks in states like California and Colorado that have legalized recreational
marijuana (Montgomery, 2017). For instance, in California edible marijuana sales
reached $181 million in 2016, and in Colorado sales reached $53 million during the third
quarter of 2016 where sales were just $17 million during the first quarter of 2014
(Montgomery, 2017). Demonstrating a three-fold increase in Colorado sales in less than
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two years. However, while consumption of marijuana products is growing in popularity it
is not without risk and challenges.
In a related article, Barrus et al. (2016) explores various aspects surrounding
edible marijuana products with particular attention on challenges arising for users and
policy makers as well as attempts at regulation (Barrus et al., 2016). The researchers first
explain the process involved with producing the cannabinoid-infused oil required for
making edible marijuana products (Barrus et al., 2016). This involves extracting the
primary cannabinoids (THC & CBD) from the marijuana plant. Which is achieved by
heating the raw female marijuana plant (flowers and leaves) in an oil-based liquid (Barrus
et al., 2016). Heating of the marijuana plant products serves to convert THC from its nonpsychoactive form, Delta-9-tetrahydrocannbinolic Acid (THCA) into its psychoactive
form, Delta-9-tetrahydrocannabinol (Δ9-THC) (Barrus et al., 2016). This psychoactive
form is responsible for the high that many marijuana users seek. It along with other
cannabinoids, such as CBD the medicinal (non-psychoactive) cannabinoid is extracted
into the oil-based liquid (Barrus et al., 2016). The remaining plant products are removed
and discarded, and the cannabinoid-infused oil is ready for use in consumable products
and/or retail sale in dispensaries (Barrus et al., 2016). The researchers report that in
Colorado, while consumption of edibles accounts for a significant amount of use by both
medical and recreational marijuana users (Barrus et al., 2016). The actual rates of edible
use by both populations is likely underestimated because data obtained only represents
sales of cannabis-infused products. This data does not reflect how much cannabinoidinfused oil or cannabis was bought and used by consumers to make homemade edibles.
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Nor does it reflect inter-state transfer of these products to other regions (states) for
medicinal and/or recreational use (Barrus, et al., 2016). Nevertheless, in Colorado in
2014, medicinal cannabis infused products with high CBD low THC concentrations, and
retail cannabis-infused products (high THC low CBD) accounted for approximately 45%
of all cannabis sales in the state (Barrus et al., 2016).
Barrus et al., (2016) identifies the following three perceptions that may be
attributing to the increased interest in edible products: “(1) edibles are a discreet and
more convenient way to consume cannabis; (2) edibles offer a “high” that is calmer and
more relaxing than smoking cannabis; and (3) edibles avoid the harmful toxins and health
risks that come with smoking cannabis” (para. 12).
Regardless of the method of marijuana use, whether it be smoking, vaping, or
consumption of edibles. Or the reason (medical or recreational) the primary goal among
marijuana users is to feel better (Barrus et al., 2016). However, while there has been a
significant amount of research conducted on the health benefits of marijuana. Most of
these studies have focused on pharmaceutical preparations of synthetic analogs of THC
as oppose to natural marijuana use, and/or products containing natural preparations of
THC and CBD cannabinoids (Barrus, 2016). Nevertheless, the studies that have been
conducted typically focused on the following limited number of medical conditions:
muscle spasms; chronic pain; nausea and vomiting; epilepsy; appetite stimulation; cancer;
post-traumatic stress disorder; anxiety; and depression (Barrus et al., 2016). Wherein the
benefits of marijuana for these conditions has primarily been based personal
proclamations rather than facts or research (Barrus et al., 2016). Thus, evidence based on
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well controlled clinical studies is limited. Barrus et al., (2016) posited that the lack of
strong studies on the therapeutic effectiveness of cannabis and cannabinoid products is
due in part to the continued classification of cannabis (marijuana) as a Schedule I drug by
the U.S. Drug Enforcement Agency. However, Barrus and fellow colleagues hold
promise that the widespread and continued state-level legalization of medical and
recreation marijuana may serve as the driving force to promote funding for better
controlled studies (Barrus et al., 2016). Which is needed as there has only been a limited
number of studies comparing pharmaceutical products of synthetic Δ9-THC to natural
preparations and other methods of cannabis use. However, the limited studies available
tend to indicate that most patients prefer natural products and uses as oppose to the
synthetic preparations (Barrus et al., 2016). In addition, according to subjective patient
reports the natural methods of smoking and consumption of edibles produce less adverse
effects and better efficacy than synthetic preparations (Barrus et al., 2016).
The consumption of edibles for medicinal and recreational purposes has several
benefits. Among these include a longer duration of action when compared to smoking
and the consumption of edibles in easier to conceal. Both of which are especially
advantageous to the medicinal user as smoking marijuana is still illegal in many states
with medical marijuana laws (Barrus el al., 2016). So, the medicinal user can consume
edibles at work and in public without exposing their use, and the longer duration of action
mean reduced dosing times. The concealability of marijuana infused products is also
advantageous because despite growing acceptance many patients and recreational users
still express concerns about the stigma associated with the perception of marijuana use
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(Barrus et al., 2016). Thus, some users may prefer the consumption of edibles in public or
in the workplace. Choosing to vape or smoke at home and outside of work (Barrus rt al.,
2016). Another significant reason why many users prefer the consumption of marijuanainfused products is the perception that this method of use is less harmful than smoking
marijuana (Barrus, 2016). This is because of the perception that smoking marijuana may
pose risk and other harmful effects similar to smoking tobacco (Barrus, 2016).
Until recent events in Colorado, marijuana had not been directly attributed to any
lethal consequences as no deaths had been associated with acute marijuana toxicity
(Barrus et al., 2016). However, serious and severe consequences have occurred in
association with marijuana toxicity or overdose. Barrus et al., (2016) provided support for
this understanding based on reports from 65% of medicinal cannabis users that indicate
overuse has resulted in the following signs and symptoms: cognitive and motor
impairment; extreme sedation; agitation; anxiety; cardiac stress; and vomiting (Barrus et
al., 2016); In addition, larger doses of Δ9-THC have been associated with cannabisinduced psychosis while usually transient in healthy adult users some users report
symptoms that persist for several days. These psychotic symptoms reportedly can include
hallucinations, delusions, and anxiety (Barrus et al., 2016).
While the information on cannabis-induced psychosis is limited reports indicate
than many of these cases are the result of ingestion/overconsumption of edible marijuana
products (Barrus, et al., 2016). The reason why this may occur more commonly with
ingestion as oppose to smoking is most likely associated with the route of administration
and cannabinoid pharmacokinetics (Barrus et al., 2016). This simply means how
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marijuana is processed by the body when it is eaten versus smoked. For instance, when
someone ingestion cannabis-infused products it is first processed in the gastrointestinal
tract where Δ9-THC is absorbed enters the blood stream and travels to the liver (Barrus et
al., 2016). Once in the liver, Δ9-THC is converted to 11-hydroxytetrahydrocannabinol
(11-OH-THC). This hydroxylation step is mediated primarily by the cytochrome-P450
enzymatic system of the liver (Barrus et al., 2016). More importantly, 11-OH-THC is a
potent psychoactive metabolite of Δ9-THC that can easily cross the blood brain barrier to
elicit its effects (Barrus et al., 2016). Consequently, 11-OH-THC is more potent than Δ9THC and ingestion of marijuana results in higher blood levels of 11-OH-THC than
smoking (Barrus et al., 2016). Hence, the stronger effects and longer duration of action
demonstrated when someone ingest cannabis-infused products (Barrus et al., 2016).
When someone smokes or vapes marijuana the effects are almost immediate,
occurring within minutes and peaking about 20 to 30 minutes after inhalation (Barrus et
al., 2016). With the effects usually lasting about 2-3 hours (Barrus et al., 2016).
Conversely, when someone ingest marijuana it takes about 30 to 90 minutes for the
psychoactive effects to kick in and they last longer as the effects of edibles does not
typically peak until about 2 to 4 hours after ingestion (Barrus et al., 2016). Further
complicating the matter is the fact that the concentration of Δ9-THC found in edible
products can vary across edible products and batches (Barrus et al., 2016). This lack of
consistency and delay onset of action may lead to increased ingestion of cannabis-infused
products resulting in unintentional consequences (Barrus et al., 2016). Attempts at
regulation have set the limit for a maximum recommend dose of Δ9-THC at 10 mg per
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serving (Barrus et al., 2016). However, Barrus et al., (2016) posited that “a single
chocolate bar could contain 100 milligrams (10) servings of Δ9-THC” (para. 31). But the
delayed onset of action and small portions may make it difficult for the user to control
their intake resulting in serious and potentially lethal consequences (Barrus et al., 2016).
This is evidenced by one tragic event in which a 19-year-old Colorado man was
instructed to eat just one-sixth (one serving) of a cookie that contained approximately 10
mg of Δ9-THC (Barrus et al., 2016). However, after about an hour the man had not felt
any effects and consumed the remain amount over a 2-hour period (Barrus et al., 2016).
Unfortunately, the intoxicating effects resulted in his death after he jumped off a fourthfloor balcony (Barrus et al., 2016). At autopsy the examiner identified cannabis
intoxication as the primary cause of death. This event while tragic, lead to the
implementation of packaging and labeling regulations in Colorado that require clear
demarcations of the standardized 10 mg dose servings of cannabis-infused products
(Barrus et al., 2016). The state of Washington has also implemented similar regulations
(Barrus et al., 2016).
Thus, regulation of edibles occurs at the state level, this is because marijuana is
still illegal at the federal level (Barrus et al., 2016). Therefore, various entities within
each individual state regulate the taxing, licensing for cultivation and distribution, and
retail sales by marijuana dispensaries on a state-by-state basis (Barrus et al., 2016).
Therefore, states that have legalized marijuana for recreational sales have specific statelevel requirements for labeling of cannabis-infused edibles (Barrus et al.,2016).
Typically, these requirements must include warnings about potential harmful and
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intoxicating effects as well as nutritional information (Barrus et al., 2016). However,
nutritional information usually various by state. For instance, Colorado and Oregon
require that information on labels of cannabis-infused products to be much like that on
regular food products (Barrus et al., 2016). Whereas, Washington state only requires that
labels include a listing of ingredients (Barrus et al., 2016). But most states have
requirements for labeling that include pesticides used during production as well as
requirements for an expiration or best if used by date (Barrus et al., 2016).
Thus, while many medicinal and recreational users view consumption of
marijuana edibles as a safe alternative method of with marijuana use that is more
convenient and easier to conceal than smoking (Wardarski, 2015). It’s important to point
out these are not the marijuana products of years ago and edible products are usually
more potent than smokable marijuana products (Wardarski, 2015). For instance, while
strains of marijuana sold in most dispensaries for smoking typically has a THC level in
the range of 12 to 25 percent. Marijuana infused edibles are being made using marijuana
concentrates as potent as 50 to 90 percent THC (Wardarski, 2015). This is a serious
concern as in Colorado alone, where some doctors posited that consumption of edibles
are responsible for the rise in marijuana related hospitalizations (Wardarski, 2015).
Which has more than doubled since 2009 after commercialization and expansion of
medical marijuana (Rocky Mountain High Intensity Drug Trafficking Area (RMHIDTA),
2014; Wardarski, 2015;).
Barrus et al., (2016) posited that an important concern for public safety is the lack
of available research comparing the therapeutic efficacy and subjective effects of
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marijuana ingestion to other methods of use. In addition, accidental ingestion and over
consumption, whether it be intentional or unintentional is another concern for public
health and health care leaders (Cao, Srisuma, Bronstein, & Hoyte, 2016). As previously
stated, over consumption of edible products is commonly associated with the delayed
onset of action observed with ingestion as the effects are not immediate like smoking
(Barrus et al., 2016). This may prompt the user to consume more product in an attempt to
achieve the desired effect resulting in over consumption and leading to unintended
adverse effects (Barrus et al., 2016).
In a related broad-based study, Cao, Srisuma, Bronstein, & Hoyte, (2016)
conducted a national analysis of human exposure calls for consumption/ingestion of
marijuana products reported to poison control centers around the United States. These
state-level centers intern report data to the National Poison Data System (NPDS). In this
retrospective study, Cao et al., (2016) obtained data reported to the NPDS over a 36month period between January 2013 through December 2015. The study analyzed
subgroups based on age and state level marijuana laws for ingestion of edible marijuana
products (Cao et al., 2016). The marijuana infused products included: cookies; candies;
brownies; beverages and other food products (Cao et al., 2016, para. 1). The researchers
also considered both intentional and unintentional exposures as these products are often
indistinguishable from similar non-marijuana infused products (Cao et al., 2016). As
children as well as adults are typically unable to recognize differences in taste or
appearance (Cao et al., 2016).
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The results of this study revealed that the majority of calls for exposure were for
individuals less than or equal to five years of age (Cao et al., 2016). With 99% of these
incidents due to unintentional exposure. Individuals age 1-19 years old represented the
next highest age group for exposure calls with individuals age 20-29 years of age making
up the third highest age group (Cao et al., 2016). Among these individuals those age 6-19
predominated the intentional exposure group with 89% of these due to abuse versus 10%
for misuse (Cao et al., 2016). Additionally, among the states observed Colorado and
Washington led the way with the highest number of exposure calls as overall states with
MMLs and/or RMLs accounted for approximately 91% of all calls (Cao et al., 2016).
Thus, lending support to the premise that marijuana legislation effects marijuana use,
abuse, misuse, exposure and preference.
Furthermore, the methods of use that further increase the potency of an already
highly potent marijuana product should definitely be a serious concern of public health
leaders. This is evidenced a related study conducted in the Netherlands researchers
explored the relationship between changes in marijuana potency and admissions to drug
treatment programs (Freeman, et al., 2018). This 16-year study analyzed THC
concentrations sold at retail stores from the year 2000 through 2015. This analysis
revealed that THC concentrations increased from 8.62% to 20.38 % from 2000 to 2004
and decreased in 2015 to 15.31% (Freeman, et al., 2018). During this time first
admissions to drug treatment increased from 7.08% to 26.36% between 2000 to 2010 and
decreased to around 20% in 2015 (Freeman, et al., 2018).
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Freeman, et al., (2018), concluded that a positive time-dependent association does
exists between changes in marijuana potency and first-time admissions to drug treatment.
The researchers also point out that other factors may also be important. Nevertheless, the
results indicate that the strongest association occurred at 5 years into the study, and after
adjusting for participant demographics and non-cannabis drug treatment admissions the
results reveal a statistically significant positive association (Freeman, et al., 2018). Which
is evident as Freeman, et al., (2018), posits that “each 1% increase in THC was associated
with a 0.082 (0.052, 0.111) rise in first-time admissions per 100,000” (para.14). The
researchers further posited that these trends are not confined to the Netherlands as
increases in first time admissions to drug treatment programs for marijuana are consistent
across all of Europe (Freeman, et al., 2018). As was indicated in an analysis submitted to
the European Monitoring Centre for Drugs and Drug Addiction which reported increases
in admissions in 16 out of 22 European countries examined (Freeman, et al., 2018).
While there is limited literature available on the effects of medical and
recreational marijuana laws on marijuana potency, that which is available suggest that
these laws have not only led to increased potency but also to increases in unintentional
childhood exposure as well as adult cannabis use and adult cannabis use disorder (Hasin,
2017). In addition, some studies also suggest that medical marijuana laws have led to
increased use of cannabis as substitutes for opioids and psychiatric medications (Hasin,
2017). Thus, supporting to the premise that some marijuana users may be self-medicating
for various conditions.
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Based on my understanding of the literature review, as more states continue to
implement MMLs and RMLs access to marijuana and marijuana products will continue
to increase while public perception of risk and social stigma associated with marijuana
use will continue to decrease. Thus, the combined effects of these events may lead to an
overall increase in marijuana use and exposure, both intentional and unintentional. In
addition, there is also lack of sufficient literature from evidenced-based studies on the
long-term effects of legalization, rising THC levels, consumption of marijuana-infused
products, use of concentrated marijuana products, and methods of marijuana use like,
dabbing, vaping and e-cigarettes.
Therefore, peer-reviewed articles such as those presented here provide additional
support for the premise of this study which seeks to explore the possible associations
between medical and recreational laws, marijuana potency and the effects on mental
health conditions like depression and suicide ideation. This is particularly important as
those who serve in public health and health care have an obligation to inform the public
about the risk associated with marijuana use, especially when considering trends of
increasing potency, growing public acceptance, decreased risk perception of marijuana
use and the continued wide spread legalization of marijuana.
Critique of Methods
Salomonsen-Saulel et al. (2012) utilized the several tools to measure and analyze
adolescent use of medical marijuana among patients treated at two substance abuse
facilities in Denver Colorado. The results of this study demonstrated that the majority of
adolescents, approximately 74% of the 164 adolescents in treatment, had used medical
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marijuana obtained from registered medical marijuana patients (Salomonsen-Saulel, et
al., 2012). Thus, demonstrating a high rate and widespread pattern of medical marijuana
use by the non-patient recreational using population (Salomonsen-Saulel, et al., 2012).
However, the study results may be limited by a lack of comparison between states where
marijuana is legal versus illegal. One example wherein this comparison would be relevant
is in areas where legalization of medical marijuana contributed to greater acceptance of
marijuana because of a more favorable marijuana attitude or a decrease in perceived risk
post-legalization (Salomonsen-Saulel et al., 2017). As a result, the use of marijuana may
be higher in these areas and reflected in the results of the study versus areas without
legalization where marijuana use may be lower. In addition, this study was conducted at
two rehabilitation facilities at one point in time (Salomonsen-Saulel et al., 2017). This
would in turn effect determination of causality (Salomonsen-Saulel, et al., 2017). Thus,
comparing marijuana use to states with varying laws in other states and at different points
in time is essential to making inferences about causality (Salomonsen-Saulel et al., 2017).
Finally, Salomonsen-Saulel et al. (2012) also indicates that the timing of marijuana law
implementation may also affect studies on patterns of marijuana use. Therefore,
additional time may be needed to observe the effects of recently implemented laws
(Salomonsen-Saulel et al., 2017).
In a related study by Wen, Hockenberry, & Cummings (2015), the researchers
addressed the effect of medical marijuana laws on marijuana use in ten states with
medical marijuana laws. The study also addressed the effects of MMLs on the use of use
alcohol, and other hard drugs (such as, cocaine and heroin) as well as pain medication
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misuse (Wen et al., 2015). While this study presented relevant data implementing MMLs
to a rise in marijuana use as well as an increase in abuse/dependence among participants
age 21 and older. A potential limiting factor is concerned with the National Survey on
Drug Use and Health (NSDUH) used in this study. This survey does not differentiate
between the marijuana patient and non-patient populations participating in the study
(Wen et al., 2015). Thus, the spillover effect may not solely reflect an increased
marijuana use among registered marijuana patients as the non-patient or recreational
using population may potentially contribute to a greater percentage of the individuals
participating in the study (Wen et al., 2015). This limitation is evidenced by Wen et al.,
(2015) which indicates that, among the states studied with MMLs, medical marijuana
patients comprised only 0.8 percent of the total population.
Regarding methods used to assess the association between mental health and
marijuana use. A notable study reviewed here by van Gastel, et al., (2013), used a
population-based analysis to determine whether cannabis use is associated with poor
psychosocial functioning and therefore a potential risk factor for future mental health
problems (van Gastel, et al., 2013). While the results of this study demonstrated a
potential association between the use of marijuana and future mental health problems, the
study was not without limitations. Most importantly, is the cross-sectional approach that
is limited because it provides an analysis of the association between variables (exposure
and outcome) at one point in time and therefore does not provide information relevant to
the time spatial association between the exposure and outcome variables (Christian,
2015). Thus, limiting conclusions with respect to the causal inference between these
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conditions. In addition, since the methods used to gather data involved self-reporting then
another study limitation may result from over or under reporting which is observed when
gathering information of sensitive issues, such as drug use (van Gastel, et al., 2013).
The notion that marijuana use may cause psychosis is not a new concept as
several studies have demonstrated this association (Murray, Quigley, Quattrone, Englund
& Di Forti, 2016). In one such study, Davis, Compton, Wang, Levin, & Blanco (2013)
conducted a population-based study demonstrating that the use of marijuana may serve as
a possible risk factor for psychosis and schizotypal personality disorder (SPD). The study
further demonstrated that the risk of psychosis and SPD increased with the extent of
marijuana use in a dose-dependent fashion (Davis et al., 2013). Which supports this
current studies premise that highly potent marijuana would be expected to increase the
occurrence or exacerbate these conditions. However, the cross-sectional nature of this
population-based study limits inferences about causality or the time-spatial relationship
between marijuana use and the development of psychosis and SPD (Davis et al., 2013).
In addition, this study used self-reporting to gather data on the participants diagnosis of
schizophrenia or psychotic disorders. And according to Davis et al (2013) the reliability
of self-reporting on these diagnoses is questionable. Which may limit the results of this
study. In addition, self-reporting may also be subject to recall bias (Hasan, 2005). And
finally, the cross-sectional nature of this study may limit inferences on causality as
observations are made at one point in time (Davis et al., 2013). However, the researchers
also point out that previous studies utilizing self-reporting for these diagnoses are
consistent with the findings presented (Davis et al., 2013).
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In a related literature review, Moore et al. (2007) provided support for the results
observed in the study by Davis and fellow colleagues. Wherein Moore et al. (2007)
addressed the association between marijuana use and the development of psychosis or
affective mental health outcomes. This study demonstrated an increase in psychosis and
affective mental health outcomes with a dose-response relationship as the rate of
psychosis increased 50 to 200% for heavy marijuana users versus moderate users and
non-marijuana users (Moore et al., 2007). However, since a review of the literature is
typically observational in nature, then the study is subject to several limitations. One
limitation of this approach is publication bias as studies presenting statistically significant
results may be selected for publication and cited more often than others and are therefore
more likely to be included in literature reviews (Egger, Dickersin & Smith, 2001).
Another limitation is the methodology or findings of the articles reviewed. If the data or
results of these studies are compromised, then the results presented by the literature
review will subsequently be affected as well (Egger et al., 2001). In addition, a literature
review may be subject to a form of selection bias, wherein researchers select particular
articles or studies for review based on the results that favor the researchers’ premise
(Egger et al., 2001).
Knowledge Gap
The study conducted by Salomonsen-Saulel and colleagues which demonstrated
that medical marijuana is finding its way into the hands of the non-patient recreational
using population in Denver, CO (Salomonsen-Saulel et al., 2012). However, this study
was limited to adolescent patients from two substance abuse treatment facilities
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(Salomonsen-Saulel, et al., 2012). Therefore, demonstrating a potential gap in the
research as the results may not be representative of the general population of marijuana
users. Support for this premise is provided by Salomonsen-Saulel, et al. (2012) which
posited that additional research should focus on patterns of medical marijuana use and
diversion of medical marijuana within the general adolescent population (SalomonsenSaulel, et al., 2012). Addressing his gap would also require focusing on young and older
adults in the population as these groups also contribute to the general marijuana using
population
Sevigny, Pacula & Healon, (2014) addressed the effects of marijuana legalization
on potency ultimately demonstrating no statistically significant association between these
two variables. However, the authors acknowledge that previous studies on the effect on
legalization on potency have revealed mixed results both for and against the premise that
marijuana legalization has contributed to a rise in marijuana potency. However, Sevigny
et al., (2014) further identified a possible gap in the research as the lack of studies to
assess the effects of rising marijuana potency on marijuana use.
Sevigny et al., (2014) also identified other areas for future research. For instance,
the researchers surmised that use of highly potent marijuana could possibly result in a
decrease in marijuana use as less marijuana would be required to achieve the desired
effect. Another area for additional research is the possibility that highly potent marijuana
may also contribute to a decrease in charges for Driving While Impaired (DWI) as
individuals who use both alcohol and marijuana would be less prone to drive after
concurrent use of these substances (Sevigny et al, 2014) In addition, Sevigny et al.,
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(2014) further posited that the use of highly potently marijuana may result in a decrease
in the amount of opiate pain relievers taken as less medication may be required due to the
pain relieving effects of highly potent marijuana. In fact, some patients taking opiate pain
relievers may opt to use marijuana for pain relief as oppose to narcotics (Sevigny, Pacula
& Healon, 201).
The study conducted by van Gastel, et al., (2013), presented relevant information
on the association between the use of marijuana and future mental health problems. This
study demonstrated that marijuana use, and factors associated with marijuana use and
poor psychosocial functioning may serve as indicators of risk for future adolescent
mental health problems (van Gastel, et al., 2013). The researchers however point out that
future research and public health efforts should focus on using the indicators of risk
identified in this study to design an adolescent risk profile (van Gastel, et al., 2013).
The study conducted by Moore et al. (2007) served to demonstrate an increase in
psychosis and affective mental health outcomes with a dose-response relationship among
marijuana users. The researchers point out the need for additional research to determine if
younger marijuana users are subjected to greater risk or more harmful effects (Moore et
al., 2007). The researchers also indicate that additional research should address the
effects of genetics and other factors on these results (Moore et al., 2007).
Summary and Conclusions
In the United States, substance abuse and addiction cost the American tax payer
over $700 billion dollars a year (NIDA, 2016). The consequences of substance abuse are
evidenced by approximately 90,000 Americans that die every year as a result of illicit and
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prescription drug and alcohol use (NIDA, 2016). Thus, substance abuse is an important
public health concern that has a prodigious impact on our society.
Among the substances of abuse, marijuana is by far the most commonly used as
in 2018, 43 million Americans reportedly used marijuana in the past year (Statista, 2019).
A growing public health concern is the potency of marijuana as the level of
Tetrahydrocannabinol (THC) has been increasing since legalization began in 2012
(Cabrera, 2016). This is a growing concern since THC elicits the desired psychological
effects most marijuana users seek (Bradford, 2015).
Lab test reveal that the potency of marijuana in Colorado since legalization is
more than twice as potent as illegal marijuana of the past ten years and some strains of
legal marijuana is three times as potent (Briggs, 2015). Prior to legalization the levels of
THC were typically below 10 percent. However, research now indicates that the postlegalization levels of Colorado’s marijuana averages around 18.7 percent with some
marijuana strains containing THC levels of 30 percent or more (Briggs. 2015). These
results were provided by Charas Scientific, a Denver based lab licensed and hired by the
state to test and measure the THC levels of marketable marijuana (Briggs, 2015).
Addressing this concern at this point in time is particularly important because as
of as 2019, 33 states and the District of Columbia plus Guam and Puerto Rico have had
passed laws legalizing medical marijuana with 11 of these states and the District of
Columbia also implementing recreational marijuana laws (Hartig & Geiger, 2018; NCSL,
2019; Governing Data, 2019) However, these laws vary by state. For instance, Colorado
has legalized marijuana for both recreational and medical use (Governing, 2018). While
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other states, like Georgia have only legalized medical marijuana products that have High
CBD/Low THC concentrations for specific medical conditions (Governing Data, 2018;
National Conference of State Legislatures [NCSL], 2019). With only a few states like
Idaho that have not legalized marijuana for any reason (Governing, 2018; NCSL, 2019).
Nevertheless, the trend in attitude toward marijuana is ever evolving. My study was
intended to address the effects of continued marijuana legalization on the mental health
conditions, depression and suicide ideation. This aim was achieved by comparing the
year 2008 when only 13 states had legalized medical marijuana to the year 2017 when 27
states and District of Columbia had legalized medical marijuana with seven of these
states and the District of Columbia also legalizing recreational marijuana (Governing
Data, 2018; NCSL, 2019).
In the United States, marijuana has experienced a controversial and highly
debated path. For several years proponents of marijuana have lobbied for legalization of
the substance touting the medical implications and attempting to the discredit the
implications of its harmful effects. However, despite these efforts the Drug Enforcement
Administration (DEA) still classifies marijuana as a schedule I controlled substance (U.S.
Department of Justice, 2017). Nevertheless, the current trend in attitude favoring
marijuana use for medical and recreational purposes is growing. This is evidenced by
reports indicating a decline in individuals who consider the occasional use (1-2 times per
week) of marijuana as a perceived risk (Schuermeyer et al., 2014). For instance, in
Colorado the percent of those who believe marijuana use is a perceived risk declined
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from 45% to 31% between groups studied from 2007 to 2008 and those studied from
2010 to 2011, respectively (Schuermeyer, et al, 2014).
Considering the current trend in marijuana liberalization, it is more important now
than ever for policy makers, public health and health care personnel to emphasize or
reiterate the potential adverse effects of the substance. This is especially important given
the rising THC levels seen in medical and recreational marijuana and products produced
from marijuana. It is also reasonable to assume that as legalization gains greater
acceptance the use of marijuana will also increase and therefore so will the occurrence of
adverse effects.
Sevigny et al., (2014) addressed the potency of medical marijuana that has
reportedly increased since legalization. This increase in potency is presumably due to less
restrained regulations that created an environment of improved cultivation and production
techniques. Sevigny et al., (2014) identified two marijuana markets, medical and
recreational, and these markets are interrelated such that cross over in technological
advances for production and cultivation occurs. The authors further posited that surplus
medical marijuana is being diverted to the recreational market (Sevigny, Pacula, &
Heaton, 2014). The results of the first model in this study demonstrated a significant
increase in marijuana THC content in jurisdictions that legalized marijuana for medical
purposes (Sevigny et al., 2014). However, the remaining models added potentially
competing variables which provided results that were not statistically significant.
In addition, support for the cross-over or diversion of marijuana premise
presented by Sevigny and colleagues is provided in a related study. In which

134

Salomonsen-Saulel, et al. (2012) addressed the extent of medical marijuana use by the
non-registered (non-patient) marijuana using population. The results of this study
demonstrated that the majority, approximately 74% adolescents in treatment had used
medical marijuana obtained from registered medical marijuana patients (SalomonsenSaulel et al., 2012). Thus, demonstrating a high rate and widespread pattern of medical
marijuana use by the non-patient recreational using population. Thus, the effects of
producing high-potency medical marijuana potentially impacts the quality and
availability of these highly potent marijuana strains to the recreational using market.
In another study, Wen, Hockenberry, and Cummings (2015) addressed the effects
of MMLs on the use of marijuana and other controlled substances. This study
demonstrated that implementation of MMLs resulted in a parallel increase in marijuana
use among participants age 21 and older (Wen et al., 2015). These increases occurred
immediately after MMLs were implemented and continued for three years after
implementation (Wen et al., 2015). In addition, Wen et al., (2015) reported a 10%
increase in marijuana abuse/dependence among participants age 21 and older. Thus,
indicating cause for public health concern as MMLs may have the potential to increase
risk of progressing to marijuana abuse/dependence (Wen et al., 2015).
The effects of marijuana potency on health is an important public health concern
as there is a growing body of evidence supporting the association between cannabis use
and the development of psychotic or mental health disorders (Moore et al., 2007).
However, few studies have addressed this association since the rise in THC demonstrated
post legalization. Volkow et al., (2014) posited that previous research has demonstrated
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that anxiety, depression, and psychosis are associated with regular marijuana use.
However, causality is not well founded as determining causality is hindered by
confounders that also contribute to the development of these conditions (Volkow et al.,
2014).
In a previous related study, Lev-Ran et al. (2014) conducted a systematic review
and meta-analysis of existing longitudinal studies to determine patterns of cannabis use
that are associated with the development of depression. Lev-Ran et al. (2013) concludes
that the risk of developing depressive disorders is increased by cannabis use, and this risk
is more significant among heavy cannabis users and those with cannabis use disorder.
These findings are supported by van Gastel et al. (2013) which also indicates that
marijuana use has been associated with psychiatric symptoms and the risk is increased by
regular or heavy marijuana use.
These studies demonstrate support for the gap in the research that highly potent
marijuana presents and this study intended to address. The notion that marijuana use may
cause or exacerbate mental illness and psychosis is not a new concept as several studies
have demonstrated this association (Murray et al., 2016). However, many of these
previous studies were conducted prior to the legalization of marijuana and the concurrent
increase in marijuana potency as the level of THC has been rising. The use of highly
potent marijuana would be expected to have effects similar to that seen in heavy users or
those who abuse marijuana. Additional support for this gap in the research is provided by
Di forte et al. (2009) which posited that previous studies have demonstrated an increase
of psychosis in association with marijuana use. However, Di forte et al. (2009) further
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posited that “these studies have not collected detailed data on the patterns of use or
potency of the cannabis used, which may be important factors moderating the associated
risk” (para. 6). Therefore, my current study intended to address this gap in the research as
the potential implications of widespread legalization and highly potent marijuana with
elevated THC levels should be a major public health concern. Chapter three which
follows is intended to provide an in-depth description of the research design and
statistical analysis, the National Survey on Drug Use and Health (NSDUH) data set.

137

Chapter 3: Research Method
Population
The NSDUH is conducted by RTI International, Research Triangle Park, North
Carolina and sponsored by the Center for Behavioral Health Statistics and Quality
(CBHSQ), Substance Abuse and Mental Health Services Administration (SAMHSA), an
agency within the U.S. Department of Health and Human Services (NSDUH-codebook,
2017; NCBI, 2018). The mission of SAMHSA is “to reduce the impact of substance
abuse and mental illness on America's communities” (National Center for Biotechnology
[NCBI], 2018; para. 1). Therefore, understanding the nature of the relationship between
marijuana and mental health conditions is important to developing evidence-based health
policies as this information can serve to inform policy makers, practitioners, and public
health professionals.
Sampling
In order to ensure adequate representation, the NSDUH sampling plan used
multilayer stratification which consisted of three levels or strata. For the first or primary
level, each state was divided into state sampling regions (SSRs) that were approximately
equal in size geographically. Such that each SSR would yield about the same number of
interviews per sampling period. Nevertheless, in all the United States was divided into
750 SSRs, with the following breakdown by state,
“36 SSRs in California; 30 SSRs each in Florida, New York, and Texas; 24 SSRs
each in Illinois, Michigan, Ohio, and Pennsylvania; 15 SSRs each in Georgia,
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New Jersey, North Carolina, and Virginia; and 12 SSRs each in the remaining 38
states and the District of Columbia” (NSDUH-codebook, 2015, p. i-14).
The second level (strata) was based on census tracts that were aggregated within
SSRs to meet the minimum number of dwelling unit (DU) requirements by state. Each
SSR included 48 census tracts. The third level or strata was created by establishing
census block groups within each census tract. Each census block group was then
partitioned into smaller geographical regions and grouped into adjacent clusters. These
geographical clusters or tertiary sampling units (TSUs) were used for the coordinated
sampling design (NSDUH-codebook, 2017.
Data Collection
Prior to participant recruitment, census tracts, census blocks, and census segments
were selected within each SSR (NSDUH-codebook, 2017). After which DUs were then
identified within each census segment. DU selection was based on the classification of
the state where the segment belonged (NSDUH-codebook, 2017). Once the DUs were
identified, individuals were then selected based on the age of residents within the DU
(NSDUH-codebook, 2017). The DU would then receive an introductory letter informing
the residents that they had been randomly selected for participation in the NSDUH
(Center for Behavioral Health Statistics and Quality [CBHSQ], 2016). The field
interviewer conducted in-person interview with an adult respondent of the dwelling unit
to obtain basic demographic information. Then depending on the composition of the
household, two residents of the DU were selected for interviewing based on a
preprogrammed selection algorithm (CBHSQ, 2016). After the screening process, the
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interview was conducted in a private area of the home. The interviewer used both
computer-assisted personal interviewing (CAPI) and audio computer-assisted selfinterviewing (ACASI) techniques (CBHSQ, 2016). The CAPI portion of the interview
was used to collect and record verbal responses to questions read aloud by the interviewer
who entered these responses into a computer (CBHSQ, 2016). In contrast, the ACASI
portion of the interview is used to collect information on answers to sensitive questions
(NSDUH-codebook, 2017). During this portion of the interview, respondents use
headphones to listen to questions and enters responses directly into a computer (NSDUHcodebook, 2017). Throughout the interview process (written and oral) respondents are
assured that their confidentiality, anonymity, and responses are protected and handled
according to federal law compliance regulations (CBHSQ, 2016; NSDUH-codebook,
2017). After the respondent completed the ACAI portion of the interview, the field
interviewer returned to CAPI mode to complete the interview by asking questions
pertaining to the respondent’s household composition, health insurance, and personal and
family income, handled in strict compliance with federal law (CBHSQ, 2016). Finally,
each respondent that completed the survey process was given $30 cash incentive
(CBHSQ, 2016).
Data Analysis Plan
In my study, I assessed whether the trend in marijuana policies and legalization
which favor marijuana acceptance for both medical and recreational use effects mental
health conditions. Moreover, I addressed depression and suicide ideation and compared
early marijuana legalization years when only a few states had medical marijuana laws to
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later marijuana legalization years when numerous states have adopted medical and
recreational marijuana laws. For this purpose, two years were selected for comparing
these periods in time. For early marijuana legalization period, 2008 NSDUH data was
selected and for later marijuana legalization period, 2017 NSDUH data was selected. In
2008, only 13 states had implemented laws legalizing marijuana use for medical purposes
only (NCSL, 2019). By 2017, 29 states and the District of Columbia had passed laws
legalizing medical marijuana with seven of these states and the District of Columbia also
implementing recreational marijuana laws (Governing Data, 2018; NCSL, 2019). Further
support for the premise of this study is provided by Keyhani, et al., (2018) who posited
that “these legal changes have been accompanied by an increase in daily marijuana use,
as well as in marijuana dependence, among adults in the U.S. population” (para. 1). This
is evidenced by an increase in prevalence for marijuana use among adults in the general
population which has doubled over the course of the last decade as 13.3% of respondents
in this group reported using marijuana during the past year in 2014 (Keyhani, et al.,
2018).
I used Chi-Square and complex samples logistic regression analyses in this
quantitative study to assess the statistical significance of marijuana use and mental health
as legalization changed from 2008 to 2017. In order to derive the weighing amounts,
certain calculations were made first. Three steps of calculations were made for sample
weights. First of all, the final probability was determined by calculating the product of the
probability of an individual being selected, the probability of the household being
selected, the probability of the section of the PSU being selected, and the probability of
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the PSU being selected (CDC, 2020). This then had to be adjusted for nonresponse. The
final adjustment that is made is the poststratification adjustment for the purpose of
matching the control totals derived from the year 2000 and 2010 United States Census
population. SPSS statistical software was used to perform all calculations. Descriptive
statistics include past year marijuana use, state medical marijuana status, age, sex, and
socioeconomic status, as well as adult and youth major depressive episodes and suicide
ideation in the past year.
Inferential statistics for this analysis were conducted based on the following
research questions and hypotheses.
Research Questions
This study was guided by three research questions to assess the association
between marijuana and depression, between marijuana and suicide ideation, and whether
these associations were stronger in 2017 than in 2008 for both adults and adolescents.
The research questions were as follows.
RQ1: Is marijuana use associated with depression and suicidal ideation in adults
in 2008 and 2017, either in isolation using raw (unadjusted) values or using values
adjusted for age, sex, annual family income, and education?
RQ2: Is marijuana use associated with depression and suicidal ideation in
adolescents in 2008 and 2017, either in isolation using raw (unadjusted) values or using
values adjusted for age, sex, annual family income, and education?
RQ3: Are the associations between marijuana use and depression and between
marijuana use and suicide ideation higher in 2017 than in 2008 for both adults and
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adolescents, either in isolation using raw (unadjusted) values or using values adjusted for
age, sex, annual family income, and education?
Study Hypotheses
Accordingly, the hypotheses for this study, each stated in null form, were as
follows.
For the 2008 data:
H01: There will be no statistically significant relationship between MJ use and
depression (major depressive episode in the last year) in the adult 2008 cohort,
either in isolation using raw (unadjusted) values or using values adjusted for age,
sex, annual family income, and education.
H02: There will be no statistically significant relationship between MJ use and
suicidal ideation in the adult 2008 cohort, either in isolation using raw
(unadjusted) values or using values adjusted for age, sex, annual family income,
and education.
H03: There will be no statistically significant relationship between MJ use and
depression (major depressive episode in the last year) in the adolescent 2008
cohort, either in isolation using raw (unadjusted) values or using values adjusted
for age, sex, annual family income, and education.
H04: There will be no statistically significant relationship between MJ use and
suicidal ideation in the adolescent 2008 cohort, either in isolation using raw
(unadjusted) values or using values adjusted for age, sex, annual family income,
and education.
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For the 2017 data:
H05: There will be no statistically significant relationship between MJ use and
depression (major depressive episode in the last year) in the adult 2017 cohort,
either in isolation using raw (unadjusted) values or using values adjusted for age,
sex, annual family income, and education.
H06: There will be no statistically significant relationship between MJ use and
suicidal ideation in the adult 2017 cohort, either in isolation using raw
(unadjusted) values or using values adjusted for age, sex, annual family income,
and education.
H07: There will be no statistically significant relationship between MJ use and
depression (major depressive episode in the last year) in the adolescent 2017
cohort, either in isolation using raw (unadjusted) values or using values adjusted
for age, sex, annual family income, and education.
H08: There will be no statistically significant relationship between MJ use and
suicidal ideation in the adolescent 2017 cohort, either in isolation using raw
(unadjusted) values or using values adjusted for age, sex, annual family income,
and education.
For comparing 2008 and 2017 data:
H09: There will be no statistically significant increase in the strength of the
relationships between MJ use and depression (Major Depressive Episode in the
last year) in the adult 2017 cohort compared to the adult 2008 cohort.
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H010: There will be no statistically significant increase in the strength of the
relationships between MJ use and suicidal ideation in the adult 2017 cohort
compared to the adult 2008 cohort.
H011: There will be no statistically significant increase in the strength of the
relationships between MJ use and depression (Major Depressive Episode in the
last year) in the adolescent 2017 cohort compared to the adolescent 2008 cohort.
H012: There will be no statistically significant increase in the strength of the
relationships between MJ use and suicidal ideation in the adolescent 2017 cohort
compared to the adolescent 2008 cohort.
I used crosstabs and a logistic regression analysis to assess the association
between the dependent variable(s) and the independent variable. The early legalization
year was appointed as 2008 and later legalization year as 2017. The independent variable
for these research questions was past year marijuana use while the dependent variables
were depression and suicide ideation. I also used Pearson’s χ2 test to determine
inferential statistics for H01 and Ha1. To reject the null hypotheses the proper P-value is
less than 0.05 (KSU, 2018). Table 3 describes the independent, dependent, and control
variables.
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Table 3
Variable Table
Variable Name
Marijuana Use
Age
Sex
Level of Education
Family Income
Depression
Suicide Ideation

Type Variable
Independent Variable
Control Variable
Control Variable
Control Variable
Control Variable
Dependent Variable
Dependent Variable

Level of Measurement
Nominal Dichotomous
Interval/Ratio
Nominal Dichotomous
Interval/Ratio
Interval/Ratio
Nominal Dichotomous
Nominal Dichotomous

Measures
The NSDUH-Codebook (2017) provides the following descriptions and recoding
for measures (variables & covariates) used:
Marijuana Past Year Use
The independent variable MRJYR defines marijuana use in the past year. The
variable was recoded as “0 = Did not use in the past year” and “1= used within the past
year” (NSDUH-codebook, 2008 p.130).”
Adolescent (Youth) Major Depression Past Year
This variable was coded as YMDEYR and identifies and individual as having a
major depressive episode in the past year. The variable was recoded as YMDEYR = 1 for
“respondents who were classified with lifetime MDE (YMDELT=1) and who reported
that during the past 12 months they had a period of depression lasting 2 weeks or longer,
while also having some of the other symptoms mentioned, were classified as having past
year depression” (NSDUH-codebook, 2017, p. 454-455). While YMDEYR = 2 for
“respondents with no lifetime MDE (YMDELT=1 for youths) or respondents with
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lifetime MDE (YMDELT=1) but no period of depression lasting 2 weeks or longer while
having other symptoms were defined as not having past year MDE” (NSDUH-codebook,
2017, p.454-455).
Adult Major Depression Past Year
This variable was coded as AMDEYR and identifies and individual as having a
major depressive episode in the past year. The variable was recoded as AMDEYR = 1 for
“respondents who were classified with lifetime MDE (AMDELT=1) and who reported
that during the past 12 months they had a period of depression lasting 2 weeks or longer,
while also having some of the other symptoms mentioned, were classified as having past
year depression” (NSDUH-codebook, 2017, p.454-455) While AMDEYR = 2 for
“respondents with no lifetime MDE (AMDELT=2 for adults) or respondents with
lifetime MDE (AMDELT=1) but no period of depression lasting 2 weeks or longer while
having other symptoms were defined as not having past year MDE” (NSDUH-codebook,
2017, p.454-455).
Suicide Ideation
This variable was coded as MHSUITHK and identifies individuals that “seriously
thought about killing self in past year” (NSDUH-codebook, 2008, p.464, 467).” The
variable was coded as SUICTHNK. Wherein 0 = No (SUICTHNK=2) and 1 = Yes
(SUICTHN=1) (NSDUH-codebook, 2008, p.464, 467).

147

Age
This covariable coded as CATAG6 defines the age of participants and was
recoded as “1=12-17 years old,” “2=18-25 years old,” “3=26-34 years old,” “4=35-49,”
“5=50-64 years old,” “6=65 or older” (NSDUH-codebook, 2017, p.548).
Sex
This covariable SEX defines the gender of participants and recoded as 1=Male,
and 2=Female.
Socioeconomic Status
Respondent’s Family income was used for Socioeconomic Status. The variable
IRFAMIN3 defines the income of the household that the participant resides in. This
variable was recoded as “1 = Less than $10,000”, “2 = $10,000 - $19,000,” “3 = $20,000
- $29,999,” “4 = $30,000 – 39,999”; “5 = $40,000 – 49,999”; “6 = $50,000 - $74,999”
and “7 = $75,000 or More” (NSDUH-codebook, 2017, P.575).
Education
For Adult level of education, this covariable coded as EDUCCAT2 defines the
level of education adults achieved. This variable was recoded as “1= Less than High
School Diploma”, “2 = Completed High School”, “3 = Some College”, “4 = Completed
College” and “5 = 12 to 17-year old” (NSDUH-codebook, 2008, p. 598).
For Adolescent level of education, this covariable coded as EDUSCHGRD2
defines the level of education adolescents achieved “1 = 5th Grade or lower”, “2 = 6th
Grade”, “3 = 7th Grade”, “4 = 8th Grade”, “5 = 9th Grade”, “6 = 10th Grade”, “7 = 11th
Grade”, “8 = 12th Grade”, 9 = College or university/1st year”, 10 = College or
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university/2nd Year, 3rd year, 11 = College or university/4th Year, 5th or higher year”
(NSDUH-codebook, 2017, p. 550).
Threats to Validity
Addressing threats to external validity is important to ensuring that the research
study sample and results are generalizable to the population of interest as well as across
different populations, settings, & time (Laerd dissertation, 2012). Researchers must
therefore mitigate these threats to ensure that conclusions or inferences made are due to
the study design and not some other factor (Creswell, 2009). Threats to internal validity
occurs when there are problems with the experimental procedure, treatments or
participant experiences that threaten the researchers’ ability to make correct inferences
about the population of interest using the data obtained. According to Creswell (2009) the
following list represents examples of threats to internal validity: History; Maturation;
Regression; Selection; Mortality; Diffusion; Compensatory Demoralization;
Compensatory Rivalry; Testing and Instrumentation. This study utilizes secondary data
obtained from the NSDUH which utilizes a cross-sectional, non-experimental, random
selection approach which served to reduce or eliminate many of these threats. For
instance, the cross-sectional approach reduces or eliminates threats associated with
history, maturation, and testing (Laerd Dissertation – Internal Validity, (2012), p.1-3). In
contrast, the non-experimental nature of the study reduces threats associated with
diffusion of treatment, compensatory demoralization, and compensatory rivalry (Laerd
Dissertation – Internal Validity, 2012, p.4). Finally, random selection reduces threats
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associated with regression and selection (Laerd Dissertation – Internal Validity, (2012),
p.5).
In contrast, threats to external validity occurs when the researcher applies
incorrect inferences to other populations, settings, or time (Creswell, 2009). Thus, threats
to external validity are concerned with the generalizability of the study’s results
(Frankfort-Nachmias & Nachmias, 2007). According to Frankfort-Nachmias and
Nachmias (2007) there are three major concerns when addressing external threats to
validity these include: 1) Representativeness of the sample; and 2) Reactive
rearrangements in the research procedure; and 3) Interaction of selection and treatment;
To reduce these threats the NSDUH sampling plan utilized multilayer stratification which
consisted of three levels or strata (NSDUH-codebook, 2017). For the first or primary
level, each state was divided into State Sampling Regions (SSRs) that were
approximately equal in size geographically; such that each SSR would yield about the
same number of interviews per sampling period (NSDUH-codebook, 2017). The second
level (strata) was based on census tracts that were aggregated within SSRs to meet the
minimum number of dwelling unit (DU) requirements by state. The third level or strata
was created by establishing census block groups within each census tract. Each census
block group was then partitioned into smaller geographical regions and grouped into
adjacent clusters. These geographical clusters or tertiary sampling units (TSUs) were
used for the coordinated sampling design (NSDUH-codebook, 2017). External threats
were further reduced by the data collection process, wherein the interview was conducted
in a private area of the home using both computer-assisted personal interviewing (CAPI)
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and audio computer-assisted self-interviewing (ACASI) techniques (CBHSQ, 2016). The
CAPI portion of the interview was used to collect and record verbal responses to
questions read aloud by the interviewer who entered these responses into a computer and
the ACASI portion of the interview is used to collect information on answers to sensitive
questions (CBHSQ, 2016; NSDUH-codebook, 2017). During the ACASI portion of the
interview, respondents used headphones to listen to questions and enter responses directly
into a computer (NSDUH-codebook, 2075). All information was de-identified and
throughout the interview process (written and oral) respondents were assured that their
confidentiality, anonymity, and responses were protected and handled according to
federal law compliance regulations (CBHSQ, 2016; NSDUH-codebook, 2017).
Sample Size
The sample size for the 2008 and 2017 NSDUH datasets consisted of responses
from 67,928 and 68,032 participants, respectively (NSDUH-codebook, 2008; NSDUHcodebook, 2017). In this study I evaluated U.S. residents 12 years and older residing in
all 50 states and the District of Columbia. The quantitative approach allows one to study
effects in small groups of people and make inferences about larger populations (Ellis,
2010). However, obtaining statistically significant results is reliant on sample size as the
larger the sample size the more likely an effect will be accepted as statistically significant
(Ellis, 2010). For instance, Ellis (2010) posit that “if the expected effect size is
overestimated, required sample sizes will be underestimated and the study will be
inadequately powered” (p.61).
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Determining an appropriate sample size relies on three variables: 1) the
significance level or criterion (α), the power (1-β), and the effect size (d) (Ellis, 2010).
The significance criterion or Alpha (α) level is the error rate that the researcher is willing
to accept and is often set at .05 or .01 (Ellis, 2010; Suresh & Chandrashekara, 2012). In
this study, I used an Alpha level of .05 and this means I was willing to accept that there is
a 5% (or five percent?) chance that the study results are due to chance (Ellis, 2010;
Suresh & Chandrashekara, 2012). The alpha (α) level is a measure of Type I error which
occurs when the null hypothesis is inadvertently rejected when it is actually true
(Banerjee, Chitnis, Jadhav, Bhawalkar, & Chaudhry, 2009). In contrast, power refers to
the likelihood that a statistical analysis will correctly identify an effect in a population if
one exists. Power (1-β) is inversely related to the probability of making a type II error
which occurs when the null hypothesis is not rejected when it is actually false (Banerjee,
Chitnis, Jadhav, Bhawalkar, & Chaudhry, 2009). The commonly set value for power is
0.80 (Ellis, 2010). Type I and II errors can lead to erroneous inferences that researchers
seek to avoid by selecting an appropriate sample size as larger sample sizes are less likely
to differ substantially from the study population (Banerjee et al., 2009). Finally, effect
size is related to the magnitude of difference that exists between two groups and is
quantified as the size of the association that a study seeks to detect in a sample (Ellis,
2010; Banerjee et al., 2009).
The sample size was calculated utilizing G*Power software, obtained from the
Heinrich Heine University website (Heinrich Heine University Dusseldorf [HHU], 2018).
In this study I used multiple logistic regression with one dependent variable and multiple
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independent variables. Therefore, the test family selected was “z tests” with logistic
regression selected as the statistical test. The following values were entered into the
G*Power software: an α error probability of 0.05, the desired power was 0.80, and an
effect size (odds ratio) of 1.3 was designated as demonstrated in similar studies of this
type (Han, Compton, Blanco, & Jones, 2018). The G*Power software estimated a
minimal sample size of 1,447. To ensure adequate power, I used a larger sample size than
the minimal recommended by G*Power software.
Ethical Considerations/Procedures
Since I used secondary data obtained from the NSDUH then informed consent
was obtained, and data was de-identified prior to my use (NSDUH-codebook, 2017). For
instance, in order to protect the confidentiality of data the NSDUH used a statistical
disclosure limitation method which served to eliminate all personal identifying
information such as, name, phone number, address, and geographical information
(NSDUH-codebook, 2017). In addition, the NSDUH obtains information in a secure
manner and this data is available for public use. Nevertheless, the Walden Institutional
Review Board (IRB) confirmed that this doctoral capstone meets the University’s ethical
standards and will oversee the capstone data analysis and results reporting. Approved on
12-3-2018, IRB Approval number 12-3-18-0188278.
Summary
This chapter presents a detailed description of the research methods used in this
study. The chapter begins with a description of the NSDUH, the source of secondary data
intended for use in this study, a description of the research design and rationale and the
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methodology used to identify the target population, as well as sampling, and data
collection methods. This chapter then describes the data analysis plan which includes the
research questions and a description of the independent and dependent variables,
measures, and coding/re-coding of variables. Finally, this chapter describes and addresses
threats to validity, provides an explanation for determining sample size and discusses
ethical considerations of the study. Chapter 4 which follows will serve to analyze,
present, and describe research findings.
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Chapter 4: Results
Introduction
This quantitative study was designed to investigate whether there were
statistically significant associations between marijuana use and the mental health
conditions (MHC) of MDE and suicide ideation in adolescents and adults, and whether
these associations increased from 2008 to 2017. Study data from the NSDUH database
were used to compare an early medical marijuana legalization year (2008), when only 13
states had legalized marijuana for medicinal purposes only, to a more current legalization
year (2017), when 28 states and the District of Columbia had implemented medical
marijuana laws and eight of these states plus the District of Columbia also legalized
recreational marijuana (Governing Data, 2018; NCSL, 2019).
This chapter begins with a review of the research questions and study hypotheses.
Data collection steps are reviewed, followed by a review of the data analysis plan.
Results from hypothesis testing are provided. This chapter ends with a summary of major
findings.
Research Questions
In this study I was guided by three research questions to assess the association
between marijuana and depression, between marijuana and suicide ideation, and whether
these associations were stronger in 2017 than in 2008 for both adults and adolescents.
The research questions were as follows.
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RQ1: Is marijuana use associated with depression and suicidal ideation in adults
in 2008 and 2017, either in isolation using raw (unadjusted) values or using values
adjusted for age, sex, annual family income, and education?
RQ2: Is marijuana use associated with depression and suicidal ideation in
adolescents in 2008 and 2017, either in isolation using raw (unadjusted) values or using
values adjusted for age, sex, annual family income, and education?
RQ3: Are the associations between marijuana use and depression and between
marijuana use and suicide ideation higher in 2017 than in 2008 for both adults and
adolescents, either in isolation using raw (unadjusted) values or using values adjusted for
age, sex, annual family income, and education?
Study Hypotheses
Accordingly, the hypotheses for this study, each stated in null form, were as
follows.
For the 2008 data:
H01: There will be no statistically significant relationship between marijuana (MJ)
use and depression (major depressive episode in the last year) in the adult 2008
cohort, either in isolation using raw (unadjusted) values or using values adjusted
for age, sex, annual family income, and education.
H02: There will be no statistically significant relationship between MJ use and
suicidal ideation in the adult 2008 cohort, either in isolation using raw
(unadjusted) values or using values adjusted for age, sex, annual family income,
and education.
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H03: There will be no statistically significant relationship between MJ use and
depression (major depressive episode in the last year) in the adolescent 2008
cohort, either in isolation using raw (unadjusted) values or using values adjusted
for age, sex, annual family income, and education.
H04: There will be no statistically significant relationship between MJ use and
suicidal ideation in the adolescent 2008 cohort, either in isolation using raw
(unadjusted) values or using values adjusted for age, sex, annual family income,
and education.
For the 2017 data:
H05: There will be no statistically significant relationship between MJ use and
depression (major depressive episode in the last year) in the adult 2017 cohort,
either in isolation using raw (unadjusted) values or using values adjusted for age,
sex, annual family income, and education.
H06: There will be no statistically significant relationship between MJ use and
suicidal ideation in the adult 2017 cohort, either in isolation using raw
(unadjusted) values or using values adjusted for age, sex, annual family income,
and education.
H07: There will be no statistically significant relationship between MJ use and
depression (major depressive episode in the last year) in the adolescent 2017
cohort, either in isolation using raw (unadjusted) values or using values adjusted
for age, sex, annual family income, and education.
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H08: There will be no statistically significant relationship between MJ use and
suicidal ideation in the adolescent 2017 cohort, either in isolation using raw
(unadjusted) values or using values adjusted for age, sex, annual family income,
and education.
For comparing 2008 and 2017 data:
H09: There will be no statistically significant increase in the strength of the
relationships between MJ use and depression (Major Depressive Episode in the
last year) in the adult 2017 cohort compared to the adult 2008 cohort.
H010: There will be no statistically significant increase in the strength of the
relationships between MJ use and suicidal ideation in the adult 2017 cohort
compared to the adult 2008 cohort.
H011: There will be no statistically significant increase in the strength of the
relationships between MJ use and depression (Major Depressive Episode in the
last year) in the adolescent 2017 cohort compared to the adolescent 2008 cohort.
H012: There will be no statistically significant increase in the strength of the
relationships between MJ use and suicidal ideation in the adolescent 2017
cohort compared to the adolescent 2008 cohort.
Data Collection
Data were obtained from the years 2008 and 2017 NSDUH databases. Since this
study used deidentified secondary data, there was no direct contact with survey
participants. After receiving approval from the Walden University (approval number 1203-18-0188278) and registration with the Interuniversity Consortium for Political and
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Social Research, the 2008 and 2017 data were downloaded from NSDUH in SPSS
(Statistical Package for the Social Sciences, version 23) format. The 2008 NSDUH
dataset included 37,504 adult cases and 17,606 adolescent cases. The 2017 NSDUH
dataset included 42,554 adult cases and 13,722 adolescent cases (NSDUH-codebook,
2008; NSDUH-codebook, 2017). Cases for each analysis were included if they were not
missing the data necessary to address the research questions, so the sample sizes varied
somewhat from analysis to analysis. For example, the sample sizes for adolescent suicidal
ideation were smaller than for adolescent MDE because of missing values for the
adolescent cohorts.
Data Analysis
Data descriptive included frequencies percentages or means and standard
deviation, as appropriate, for sex, age, level of education, family income distribution,
major depression episode and suicide ideation. Hypothesis testing with inferential
statistics consisted odds ratios (ORs) with 95% confidence intervals derived from
crosstabs to determine ORs in isolation and with binary logistic regression to account for
age, sex, family income, and education. Differences were considered to be statistically
significant at the p < .05 threshold. For simplicity, results are presented for 2008 adults,
2008 adolescents, 2017 adults, and 2017 adolescents, with a summary section to address
the research questions.
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2008 Adult Results
2008 Adult Descriptive Statistics
Table 4 shows that the 2008 adult sample was well divided between males (47%)
and females (53%). Ages ranged from 18 to over 65. Roughly half of cases were between
20 and 34 years old (51%). Education levels ranged from less than high school diploma
to college degree. Roughly half (49%) had some college education or completed college.
Annual family incomes ranged from less than $10,000 to $75,000 or greater. Roughly
half (52%) reported annual family incomes of $40,000 or greater.
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Table 4
2008 Adults Demographic Frequencies and Percentages (N = 34,504)
Demographic
Sex
Males
Females
Age
18
19
20
21
22 or 23
24 or 25
26 to 29
30 to 34
35 to 49
50 to 64
65 or older
Education Level
Less than High School Diploma
Completed High School
Some College
Completed College
Family Income Distribution
Less than $10,000
$10,000 - $19,999
$20,000 - $29,999
$30,000 - $39,999
$40,000 - $49,999
$50,000 - $74,999
$75,000 or more

n

%

17440
20064

47
53

2811
2468
2280
2342
4520
4468
2732
2806
7788
3290
1999

7
7
6
6
12
12
7
7
21
9
5

6682
12489
10811
7522

18
33
29
20

4303
4844
4414
4387
4303
6441
8812

11
13
12
12
11
17
23
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2008 Adult Hypothesis Testing
Marijuana use and depression, 2008 Adults. Overall MJ use was 18% in the
2008 Adult cohort (6810 of 37186) for this analysis and the rate of MDE was 8% (3024
of 37186). Table 5 shows that 12% of MJ users reported MDE in the recent year
compared to (7%) for non-MJ users. This disproportionality was statistically significant,

2 (df = 1) = 171.8, p < .0001. The odds of MDE was 0.14 for users and .08 for nonusers. The odds ratio of 1.75, indicated that adult MJ users had 75% greater odds of
having MDE in the previous year than non-users (see Gertsman, 2008). This statistically
significant finding rejected Null Hypothesis 1 (H01).
Table 5
Marijuana and Depression: 2008 Adults
Marijuana
Use
No
Yes
Total

Stat
Count
%
Count
%
Count
%

Major Depressive Episode
Yes
No
2203
28173
7%
93%
821
5989
12%
88%
3024
34162
8%
92%

Total
30376
100%
6810
100%
37186
100%

Odds
0.08
0.14
1.75
Odds Ratio

Table 6 shows that, after accounting for age, sex, family income, and education
level, the odds ratio for the relationship between MJ and MDE in adults was 1.39 (p <
.0001). This finding indicates that adult MJ users had 39% greater odds of having MDE
in the previous year than non-users (see Gertsman, 2008), after accounting for age, sex,
family income, and level of education. This statistically significant finding rejected Null
Hypothesis 1.
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Table 6
Coefficients Table: 2008 Adults MDE
Variable

B

S.E.

df

p-value

OR

Marijuana Use
Yes
.33
0.11 1
0.005
1.39
No
Reference
Sex
Female
.88
0.12 1
<.0001
2.42
Male
Reference
Income
-.04
0.02 1
0.09
0.95
Education
Less than
-.03
0.12 1
0.82
0.97
High School
High School
-.40
0.16 1
0.02
0.68
Graduate
Some College
-.04
0.14 1
0.78
0.96
Completed
Reference
College
Age
.02
0.03 1
0.48
1.02
Note: The degrees of freedom in computing the confidence limits is 60

Confidence
Intervals
1.11

1.75

1.87

3.13

0.90

1.01

0.77

1.23

0.49

0.94

0.73

1.26

0.96

1.09

Marijuana use and suicidal ideation, 2008 Adults. Overall adult MJ use in the
2008 cohort was 18% (6,849 of 37,360) for this analysis. Table 7 shows that 11% of MJ
users reported suicidal ideation in the recent year compared to 5% for non-MJ users. This
disproportionality was statistically significant, 2 (df = 1) = 353.4, p < .0001.
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Table 7
Marijuana and Suicidal Ideation: 2008 Adults
Marijuana
Use
No
Yes
Total

Stat
Count
%
Count
%
Count
%

Suicidal Ideation
Yes
No
1383
29128
5%
95%
706
6143
10%
90%
2089
35271
94%
6%

Total
30511
100%
6849
100%
37360
100%

Odds
0.05
0.11
2.42
Odds Ratio

The odds of suicide ideation were 0.11 for users and 0.05 for nonusers. The odds
ratio of 2.42 indicated that adult MJ users had more than double the odds of having
suicidal ideation in the previous year than nonusers. This statistically significant finding
rejected Null Hypothesis 2.
Table 8 shows that, after accounting for age, sex, family income, and education
level, the odds ratio for the relationship between MJ and suicidal ideation was 1.50 (p =
.0016) This finding indicates that adult MJ users had 50% greater odds of having suicidal
ideation in the previous year than nonusers (see Gertsman, 2008), after accounting for
age, sex, family income, and level of education. This statistically significant finding
rejected Null Hypothesis 2.
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Table 8
Coefficients Table: 2008 Adults Suicide Ideation
Variable

B

S.E. d
f

p-value

OR

Confidence
Intervals

Marijuana
Use
Yes
.40
.12 1
.002
1.50
1.18
No
Reference
Sex
Female
.33
.14 1
.02
1.40
1.05
Male
Reference
Income
-.01
.02 1
.63
.99
.94
Education
-.08
.06 1
.18
.92
.81
Less than
.16
.43 1
.71
1.17
.50
HS
HS
.04
.48 1
.93
1.04
.40
Graduate
At least some Reference
College
Age
-.05
.03 1
.16
.95
.89
Note: The degrees of freedom in computing the confidence limits is 60

1.92

1.87
1.04
1.04
2.77
2.70

1.02

Summary of 2008 Adult Cohort. Combined, these findings indicate a
statistically significant relationship between MJ use and MDE (H01) and between MJ use
and suicidal ideation (H02) in the 2008 Adult cohort.
2008 Adolescent Results
2008 Adolescent Descriptive Statistics
Table 9 shows that the 2008 adolescent sample was well divided between males
(51%) and females (49%). Ages ranged from 12 to 17. Roughly half of cases were less
than 15 years old (47%). Education ranged from fifth grade to college level. Roughly half
(55%) reported an education level of ninth grade or lower. Annual family incomes ranged
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from less than $10,000 to $75,000 or greater. Roughly half (49%) reported annual family
incomes of less than $50,000.
Table 9
2008 Adolescent Demographic Frequencies and Percentages (N =17,606)
Demographic
Sex
Males
Females
Age
12
13
14
15
16
17
Education Level
5th Grade
6th Grade
7th Grade
8th Grade
9th Grade
10th Grade
11th Grade
12th Grade
Some College/University
Family Income Distribution
Less than $10,000
$10,000 - $19,999
$20,000 - $29,999
$30,000 - $39,999
$40,000 - $49,999
$50,000 - $74,999
$75,000 or more

n

%

8988
8618

51
49

2615
2781
2884
3062
3180
3084

15
16
16
17
18
18

84
971
2591
2835
3016
3045
2954
1695
138

<1
6
15
16
17
17
17
10
1

967
1850
1892
1937
1939
3344
5677

5
11
11
11
11
19
32
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2008 Adolescent Hypothesis Testing
Marijuana use and depression, 2008 Adolescents. Overall MJ use was 14% in
the 2008 Adolescent cohort (2,348 of 17,254) for this analysis and the rate of MDE was
8% (1,471 of 17,254). Table 10 shows that 18% of MJ users reported MDE in the recent
year compared to 8% for non-MJ users. This disproportionality was statistically
significant, 2 (df = 1) = 141.9, p < .0001. The odds of MDE was 0.18 for users and 0.08
for nonusers. The odds ratio of 2.15 indicated that 2008 adolescent MJ users had greater
than double the odds of having MDE in the previous year than nonusers. This statistically
significant finding rejected Null Hypothesis 3.
Table 10
Marijuana and Depression: 2008 Adolescents
Marijuana
Use
No
Yes
Total

Stat
Count
%
Count
%
Count
%

Major Depressive Episode
Yes
No
1121
13785
8%
92%
350
1998
15%
85%
1471
15783
9%
91%

Total
14906
100%
2348
100%
17254
100%

Odds
0.08
0.18
2.15
Odds Ratio

Table 11 shows that, after accounting for age, sex, family income, and education
level, the odds ratio for the relationship between MJ and MDE in 2008 adolescents was
1.99 (p < .0001). This finding indicates that adolescent MJ users had double odds of
having MDE in the previous year than non-users (see Gertsman, 2008), after accounting
for age, sex, family income, and level of education. This statistically significant finding
rejected Null Hypothesis 3.
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Table 11
Coefficients Table: 2008 Adolescent MDE
Variable
B
S.E.
df
p-value
OR
Marijuana
Use
Yes
.68
.09
1
<.0001
1.99
No
Reference
Sex
Female
1.17
.08
1
<.0001
3.24
Male
Reference
Income
-.006
.02
1
.77
0.99
Education
-.02
.05
1
.40
0.95
Age
.20
.06
1
.002
1.22
Note: The degrees of freedom in computing the confidence limits is 60

Confidence Intervals

1.63

2.42

2.72

3.86

0.95
0.85
1.08

1.04
1.07
1.38

Marijuana use and suicidal ideation, 2008 Adolescents. Overall MJ use was
22% in the 2008 Adolescent cohort (1867 of 2623) for this analysis and the rate of
suicidal ideation was 71% (1471 of 2623). Table 12 shows that 78% of MJ users reported
suicidal ideation in the recent year compared to 69% for non-MJ users. This
disproportionality was statistically significant, 2 (df = 1) = 17.5, p < .0001. The odds of
suicidal ideation were 3.59 for users and 2.25 for non-users. The odds ratio of 1.59,
indicated that adolescent MJ users had 59% greater odds of having suicidal ideation in
the previous year than non-users (see Gertsman, 2008). This finding rejected Null
Hypothesis 4.
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Table 12
Marijuana and Suicidal Ideation: 2008 Adolescents
Marijuana
Use
No
Yes
Total

Stat
Count
%
Count
%
Count
%

Suicidal Ideation
Yes
No
1422
632
69%
31%
445
124
78%
22%
1867
756
71%
29%

Total
2054
100%
569
100%
2623
100%

Odds
2.25
3.59
1.59
Odds Ratio

Table 13 shows that, after accounting for age, sex, family income, and education
level, the odds ratio for the relationship between MJ and suicidal ideation in 2008
adolescents was 1.74 (p = .0001). This finding indicates that adolescent MJ users had
74% greater odds of having suicidal ideation in the previous year than non-users, after
accounting for age, sex, family income, and level of education (Gertsman, 2008). This
statistically significant finding rejected Null Hypothesis 4.
Table 13
Coefficients Table: 2008 Adolescent Suicide Ideation
Variable
B
S.E,
df
p-value
OR
Confidence Intervals
Marijuana
Use
Yes
.55
.13
1
.0001
1.74
1.33
2.29
No
Reference
Sex
Female
.58
.12
1
<.0001
1.80
1.40
2.32
Male
Reference
Income
-.01
.02
1
.69
.99
.93
1.05
Education
-.02
.09
1
.80
.98
.80
1.19
Age
-.02
.10
1
.84
.98
.80
1.20
Note: The degrees of freedom in computing the confidence limits is 60
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Summary of 2008 Adolescent Cohort. Combined, these findings indicate a
statistically significant relationship between MJ use and MDE (H03) and between MJ use
and suicidal ideation (H04) in the 2008 Adolescent cohort.
2017 Adult Results
2017 Adult Descriptive Statistics
Table 14 shows that the 2017 adult sample was well divided between males
(47%) and females (53%). Ages ranged from 18 to over 65. Roughly half of cases were
between 20 and 34 years old (53%). Education levels ranged from less than high school
diploma to college degree. More than half (61%) had some college education or
completed college. Annual family incomes ranged from less than $10,000 to $75,000 or
greater. Roughly half (49%) reported annual family incomes of $40,000 or greater.
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Table 13
2017 Adults Demographic Frequencies and Percentages (N = 42,554)
Demographic
Sex
Males
Females
Age
18
19
20
21
22 or 23
24 or 25
26 to 29
30 to 34
35 to 49
50 to 64
65 or older
Education Level
Less than High School Diploma
Completed High School
Some College
Completed College
Family Income Distribution
Less than $10,000
$10,000 - $19,999
$20,000 - $29,999
$30,000 - $39,999
$40,000 - $49,999
$50,000 - $74,999
$75,000 or more

n

%

19987
22567

47
53

1730
1626
1636
1614
3555
3679
3989
4797
11214
4997
3717

4
4
4
4
8
9
9
11
26
12
9

5395
11269
14288
11602

13
26
34
27

3677
4693
4555
4410
4356
6704
14159

9
11
11
10
10
16
33
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2017 Adult Hypothesis Testing
Marijuana use and depression, 2017 Adults. Overall MJ use was 21% in the
2017 Adult cohort (8912 of 42066) for this analysis and the rate of MDE was 9% (3024
of 42066). Table 15 shows that .19 of MJ users reported MDE in the recent year
compared to 0.08 for non-MJ users. This disproportionality was statistically significant,

2 (df = 1) = 633.8, p < .0001.
Table 14
Marijuana and Depression: 2017 Adults
Marijuana
Use
No
Yes
Total

Stat
Count
%
Count
%
Count
%

Major Depressive Episode
Yes
No
2497
30657
8%
93%
1452
7460
16%
84%
3949
38117
9%
91%

Total
33154
100%
8912
100%
42066
100%

Odds
0.08
0.19
2.39
Odds Ratio

The odds of MDE was 0.19 for users and .08 for non-users. The odds ratio of 2.39
indicated that adult MJ users had more than double the odds of having MDE in the
previous year than non-users (see Gertsman, 2008). This statistically significant finding
rejected Null Hypothesis 5.
Table 16 shows that, after accounting for age, sex, family income, and education
level, the odds ratio for the relationship between MJ and MDE in 2017 adults was 2.19 (p
< .0001). This finding indicates that adult MJ users had more than double the odds of
having MDE in the previous year than non-users, after accounting for age, sex, family
income, and level of education. This statistically finding rejected Null Hypothesis 5.
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Table 16
Coefficients Table: 2017 Adult MDE
Variable
B
S.E.
df
p-value
OR
Confidence Intervals
Marijuana
Use
Yes
.78
.05
1
<.0001
2.19
1.97
2.43
No
Reference
Sex
Female
.58
.04
1
<.0001
1.79
1.63
1.97
Male
Reference
Income
-.11
.01
1
<.0001
.89
.862
.913
Education
.07
.01
1
<.0001
1.08
1.05
1.11
Age
-.11
.01
1
<.0001
.89
.876
.911
Note: The degrees of freedom in computing the confidence limits is 50

Marijuana use and suicidal ideation, 2017 Adults. Overall MJ use was 21%
(8952 of 42240) for this analysis. Table 17 shows that 12% of MJ users reported suicidal
ideation in the recent year compared to 4% for non-MJ users. This disproportionality was
statistically significant, 2 (df = 1) = 744.2, p < .0001. The odds of suicide ideation were
0.14 for users and 0.05 for non-users. The odds ratio of 2.98 indicated that adult MJ users
had roughly three times greater odds of having suicidal ideation in the previous year than
non-users (see Gertsman, 2008). This statistically finding rejected Null Hypothesis 6.
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Table 15
Marijuana and Suicidal Ideation: 2017 Adults
Marijuana
Use
No
Yes
Total

Stat
Count
%
Count
%
Count
%

Suicidal Ideation
Yes
No
1490
31798
4%
96%
1098
7854
12%
88%
2588
39652
6%
94%

Total
33288
100%
8952
100%
42240
100%

Odds
0.05
0.14
2.98
Odds Ratio

Table 18 shows that, after accounting for age, sex, family income, and education
level, the odds ratio for the relationship between MJ and suicidal ideation was 2.29 (p <
.0001) This finding indicates that adult MJ users had more than double the odds of having
suicidal ideation in the previous year than non-users, after accounting for age, sex, family
income, and level of education (see Gertsman, 2008). This statistically significant finding
rejected Null Hypothesis 6.
Table 18
Coefficients Table: 2017 Adult Suicide Ideation
Variable
B
S.E.
df
p-value
OR
Confidence Intervals
Marijuana
Use
Yes
.82
.06
1
<.0001
2.29
2.00
2.61
No
Reference
Sex
Female
.18
.05
1
.003
1.21
1.07
1.36
Male
Reference
Income
-.10
.01
1
<.0001
.90
.87
.93
Education
.03
.01
1
.108
1.03
.99
1.08
Age
-.16
.01
1
<.0001
.85
.83
.87
Note: The degrees of freedom in Computing the Confidence Limits is 50
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Summary of 2017 Adult Cohort. Combined, these findings indicate a
statistically significant relationship between MJ use and MDE and between MJ use and
suicidal ideation in the 2017 Adult cohort.
2017 Adolescent Results
2017 Adolescent Descriptive Statistics
Table 19 shows that the 2017 adolescent sample was well divided between males
(51%) and females (49%). Ages ranged from 12 to 17. Roughly half of cases were less
than 15 years old (47%). Education ranged from fifth grade to college level. Roughly half
(55%) reported an education level of ninth grade or lower. Annual family incomes ranged
from less than $10,000 to $75,000 or greater. Roughly half (49%) reported annual family
incomes of less than $50,000.
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Table 16
2017 Adolescent Demographic Frequencies and Percentages (N = 13,722)
Demographic
Sex
Males
Females
Age
12
13
14
15
16
17
Education Level
5th Grade
6th Grade
7th Grade
8th Grade
9th Grade
10th Grade
11th Grade
12th Grade
Some College
Family Income Distribution
Less than $10,000
$10,000 - $19,999
$20,000 - $29,999
$30,000 - $39,999
$40,000 - $49,999
$50,000 - $74,999
$75,000 or more

n

%

7050
6672

51
49

2039
2268
2278
2381
2400
2356

15
17
17
17
17
17

735
1959
2174
2465
2333
2341
1560
129
26

5
14
16
18
17
17
11
1
<1

721
1485
1403
1222
1275
2043
5573

5
11
10
9
9
15
41

2017 Adolescent Hypothesis Testing
Marijuana use and depression, 2017 Adolescents. Overall MJ use was 14% in
the 2017 Adolescent cohort (1814 of 13330) for this analysis and the rate of MDE was
8% (2348 of 13330). Table 20 shows that 25% of MJ users reported MDE in the recent
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year compared to (12%) for non-MJ users. This disproportionality was statistically
significant, 2 (df = 1) = 235.1, p < .0001. The odds of MDE was 0.33 for users and 0.13
for non-users. The odds ratio of 2.50 indicated that 2017 adolescent MJ users had two
and a half times odds of having MDE in the previous year than non-users (see Gertsman,
2008). This statistically significant finding rejected Null Hypothesis 7.
Table 17
Marijuana and Depression: 2017 Adolescents
Marijuana
Use
No
Yes
Total

Stat
Count
%
Count
%
Count
%

Major Depressive Episode
Yes
No
1359
10157
12%
88%
455
1359
25%
75%
1814
11516
14%
86%

Total
11516
100%
1814
100%
13330
100%

Odds
0.13
0.33
2.50
Odds Ratio

Table 21 shows that, after accounting for age, sex, family income, and education
level, the odds ratio for the relationship between MJ and MDE in 2017 adolescents was
1.81 (p < .0001). This finding indicates that adolescent MJ users had 81% greater odds of
having MDE in the previous year than non-users, after accounting for age, sex, family
income, and level of education (see Gertsman, 2008). This statistically significant finding
rejected Null Hypothesis 7.
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Table 21
Coefficients Table: 2017 Adolescent MDE
Variable
B
S.E.
df
p-value
OR
Confidence Intervals
Marijuana
Use
Yes
.59
.08
1
<.0001
1.81
1.53
2.14
No
Reference
Sex
Female
1.22
.08
1
<.0001
3.41
2.89
4.03
Male
Reference
Income
.02
.01
1
.16
1.03
..99
1.06
Education
.07
.04
1
.12
1.08
.98
1.18
Age
.15
.05
1
.004
1.16
1.05
1.29
Note: The degrees of freedom in computing the confidence limits is 50

Marijuana use and suicidal ideation, 2017 Adolescents. Overall MJ use was
23% in the 2017 Adolescent cohort (643 of 2623) for this analysis and the rate of suicidal
ideation was 77% (2127 of 2623). Table 22 shows that 81% of MJ users reported suicidal
ideation in the recent year compared to 76% for non-MJ users. This disproportionality
was statistically significant, 2 (df = 1) = 8.5, p < .01. The odds of suicidal ideation were
4.40 for users and 3.16 for non-users. The odds ratio of 1.39 indicated that 2017
adolescent MJ users had 39% greater odds of having suicidal ideation in the previous
year than non-users (see Gertsman, 2008). This statistically significant finding rejected
Null Hypothesis 8.
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Table 18
Marijuana and Suicidal Ideation: 2017 Adolescents
Marijuana
Use
No

Suicidal Ideation
Stat
Yes
No
Total
Odds
1603
507
2110
3.16
Count
76%
24%
100%
%
524
119
643
4.40
Yes
Count
81%
19%
100%
%
2127
626
2623
1.39
Total
Count
77%
23%
100%
%
Odds Ratio
Table 23 shows that, after accounting for age, sex, family income, and education

level, the odds ratio for the relationship between MJ and suicidal ideation in 2017
adolescents was 1.24 (p < .0001). This finding indicates that in 2017 adolescent MJ users
had 24% greater odds of having suicidal ideation in the previous year than non-users,
after accounting for age, sex, family income, and level of education (see Gertsman,
2008). This statistically significant finding rejected Null Hypothesis 8.
Table 23
Coefficients Table: 2017 Adolescent Suicide Ideation
Variable
B
S.E.
df
p-value
OR
Confidence Intervals
Marijuana
Use
Yes
.21
.17
1
.22
1.24
.87
1.76
No
Reference
Sex
Female
.54
.10
1
<.0001
1.73
1.39
2.15
Male
Reference
Income
-.003
.03
1
.92
.99
.93
1.07
Education
-.05
.09
1
.56
.95
.79
1.14
Age
.06
.09
1
.49
1.06
.89
1.28
Note: The degrees of freedom in Computing the Confidence Limits is 50
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Summary of 2017 Adolescent Cohort. Combined, these findings indicate a
statistically significant relationship between MJ use and MDE (H07) and between MJ use
and suicidal ideation (H08) in the 2017 Adolescent cohort.
Comparisons Between 2008 and 2017 Results
It was hypothesized that the relationship between MJ use and depression and the
relationship between MJ use and suicidal ideation would increase in magnitude from
2008 to 2017 for adults and for adolescents. To test these hypotheses, the ORs for 2017
were assessed to determine whether they were outside of the 95% confidence intervals
(95% CI) for the corresponding 2008 OR results. This assessment was conducted for
depression and for suicidal ideation, with analyses for adults and adolescents conducted
in parallel analyses. ORs were tested using both raw (unadjusted) values and using ORs
that were adjusted for age, sex, annual family income, and level of education. If a 2017
OR was outside of the 95% CI for the corresponding 2008 data, the difference was
statistically significant at the p < .05 threshold.
MJ and Depression Changes from 2008 to 2017
The depression ORs for MJ users and non-users for the Adult and Adolescent
2008 and 2017 cohorts are displayed in Table 24. The 95% CIs are also included to foster
testing the hypotheses.
Adult MJ-related depression changes from 2008 to 2017. The 2017 raw
(unadjusted) Adult OR of 2.39 was higher than the 95% CI for the 2008 unadjusted OR
(1.61-1.91). The 2017 adjusted Adult OR of 2.18 was higher than the 95% CI for the
2008 adjusted OR (1.10-1.74). These findings rejected null hypothesis 9 (H09), which
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stated that there will be no significant increase in the strength of the relationships
between MJ use and MDE (see Gertsman, 2008).
Adolescent MJ-related depression changes from 2008 to 2017. The 2017 raw
(unadjusted) Adolescent OR of 2.50 was higher than the 95% CI for the 2008 unadjusted
OR (1.90-2.46). The 2017 adjusted Adolescent OR of 1.81 was not outside of the 95% CI
for the 2008 adjusted OR (1.63-2.41). These findings partially rejected null Hypothesis
11 (H011), which stated that there will be no statistically significant increase in the
strength of the relationships between MJ use and MDE in the adolescent 2017 cohort
compared to the adolescent 2008 cohort (see Gertsman, 2008).
Table 19
Depression Raw and Adjusted ORs for Adults and Adolescents: 2008 and 2017
Age

Year

2008
2017
2008
Child
2017

Adult

Raw
OR
1.75
2.39
2.16
2.50

95% CI
Adjusted
95% CI
Lower Upper
OR
Lower Upper
1.61
1.91
1.39
1.10
1.74
2.23
2.56
2.18
1.96
2.43
1.90
2.46
1.98
1.63
2.41
2.22
2.82
1.81
1.53
2.13

MJ and Suicide Ideation Changes from 2008 to 2017
The suicide ideation ORs for MJ users and non-users for the Adult and
Adolescent 2008 and 2017 cohorts are displayed in Table 25. The 95% CIs are also
included to foster testing the hypotheses.
Adult MJ-related suicidal ideation changes from 2008 to 2017. The 2017 raw
(unadjusted) Adult OR of 2.98 was significantly higher than the 95% CI for the 2008
unadjusted OR (2.20-2.66). The 2017 adjusted Adult OR of 2.40 was higher than the 95%
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CI for the 2008 adjusted OR (1.89-2.31). These findings rejected the null hypothesis 10
(H010), which stated that there will be no statistically significant increase in the strength
of the relationships between MJ use and suicide ideation in the adult 2017 cohort
compared to the adult 2008 cohort (see Gertsman, 2008).
Adolescent MJ-related suicide ideation changes from 2008 to 2017. The 2017
raw (unadjusted) Adolescent OR of 1.39 was within the 95% CI for the 2008 unadjusted
OR (1.28-2.01). The 2017 adjusted Adolescent OR of 1.24 was not outside of the 95% CI
for the 2008 adjusted OR (1.32-2.29). These non-significant findings failed to reject the
null hypothesis 12 (H012), which stated that there will be no statistically significant
increase in the strength of the relationships between MJ use and suicidal ideation in the
adolescent 2017 cohort compared to the adolescent 2008 cohort (see Gertsman, 2008).
Table 20
Suicidal Ideation Raw and Adjusted ORs for Adults and Adolescents: 2008 and 2017
Age

Year

2008
2017
2008
Child
2017

Adult

Raw
OR
2.42
2.98
1.61
1.39

95% CI
Adjusted
95% CI
Lower Upper
OR
Lower Upper
2.20
2.66
1.50
1.17
1.92
2.75
3.24
2.28
2.00
2.60
1.28
2.01
1.74
1.32
2.29
1.11
1.74
1.24
.877
1.76

Summary of Results
The summary of results by hypothesis are displayed in Table 26. This study of
data from the 2008 and 2017 National Survey on Drug Use and Health (NSDUH)
database revealed that MJ use was associated with significant odds of greater depression
and suicidal ideation for adults and for adolescents in 2008 and in 2017. These findings
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were consistent whether ORs were calculated using raw (unadjusted) values or when
values are adjusted for age, sex, family income, and education level using binary logistic
regression. These findings reject Null Hypothesis 1 (H01) through Null Hypothesis 8
(H08) and were consistent with the alternative hypothesis that MJ use was associated with
both depression and suicidal ideation in adults and adolescents in the 2008 and the 2017
cohorts.
Table 21
Summary of Results by Hypothesis

Hypothesis

Year

Age

H01
2008
Adult
H02
2008
Adult
H03
2008
Adolescent
H04
2008
Adolescent
H05
2017
Adult
H06
2017
Adult
H07
2017
Adolescent
H08
2017
Adolescent
H09
2008 vs 2017
Adult
H010
2008 vs 2017
Adult
H011
2008 vs 2017 Adolescent
H012
2008 vs 2017 Adolescent
Note. MHC = mental health condition.

MHC
Depression
Suicidal Ideation
Depression
Suicidal Ideation
Depression
Suicidal Ideation
Depression
Suicidal Ideation
Depression
Suicidal Ideation
Depression
Suicidal Ideation

Statistically
Significant?
Raw
Adjusted
OR
OR
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
No
No

There were statistically significant increases in the strength of the relationships
between MJ use and depression (H01) and between MJ use and suicidal ideation (H010)
in adults between 2008 and 2017. Adolescent results were mixed regarding changes over
time. There was a statistically significant increase in the strength of the relationship
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between MJ use and depression between 2008 and 2017 in adolescents using raw
(unadjusted) values (H011), but this pattern was not statistically significant when values
were adjusted for age, sex, annual family income, and education. Further, there was no
evidence of statistically significant increases in the strength of the relationships between
MJ use and suicidal ideation from 2008 to 2017 in Adolescents (H012). Thus, the Null
hypothesis (H012) is not rejected.
The following chapter provides a summary of the present study, along with
recommendations and conclusions.
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Chapter 5: Discussion, Conclusions, and Recommendations
Introduction
The changing epidemiology of marijuana legalization, use, acceptance, and
potency and the effects on mental health conditions is an important concern for policy
makers as well as public health and health care professionals. The purpose of this study
was to assess the association between marijuana use, the continued widespread
legalization of marijuana, the availability of highly potent marijuana and the effects on
mental health conditions. The literature review suggested that marijuana legalization has
led to the production of highly potent marijuana strains. This is evidenced by reports
indicating that since legalization the THC level of marijuana can now range from 6% to
28 % as oppose to pre-legalization lower potency levels that typically ranged between 4%
to 13 % (Cabrera, 2016; Ramaekers et al., 2006). Furthermore, the notion that marijuana
use is associated with the development of psychosis and mental health disorders is well
founded (Moore et al., 2007; Volkow, Ruben, Baler, Compton, & Weiss, 2014). As
previous research has demonstrated that in addition to psychosis, conditions like anxiety
and depression are also associated with regular marijuana use (Moore et al., 2007;
Volkow et al., 2014). However, very little research has been conducted post-legalization
to assess the effects of legalization and the rising THC levels. Nevertheless, since THC is
the responsible agent for the psychoactive effects of marijuana then it is highly probable
that this rise in THC concentration and ease of marijuana accessibility may contribute to
an increase in mental health consequences. This premise is evidenced by increases in
hospital admissions for psychosis and overdoses associated with marijuana intoxication
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since widespread legalization began. For instance, in Colorado, the higher levels of THC
have had a serious health toll on inexperienced users. According to the Colorado
Department of Public Health and Environment, emergency room visits for marijuana
associated conditions, such as psychosis, has increased 29% for since legalization
(Cabrera, 2016). However, when inexperienced users take in too much highly potent
marijuana, they are more likely to experience extreme anxiousness and report feelings of
“impending dome” when compared to the regular heavy marijuana users that have built
up a tolerance (Cabrera, 2016, para. 23). This is evidenced by out of state users that are
inexperienced when it comes to the high levels of THC elicited by Colorado’s legal
marijuana (Manella, 2016). Hospitalizations for out of state visitors has risen
dramatically, from 78 per 10,000 visits in 2012 to 163 per 10,000 in 2014, reflecting an
increase of 109% between the years of 2012 and 2014 (Manella, 2016).
Interpretation of Findings
Present findings revealed that marijuana use increased among the adult cohort
between 2008 and 2017. This increase in marijuana use may be the result of easing of
marijuana acceptance and reduced stigma associated with marijuana use. This finding
could also be attributed to the continued spread of marijuana legalization. In 2008, only
13 states and the District of Columbia had implemented laws legalizing marijuana use for
medical purposes only (Governing Data, 2019; NCSL, 2019), but by 2017, 29 states and
the District of Columbia had medical marijuana laws, with seven of these states and the
District of Columbia also implementing recreational marijuana laws (Governing Data,
2018; Hartig & Geiger, 2018; NCSL, 2019). Thus, more adults may use marijuana now
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that the risk of legal actions are reduced. Further support for this premise is provide by
Keyhani, et al. (2018), which posited that changes in marijuana laws “have been
accompanied by an increase in daily marijuana use, as well as in marijuana dependence,
among adults in the U.S. population” (para. 1). This is supported by an increased
prevalence of marijuana use among adults in the general population, which has doubled
over the course of the last decade (Keyhani et al., 2018).
Research Question 1
RQ1 asked whether marijuana use was associated with depression and suicide
ideation in adults in 2008 and 2017, either in isolation using raw (unadjusted) values or
using values adjusted for age, sex, annual family income, and education. The prevalence
of MDE) was higher among marijuana users than nonusers in the adult 2008 cohort, and
adult marijuana users had three times greater odds of having MDE in the previous year
than nonusers in the 2008 cohort. This statistically significant finding was also evident
after accounting for age, sex, family income, and education level. In the 2017 adult
cohort, adult marijuana users had more than double the odds of having MDE in the
previous year than nonusers, even after accounting for age, sex, family income, and
education level.
There is a growing body of evidence supporting the association between cannabis
use and the development of psychotic or mental health disorders (Moore, et al., 2007).
However, Volkow et al. (2014) posited that causality is not well founded because
addressing this association is hindered by confounders that also contribute to the
development of these conditions. Lev-Ran et al. (2014) conducted a systematic review
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and meta-analysis of existing longitudinal studies to determine patterns of cannabis use
that are associated with the development of depression. Lev-Ran, et al. cited three reasons
as cause for concern and justification for the study: (a) high cannabis use among
adolescents and young adults, (b) the increasing potency of cannabis, and (c) the
association between cannabis and mental illness. Further, regular or moderate marijuana
users have an increased risk of developing depression when compared to those who do
not use marijuana, with the greatest risk of developing depression in heavy marijuana
users (Lev-Ran et al., 2014). Lev-Ran et al. emphasized the importance of recognizing
and addressing the potential risk of heavy cannabis use, especially among adolescents
because this group has the highest rates of cannabis use.
However, conversely a study by Denson and Earleywine (2006) found the risk of
depression is not increased in adults by the use of marijuana. As according to Denson and
Earleywine, “those who used once per week or less had less depressed mood, more
positive affect, and fewer somatic complaints than non-users (p.738).” In addition, “daily
users reported less depressed mood and more positive affect than non-users” (Denson &
Earleywine, 2006, p.738). These findings are supported Hader, Morral, and Arkes (2006),
which concluded that, “past-year marijuana use does not significantly predict later
development of depression” (p. 1463). Thus, causality between marijuana use and
depression is not well founded.
Regarding suicide ideation among adults in 2008, the results of this study
revealed that in the 2008 adult cohort, marijuana users had more than double the odds of
having suicidal ideation in the previous year than nonusers. This statistically significant
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findings were consistent after accounting for age, sex, family income, and education
level. The adult 2017 cohort demonstrated that adult marijuana users again had more than
double the odds of having suicide ideation in the previous year than nonusers, even after
accounting for age, sex, family income, and education level.
In a related study, Oquendo, Currier, and Mann, (2006) addressed predictive risk
factors associated with suicidal behavior in major depressive disorders and found that the
best predictors of suicidal behavior were a past history of suicidal behavior and a history
of refractory or recurrent depressions. This evidence was consistent with the results of the
present study, which found an increase in suicidal ideation and an increase in depression
in 2017 versus 2008. Thus, the increase in suicide ideation may be associated with the
increasing rates of depression. It is also important to mention that these rates increased
concurrently with the continued spread of legalization and rising potency of marijuana.
Only 13 states and the District of Columbia had implemented laws legalizing marijuana
use for medical purposes only in 2008(NCSL, 2019; Governing Data, 2018). In 2017, 29
states and the District of Columbia had medical marijuana laws with seven of these states
and the District of Columbia also implementing recreational marijuana laws (Governing
Data, 2019; Hartig & Geiger, 2018; NCSL, 2019). Additionally, prior to legalization,
THC levels ranged from a low of 4% to a high of 13% (Ramaekers et al. 2006). But,
since legalization these ranges have increased dramatically, such that marijuana can now
range from a low of 6% THC to a high of 28% THC (Cabrera, 2016).
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Research Question 2
RQ2 asked whether marijuana use evaluated marijuana use and the association
with depression and suicide ideation for adolescents in 2008 and 2017, either in isolation
using raw (unadjusted) values or using values adjusted for age, sex, annual family
income, and education.
Marijuana use among the adolescent cohorts did not change between 2008 and
2017, with both adolescent cohorts measured at 14% marijuana use. This contrast with
the increase in adult marijuana use may be attributed to the fact the adults can legally buy
marijuana while adolescents cannot (Governing Data, 2018; NCSL, 2019).
Among the 2008 adolescent cohort, marijuana users had greater than double the
odds of having MDE in the previous year than non-users, even after accounting for age,
sex, family income, and education level. In comparison, among the 2017 adolescent
cohort, marijuana users had two and a half times greater odds of having MDE in the
previous year than nonusers, even after accounting for age, sex, family income, and
education level. Thus, the rates of marijuana associated depression increased concurrent
with the continued widespread legalization of marijuana. These rates are also concurrent
with the rising THC levels in marijuana that has occurred with the continued widespread
legalization (Cabrera, 2016).
Additionally, these findings are supported by previous research as van Gastel et
al. (2013) which indicated that marijuana use has been associated with psychiatric
symptoms and the risk is increased by regular or heavy marijuana use. According to van
Gastel et al., the risk of developing depression is more pronounced in those who began
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using marijuana before age 16. Observations among young adolescent marijuana users
typically include “delinquent behavior; conduct disorder; attention problems; anxiety as
well psychotic and depressive symptoms” (van Gastel, 2013, p.1849). Thus, developing
evidenced based interventions to address the association between marijuana and mental
health conditions is essential to ensuring the health and well fare adolescents and
therefore future generations.
With regard to suicide ideation among the 2008 adolescent cohort, marijuana
users demonstrated a doubled risk of suicide ideation than nonusers, even after
accounting for age, sex, family income, and education level, with even higher values for
the 2017 adolescent cohort. These results are consistent with peer-reviewed research
showing that suicidal ideation, attempts, and completions have been associated with both
depression and substance use in adolescence (Chabrol, Chauchard, & Girabet, 2008;
Field, Diego, & Sanders, 2001). Social factors and mental health problems in general
have been identified as associated risk factors for suicidal behaviors in adolescents.
Among these, depression has been established as a significant or major risk factor for
suicide behaviors (Chabrol et al., 2008; Field et al., 2001). In addition, Field et al. (2001)
identified marijuana use and a family history of depression, particularly maternal
depression, as important variables in adolescent suicide ideation.
Research Question 3
RQ3 asked whether the associations between marijuana use and MDE and
between marijuana use and suicidal ideation are significantly higher in 2017 than in 2008
for both adults and adolescents. Adult MDE and suicidal ideation increased significantly
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from 2008 to 2017. Results for the adolescents were mixed, with statistically significant
increases in depression from 2008 to 2017 evident using unadjusted values, but not
accounting for age, sex, family income, and education level. Further, not statistically
significant increases from 2008 to 2017 in suicidal ideation for adolescents were present.
Suicide is one of the most common causes of death worldwide among adolescents
and young adults aged 10-24, (Serafini et al., 2013). Previous research suggests that
marijuana use may be a contributing factor in the development of suicide behavior and
depression (Gander, 2019; Serafini et al., 2013). For example, Gander (2019) pooled
existing studies to assess the association between marijuana use, depression and suicidal
behavior and found that adolescents who use marijuana are at a greater risk of
experiencing depression and suicidal behavior, including suicide ideation and suicide
attempts. However, Gander acknowledged that it is difficult to assess whether
confounding variables may have affected the results, such as amount of marijuana use,
use of other substances of abuse, and marijuana potency (which has increased
substantially since legalization). Gander further offered that individuals with a
predisposition to depression or those who begin to experience symptoms of depression
may self-medicate as a way to ease these symptoms or just think and/or feel better. In
contrast, Anderson, Rees, and Sabin (2014) compared the rates of suicide in states with
medical marijuana legalization to states that did not legalize medical marijuana and found
a decrease in suicides among men aged 20 to 39 in states with medical marijuana laws.
Anderson et al. (2014) hypothesized that this negative relationship between marijuana
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legalization and suicide rates may be attributed to the use of marijuana as a method of
coping with stress.
Analysis of Theoretical Framework
There are several theoretical models developed for understanding drug use, abuse,
prevention, and cessation. For instance, there is a growing body of evidence supporting
the association between self-medicating with marijuana and depression (Shonesy et al.,
2014). Research supports the use of the SEM to understand substance use and abuse from
a multifaceted perspective (American College Health Association [ACHA], 2018).
Theorists of the self-medication theory of addiction developed by Khantzian (1977, 1974)
suggested that individuals who are afflicted with substance abuse may also have a
predisposition for psychological conditions or psychosis (Burnett & Reiman, 2014). Selfmedication theory has over 30 years of use in research (Hall & Queener, 2007).
Therefore, I used both the self-medication theory of addiction and SEM as the conceptual
frameworks.
Shonesy (2014) explored the relationship between mental health conditions, like
depression and anxiety, and receptors that respond to THC in the central nervous system.
This system is known as the endocannabinoid system and is medicated by two
cannabinoid receptors, CB1 and CB2 (Shonesy et al., 2014). These receptors respond to
both endogenous and exogenous stimulation (Shonesy et al., 2014). Natural endogenous
stimulation of CB1 receptors occurs through one of two THC-like substances,
anandamide (AEA) and 2-arachidonoylglycerol (2-AG, Shonesy et al., 2014). According
to Shonesy (2014) this system “is heavily implicated in the modulation of anxiety and
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depressive behavior and emotional learning” (p.1644). The THC in marijuana is capable
of binding CB1 receptors of the system and affects mood, such that reduced stimulation
of these receptors results in mood destabilization and increased feelings of anxiety and
depression (Shonesy et al., 2014). Thus, marijuana users who suffer from these
conditions may not be able to synthesize enough of THC-like molecules (particularly 2AG) so they use marijuana to compensate, suggesting that individuals may actually selfmedicate without knowing it to compensate for their inherent low levels of THC-like
molecules (Curry, 2014; Shonesy et al., 2014).
However, results of the present study and other supporting literature suggest that
marijuana use is associated with an increased risk of depression and suicide ideation.
Nevertheless, an explanation for these contradicting theories may lie in the ratio of THC
to CBD in marijuana. It has been demonstrated that CBD has effects that counteract the
effects of THC (Niesink & van Laar, 2013). CBD is a compound found in marijuana that
is being used for medical benefits. CBD does not produce the psychoactive effects caused
by the THC found in marijuana. In fact, CBD can serve to counteract the psychoactive
effects of THC and is used for treating marijuana induced psychosis (Niesink & van Laar,
2013). Thus, it is possible marijuana that has a high CBD to THC ratio may counter the
effects of THC-induced depression.
The (SEM is a theory-based multifaceted approach to understanding the dynamics
associated individual and population level determinants of health (ACHA, 2018). The
SEM recognizes that health is determined by influences from multiple societal and
environmental factors that affect the individual (ACHA, 2018). According to the SEM,
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the dynamic interrelationships between five levels or factors of health determinants are
significant and essential to the health behaviors of the individual (ACHA, 2018). These
five levels include (a) individual, (b) interpersonal, (c) organizational/institutional, (d)
community, and (e) policy (CDC-SEM, 2018). The first or individual level is concerned
with sociodemographic (i.e., age, gender, religion, etc.) and intrapersonal factors or
characteristics such as knowledge, beliefs, attitudes, and behaviors of the individual that
affect health decisions and outcomes (ACHA, 2018; CDC-SEM, 2018). The second or
interpersonal level is concerned with close personal relationships or associates that
influence the behavior and contributes to the life experience of the individual (ACHA,
2018; CDC-SEM, 2018). This can include family members, friends, coworkers, health
care providers, and community health workers (ACHA, 2018; CDC-SEM, 2018). These
first two levels may be associated with an increase in marijuana use as continued
legalization may result in decreased perceived risk and reduced stigma associated with
marijuana use.
The third level of SEM is concerned with local organizations and institutions that
affect individual and population health by influencing organizational systems and policies
(ACHA, 2018; CDC-SEM, 2018). This includes health care systems; state and local
health departments; professional organizations; and healthcare plans (ACHA, 2018;
CDC-SEM, 2018). The fourth level explores community and social relationships that
influence individual health determinants. This can include employers/worksites,
businesses such as bars and restaurants, community-based organizations, the media as
well as community, state and regional organizations (ACHA, 2018; CDC-SEM, 2018).
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Thus, the third and fourth levels may be associated reduced or no change in marijuana
use. This is because the third level associated with health care systems, state and local
health departments, professional organizations, and healthcare plans, may serve to inform
individuals and the public about the negative impact or consequences of marijuana use. In
addition, the fourth level is associated with organizations such as employers/worksites
many of which require drug screenings that include marijuana, thus deterring marijuana
use.
The fifth level of SEM is associated with interpreting and implementing local,
state, national, and federal laws and policies (ACHA, 2018; CDC-SEM, 2018). This level
is of particular interest to the present study, given the current trend in marijuana policies
that favor relaxed laws and increased community acceptance of legalization for
recreational and medicinal purposes. The fifth level may thereby be associated with an
increase in marijuana use as state laws favoring marijuana continue to spread. As
individuals may feel more comfortable purchasing and using marijuana without legal
consequences. However, this fifth level may result in a decrease or no change in
marijuana use as federal laws still prohibit marijuana use. Therefore, this SEM model can
be used to inform States local marijuana policies and may serve to inform the
implementation of federal laws and regulations as well.
With respect to this study, the SEM suggest that the first (individual), second
(interpersonal), and fifth (policy) levels may be associated with increased marijuana use.
As increased legalization (policy), reduced stigma associated with marijuana use and
decreased perceived risk associated with the individual, interpersonal and community
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effects may serve to increase marijuana use and affect the results of this study. In
contrast, the third (organizational/institutional) and fourth (community) levels may be
associated with a decrease or no change in marijuana use as the groups associated with
these levels may serve to deter marijuana use.
Limitations
In this study I was limited by sample, measures, and research design. The target
population for the NSDUH included non-institutionalized civilians 12 years and older
living in the United States at the time of the survey. Approximately three percent of the
US population was excluded this includes active-duty military and institutionalized
groups, such those in prisons, hospitals, nursing homes, treatment centers, etc. In all the
2008 and 2017 NSDUH datasets consisted of responses from 67,928 and 68,032
participants, respectively (NSDUH-codebook, 2008; NSDUH-codebook, 2017). Based on
this information it is important to acknowledge the exclusion of institutionalized,
incarcerated and homeless individuals because according to a report provided by the
Center for Prisoner Health and Human Rights (2019), “approximately half of prison and
jail inmates meet the requirements of the Diagnostic and Statistical Manual of Mental
Disorders, fourth edition (DSM-IV) for drug abuse or dependence” (para. 2). In addition,
according to the U.S Department of Housing and Urban Development (2016), among the
roughly 550,000 homeless persons, approximately 95,500 (17%) of these individuals
suffer from chronic substance abuse. So, inclusion of the incarcerated and homeless
populations in the demographics of NSDUH would have increased the number of users in
the study disproportionately and potentially altered the outcomes observed. Thus, while
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exclusion of these individuals may have limited the representativeness of the sample,
inclusion of these individuals may have altered the study’s results by increasing the
number of marijuana users disproportionately.
Even though the NSDUH presented samples that were stratified to be
representative of the nation’s adult and adolescent populations, in my present study I did
not explore state by state differences. Thus, while a nationwide analysis was conducted,
the NSDUH does not differentiate between states with marijuana laws compared to states
without marijuana laws. In addition, THE NSDUH was retrospective in nature and it did
not include random assignment into group or experimentally controlled levels of
marijuana use. In contrast with a true experimental design that would include random
assignment and experimentally controlled usage to assess true cause-and-effect
relationships (Creswell, 2009).
In this study I was also limited by self-reporting, which is subject to recall bias,
which can therefore result in erroneous responses due to lapses in memory (Althubaiti,
2016). Self-reporting is also subject to social desirability bias, especially in this case
which involves responses related drug use (Althubaiti, 2016). To alleviate these concerns,
the NSDUH interviewer conducted the interview in a private area of the home and used
both computer-assisted personal interviewing (CAPI) and audio computer-assisted selfinterviewing (ACASI) techniques (CBHSQ, 2016). The CAPI portion of the interview
was used to collect and record verbal responses to questions read aloud by the interviewer
who enters these responses into a computer (CBHSQ, 2016). In contrast, the ACASI
portion of the interview was used to collect information on answers to sensitive
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questions. During his portion of the interview, respondents used headphones to listen to
questions and enters responses directly into a computer (NSDUH-codebook, 2017).
Throughout the interview process (written and oral), respondents were assured that their
confidentiality, anonymity, and responses were protected and handled according to
federal law compliance regulations (CBHSQ, 2016; NSDUH-codebook, 2017).
Nevertheless, even though the NSDUH assured participants anonymity and
confidentiality, respondents may still have felt uncomfortable and may therefore not have
been completely truthful about marijuana use or may have underestimated usage amounts
or frequency (Althubaiti, 2016). Thus, socially acceptable or bias responses could have
therefore effected survey results on the prevalence and extent of marijuana use because
individuals may still have concerns about social stigma or self-incrimination (McDonald,
2008).
In my present study I only used one measure per construct. In addition, my study
was missing important variables, such as frequency and amount of marijuana use. I did
not assess whether respondents had a history of major depressive episode or suicide
ideation prior to marijuana use.
My present study was also limited by the design. Even though my study was
longitudinal in nature regarding statistical comparisons of cohorts at two time periods, the
same respondents were not followed over time because there was no tracking between the
cohort years of 2008 and 2017. Therefore, there is no way to tell if respondents changed
behavior based on marijuana laws or trends in growing acceptance of marijuana use.
Also, there was no long-term follow up after 2017. Because this was not a true
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longitudinal study, cause and effect inference is limited, and the results do not provide
strong evidence of causality between marijuana use and the mental health conditions of
MDE and suicide ideation
Areas for Future Research
An important approach for future scholars is to replicate this research using
methods to address, overcome, or reduce the limitations of this study. For instance, future
research should include variables with multiple measures of construct, such as how much
or how often individuals use marijuana. Another limitation that should be addressed are
those associated with self-reporting, including overcoming recall and social desirability
biases.
Another important approach for future scholars is to explore state-level data to
compare states with marijuana laws to states without marijuana laws. In states with
marijuana laws, future researcher should explore changes in mental health status in years
prior to legalization of marijuana to years after legalization (pre vs post-legalization). In
my present study I sought to explore and compare state-level data. However, this
information is only available on-site at one of three Research Data Centers (RDCs) in the
U.S. managed by the National Center for Health Statistics.
Future scholars should also consider whether participants had previous history of
marijuana use as well as histories of MDE and suicide ideation prior to using marijuana.
Additionally, future research should consider conducting long-term follow up as well.
Thus, to guarantee optimal outcomes and present strong evidence of causality, future
research is warranted to confirm the present findings and assess (determine) whether the
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effects observed in this study would be statistically significant in a true longitudinal
study.
Implications for Positive Social Change
The results of my study may contribute to positive social change by contributing
to present knowledge on the association between marijuana use and the mental health
conditions, depression and suicide ideation. The findings presented here imply that
marijuana use can increase the risk of depression and suicide ideation.
Addressing these concerns at this time is of particular importance given the trends
in marijuana legalization and growing acceptance. Current trends indicate that, as
marijuana legalization continues to spread, the perceived risk of marijuana use is
decreasing. These trends may contribute to an increase in marijuana use as was
demonstrated among the adult cohorts from 2008 compared to 2017 (Lynskey & Hall,
2016). In addition, with the exception of marijuana use, substance use in general has
declined among high school seniors (Lanza, Vasilenko, Dziak & Butera, 2015).
Marijuana is still the most widely used illicit substance in the world and in the United
States as in 2018, approximately 43 million Americans reportedly used marijuana in the
past year (Statista, 2019). Among these were approximately 11.8 million young adults
that reported using marijuana in the past year in 2018 (NIH-NIDA, 2019). The World
Health Organization (2018) further emphasizes the widespread use of marijuana in a
report indicating that approximately 147 million people or 2.5% of the world population
utilize marijuana in some form each year. This is compared to 0.4% combined totals of
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the world’s population that consume cocaine and opiates annually (WHO, 2018).,
demonstrating that marijuana is by far the most widely used illicit substance in the world.
The findings presented here also contribute to positive social change because
according to the NSDUH, in 2017 approximately 17.3 million adults 18 years old or older
and 3.2 million adolescents aged 12-17 years old had at least one major depressive
episode (NIMH, 2019). In addition, suicide is the tenth leading cause of death in the
United States. Thus, addressing suicidal behavior, such as suicide ideation is an important
preventive measure for public health concern.
The results of my study demonstrated a statistically significant association
between marijuana use an increased risk of major depressive episode (MDE) in both
adults and adolescents, and therefore support and extend previous reports. Furthermore,
my study also demonstrated positive correlations between time (corresponding to
increasing marijuana legalization) and rising rates or risk for MDE and suicide ideation
as the rates for these conditions increased for marijuana users from 2008 to 2017. The
findings presented here along with continued widespread marijuana legalization,
increasing permissive attitudes toward marijuana use, and decreasing perceived risk
demand that policymakers and public health professionals direct informative and
preventive efforts to reduce these risks.
The increasing permissive attitudes and decreasing perceived risk of marijuana
use among adolescents is a serious concern for the future of public health as these
individuals are entering their reproductive years and will therefore affect future
generations. In addition, it has also been demonstrated that an association exists between
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age of initiation of substance use and increased risk of substance dependency later in life
(Jordan & Andersen, 2017; CDC, 2019). Therefore, a positive social change implication
is to encourage policy makers and public health professionals in jurisdictions with laws
legalizing marijuana and those considering legalization of marijuana, to take these results
into consideration and improve efforts to inform the public about the increased risk
associated with marijuana use and the potential effects on mental health.
Another contribution to positive social change addressed by my study is the
increasing potency of marijuana and marijuana products. Prior to legalization, THC
levels ranged from a low of 4% to a high of 13% (Ramaekers, et al. 2006). However,
since legalization these ranges have increased dramatically. For instance, growers in
Colorado have produce strains that range from a low of 6% THC to a high of 28% THC
in the Williams’ Screaming Gorilla strain (Cabrera, 2016). This concern was addressed
by the Colorado state legislator which proposed an amendment to limit the THC
concentration of marijuana to 16% (Cabrera, 2016). However, these efforts failed as the
amendment did not get enough support. Previous studies have been conducted assessing
the lower levels of THC fewer studies have been conducted to assess higher levels. My
study contributes to positive social change by informing future generations of the risk
associated with highly potent marijuana and the implications of marijuana legalization on
the prevalence of mental illnesses like depression. In addition, among the health and
safety concerns addressed by the Colorado state legislator, the effects of THC on
adolescent brains was one of the primary concerns of the proponents of this amendment
(Cabrera, 2016). Thus, adolescents were included in the target population of my study
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which intended to contribute to positive social change by making information available to
inform and understand the effects on future generations as a future return on investments.
Conclusions
In my study I found that higher rates of major depressive episode and suicide
ideation in adults and adolescents were associated with marijuana use. Furthermore, I
also found that there were statistically significant increases in the strength of the
relationships between marijuana use and depression and between marijuana use and
suicidal ideation in adults between 2008 and 2017, as marijuana legalization increased.
However, adolescent results were mixed. In addition, the adult rates of marijuana use
increased between 2008 and 2017. These findings may be attributed to by the fact adults
can legally buy marijuana therefore increasing availability and use among this group.
Additionally, adults in states with recreational marijuana laws have greater access to the
highly potent marijuana being sold in dispensaries. Thus, more adults may use marijuana
now that the risk of legal actions are reduced contributing to the results observed in this
study.
Finally, the increasing permissive attitudes and decreasing perceived risk of
marijuana use among adolescents is a serious concern for the future of public health
because these individuals are entering into their reproductive years and will therefore
affect future generations. In addition, it has also been demonstrated that an association
exists between age of initiation of substance use and increased risk of substance
dependency later in life (Jordan & Andersen, 2017; CDC, 2019). As adolescents aged 1217 years old are considered to be in the critical risk period of life for initiation of
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substance use associated with greater risk of substance abuse and dependence in later life
(Strashny, 2014). Therefore, policy makers and public health professionals in
jurisdictions with laws legalizing marijuana and those considering legalization of
marijuana have an obligation to intervene in this vulnerable population. In an effort to
improve prevention and inform the public about the increased risk associated with
marijuana use and the potential effects on mental health to initiate positive social change.
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